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Overview
This thesis examines the effects of chronic use of ketamine, a non-competitive N- 
methyl-D-aspartate (NMDA) receptor antagonist, on subjective experience and 
cognition. It is important to explore the chronic effects of ketamine as the number 
of individuals using the drug recreationally is increasing both in the UK and 
worldwide. There is a paucity of research exploring the chronic effects of ketamine. 
Many studies have shown that acutely ketamine induces psychotic-like 
symptomatology and specific cognitive dysfunction in healthy, drug-naive 
volunteers. For this reason, a ketamine model of the psychoses has been proposed. 
However the few studies of the effects of chronic ketamine have provided mixed 
findings.
Part 1 of the thesis comprises a literature review, which investigates the 
psychotomimetic effects of ketamine, through the synthesis of current research 
findings, to determine whether ketamine is a useful model of the symptomatology 
characteristic of the psychoses. It presents an overview of ketamine and its 
association with the psychoses, before providing a detailed account of the 
functional psychoses and drug models of the psychoses (namely the dopamine 
hypothesis, the serotonin hypothesis and the glutamate hypothesis). The review then 
synthesises the acute and chronic ketamine studies to date, highlighting which states 
appear to be best modelled (i.e. the pre-psychotic, acute or chronic state 
experienced by individuals with idiopathic psychoses). Finally, the review briefly 
considers the treatment implications of the ketamine model of psychoses, and the 
risk chronic ketamine use poses to users in terms of developing fully-manifest 
psychotic symptomatology.
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In Part 2, an investigation of the chronic effects of ketamine on subjective 
experiences and cognitive functioning is reported, in order to determine whether 
chronic ketamine models symptomatology associated with the pre-psychotic state of 
idiopathic psychoses (where the term idiopathic refers to psychotic symptomatology 
of unknown aetiology, i.e. that which occurs in the majority of the general 
population and is not drug-induced). This investigation was part of a joint project 
conducted with 2 other trainees to investigate the chronic effects of ketamine, 
cannabis and cocaine on subjective experiences and cognitive functioning (See 
Appendix 1 for details of the contribution made by each trainee).
The empirical paper reports a between subjects study which compared 21 frequent 
ketamine users (who used ketamine daily), 20 infrequent ketamine users (who used 
ketamine a maximum of once or twice a week) and 20 controls (who reported no 
illicit drug use). On a clinical index of symptomatology (SPI-A), a ‘frequency’ 
effect was observed: frequent ketamine users were found to be higher in psychotic- 
like symptomatology (i.e. basic symptoms) than infrequent users, who in turn were 
found to be higher in symptomatology than controls. Both groups of ketamine users 
were also found to be higher in psychosis proneness on a general population index 
of psychotic-like markers (OLIFE) compared with controls. Furthermore, both 
groups of ketamine users demonstrated impaired episodic memory and working 
memory compared to controls. Group differences were found in executive 
functioning.
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Part 3 comprises a critical appraisal of the research. It includes reflections on my 
experience of the research process and conducting research with the ketamine using 
population, as well as reflections on clinically relevant observations.
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Part 1: Literature Review
How useful is ketamine as a model of the 
psychotic and cognitive symptomatology 
characteristic of idiopathic psychoses?
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Abstract
Rationale: A review of the psychotomimetic effects of ketamine was needed 
because of (i) the increasing population of recreational ketamine users in the UK 
and abroad, and (ii) ketamine’s application to the N-methyl-D-aspartate (NMDA) 
receptor hypofunction model of the psychoses. To the best of our knowledge, no 
such review of the literature had previously been conducted.
Method: The Psychlnfo database was searched using the following keywords: 
psychosis, acute, chronic, positive symptoms, negative symptoms, prodrome, early 
symptoms, basic symptoms, ultra-high risk, mania, bipolar, schizoaffective, 
ketamine, glutamate, review, and the following authors: Fletcher, Honey, and 
Kapur. Studies were selected from those published between 1994 and November 
2007, and the main exclusion criterion was non-human studies. Additional studies 
were also identified through those initially reviewed.
Findings: Acute ketamine challenge studies with healthy participants, participants 
with idiopathic psychoses and acute-on-chronic studies with self-administering 
ketamine users have found ketamine induces a dose-dependant ‘clinical syndrome’, 
characterised by (i) subtle, attenuated positive and negative psychotic-like 
symptomatology, and (ii) cognitive impairments. Thus, acute ketamine appears to 
be a valid and reliable model of the symptomatology reliably observed in within the 
pre-psychotic state.
Furthermore, the few studies which have investigated the effects of chronic 
ketamine indicate that it may better represent the chronic state experienced by
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individuals with psychoses, where negative symptomatology and specific cognitive 
symptomatology predominate. However this finding is very tentative due to the 
paucity of research into the effects of chronic ketamine use.
Conclusions: Currently, it is unclear which state experienced by individuals with 
psychoses the chronic ketamine profile best models. This author suggests that 
chronic ketamine users may present with subtle psychotic-like symptomatology, 
which has not been detected by the behavioural measures utilised in previous 
studies. Directions for further research and treatment implications of the ketamine 
model of the psychoses for individuals with idiopathic psychoses are discussed. In 
addition, it is important to communicate the effects of both acute and chronic 
ketamine use to recreational users. Ketamine’s status as a risk factor for psychotic 
symptomatology is also discussed.
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1. Introduction
1.1 Overview
This review endeavours to investigate the psychotomimetic effects of 
ketamine, through the synthesis of current research findings. To determine whether 
ketamine is a useful model of the symptomatology characteristic of the psychoses, 
the review firstly considers the factors deemed necessary and sufficient for a useful 
drug model of the psychoses. An introduction to the psychoactive drug, ketamine, is 
then provided, along with an overview of the functional psychoses and their 
associated symptomatology. Historical drug models are then briefly explored, and 
compared with the glutamate hypothesis of the psychoses, which arises in part from 
the ketamine model. The main body of the review then focuses on evaluating the 
validity, reliability and specificity of the ketamine model of the psychoses, in order 
to gain a better understanding of the type of psychotic symptomatology the 
ketamine profile may best represent. It is suggested that a useful drug model of the 
psychoses should inform the development of novel interventions for idiopathic 
psychoses, and indicate higher risk for the precipitation of idiopathic psychoses 
following repeated use of the drug in question (where the term idiopathic refers to 
psychotic symptomatology of unknown aetiology, i.e. that which occurs in the 
majority of the general population and is not drug-induced). The conclusions drawn 
include a consideration of implications for future research.
1.2 Rationale for the current literature review
The past 15-20 years has seen an explosion of interest regarding the effects 
of ketamine. This literature mainly focuses on acute ketamine-induced effects in 
healthy, drug-naive individuals, with some interest in the effects of acute dosage 
with individuals with idiopathic psychoses. However there is a paucity of studies
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concerned with chronic effects of ketamine, experienced as the result of long-term 
recreational use. Researchers are becoming increasingly interested in the 
similarities and differences between ketamine-induced symptomatology, and 
symptomatology characteristic of idiopathic psychoses.
Just as, for example, the study of amphetamine-induced effects led to the 
dopamine (DA) hypothesis of psychoses, which proved invaluable for developing 
our understanding of the neurobiological basis and phenomenology of the 
psychoses, the study of ketamine-induced effects has contributed to the glutamate 
hypothesis of psychoses. Novel approaches to the treatment and prevention of drug- 
induced and idiopathic psychoses, based on the glutamate hypothesis are currently 
being explored (Anand et al., 2000; Goff et al., 1999; Heresco-Levy et al., 1999; 
Newcomer et al., 1998, all cited in Newcomer & Krystal, 2001). Indeed, Patil et al. 
(2007) recently demonstrated that a new, glutamate-acting drug (LY210023), was 
as effective as olanzapine in attenuating psychotic symptomatology.
If ketamine consistently induces symptomatology similar to that observed in 
the psychoses, evidence to support the glutamate hypothesis of psychoses would be 
generated. Therefore, a review of the literature regarding the overlap between 
ketamine-induced symptomatology and symptomatology characteristic of idiopathic 
psychoses is crucial. To the best of the author’s knowledge, a previous review of 
this nature is not in existence. Hence, this review is a novel endeavor. In addition, 
with the growing number of recreational ketamine users both in the UK and abroad 
(Copeland & Dillon, 2005; McCambridge, Winstock & Mitcheson, 2007; Murphy 
& Roe, 2007), a review of the psychological and cognitive impact of both acute and 
chronic ketamine use is overdue.
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2. Review Methodology
A search of the relevant literature was conducted using the following 
keywords: psychosis, acute, chronic, positive symptoms, negative symptoms, 
prodrome, early symptoms, basic symptoms, ultra-high risk, mania, bipolar, 
schizoaffective, ketamine, glutamate, review, and the following authors: Fletcher, 
Honey, and Kapur. The following keywords were entered into the thesaurus 
application in Psyclnfo to ensure all similar relevant terms were searched: 
psychosis, positive symptoms, negative symptoms, prodrome, mania, bipolar, and 
schizoaffective. Search terms were combined using the AND/OR applications.
The search was initially conducted using Psyclnfo because it’s aim was to 
gather all studies which had investigated ketamine-induced experiences and 
cognitive dysfunction, rather than studies which primarily focused upon exploring 
the biological underpinnings of ketamine-induced effects and NMDA antagonism. 
Studies were selected from those published between 1994 and November 2007. 
Exclusion criteria were: non-human studies, studies that investigated ketamine for a 
purpose other than to model psychotic symptomatology, e.g. anaesthetic studies and 
studies looking at the anti-depressant effects of acute ketamine. The main inclusion 
criterion was: studies that investigate the link between ketamine and
symptomatology characteristic of the psychoses. I grouped the studies into those 
primarily focusing on glutamatergic pathways, acute ketamine challenge studies, 
and chronic ketamine studies. Additional studies were also identified through those 
initially reviewed. PubMed was then also searched using the same criteria to ensure 
no studies had been missed. No further relevant papers were found.
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3. Evaluating drug models of psychoses
3.1 What makes a useful drug model o f the psychoses?
Despite the philosophy of science literature containing copious discussion 
regarding the criteria for a good scientific theory, the question of what makes a 
useful model remains largely unanswered. In addition, a literature search (criteria: 
(drug) model / psychosis / schizophrenia) revealed no direct guidance on this 
matter. Nevertheless, Fletcher and Honey (2006) note several factors on which they 
evaluated the ketamine and cannabis models of the psychoses, which have provided 
guidance for this review. In addition, Honey et al. (2005) note that a useful drug 
model will develop the predictive and explanatory power of theories of the 
psychoses.
Fletcher and Honey (2006) note that a useful drug model of the psychoses 
should have clinical and contextual validity. The former refers to the extent to 
which symptomatology induced by a drug overlaps with psychotic 
symptomatology. The authors note that no drug model is complete in this respect. 
The latter refers to the duration and awareness of drug-induced symptomatology in 
comparison to psychotic symptomatology observed in psychoses. They also note 
that a useful drug model should be reliable, in that it can repeatedly replicate the 
syndrome it is attempting to model. Finally, the authors propose a useful drug 
model should have some degree of clinical, cognitive, transmitter and experimental 
specificity. Clinical and cognitive specificity refer to the drug’s ability to mimic 
only psychoses-related clinical or cognitive symptomatology. Transmitter 
specificity relates to the extent to which the drug in question acts upon the specific 
neurotransmitter system it is claiming to investigate, and thus implicate in 
psychoses. Experimental specificity refers to the experimental designs utilised when
16
investigating a drug model of psychoses, which could underlie the differences in 
results demonstrated in the literature reviewed below. These criteria for a useful 
drug model of the psychoses will be referred to throughout this review, where 
relevant.
3.2 Limitations o f drug models o f the psychoses
The drug models of psychoses have several central limitations. Firstly, drug 
models adhere to the medical model, which proposes that diagnosable mental health 
disorders are illnesses, which have biological antecedents, the exact nature of which 
are awaiting discovery. It has been proposed that the medical model has de­
emphasised and obscured the potential role of social and interpersonal factors (e.g. 
social and educational disadvantage, child abuse and neglect) in the development 
and maintenance of psychoses, through its dominance in the psychoses research 
literature (Boyle, 2004). Indeed, thus far drug models have been unable to mimic 
the full range of symptomatology observed in the psychoses (see section 6 for 
review), thus indicating that neurotransmitter dysfunction may well not be the 
whole picture. Furthermore, up to 75% of individuals with psychotic 
symptomatology still experience significant active psychotic and cognitive 
symptomatology whilst undergoing atypical antipsychotic therapy (Tamminga, 
1998), which have been developed primarily as a consequence of drug model 
research. Clearly evidence thus far suggests that neurotransmitter dysfunction is 
certainly not the only explanation for psychotic symptomatology, and may indeed 
not be the primary explanation. It may be that the dominance of the drug model 
literature within psychoses research, and the certain nature of the language used in 
this literature has perpetuated the belief that neurotransmitter dysfunction is key to 
psychotic symptomatology.
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Secondly, as drug models have been developed within the medical model 
the literature around them automatically takes the position that psychotic 
symptomatology can be categorised into diagnosable disorders or illnesses, which 
have biological antecedents, the exact nature of which are awaiting discovery. 
However as Mary Boyle’s (2002; 2004) work suggests, psychoses such as 
schizophrenia and bipolar disorder are constructs, which encompass organised sets 
of beliefs that have been propagated by the dominant systems in society, namely 
medicine and science. This position acknowledges there may be some genetic / 
biological involvement in psychotic symptomatology (the extent of which is 
unknown contrary to the belief propagated by medicine and science), but calls into 
question the appropriateness of categorising individuals with psychotic 
symptomatology into medically constructed categories (i.e. DSM and ICD 
diagnoses, such as schizophrenia and bipolar disorder) for which there is no clear 
evidence to confirm a specific brain disease or illness (see Boyle, 2002 for 
overview). Drug models are therefore limited as they attempt to model specific 
categorical diagnoses, rather than dimensional symptomatology. A minority of the 
drug model literature recognises this. For example, Abi-Saab, D'Souza, 
Moghaddam and Krystal (1998) suggest drug models may prove better at offering 
insight into psychotic symptomatology in general, rather than specific DSM or ICD 
diagnoses. Hence, this review has taken the approach of investigating how well the 
ketamine model models specific psychotic symptomatology associated with 
different states of the psychoses.
Thirdly, drug models of psychoses are limited because they study the 
psychotomimetic effects of one recreational drug at a time, which is proposed to 
predominately act upon one neurotransmitter system. If it is the case that
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neurotransmitter dysfunction plays an as yet unclear role in psychotic 
symptomatology, then this may be an artificial way of modeling such a process. 
Indeed, it has been proposed that a future model of the psychoses might comprise 
groups of overlapping genes which correspond to the disruption of various 
neurotransmitter systems, which pose as risk factors for a spectrum of clinical 
phenotypes, whose expression would be mediated by environmental factors 
(Craddock & Owen, 2005). For example, a risk factor for the development of 
positive psychotic symptomatology might be genetic abnormalities in DA and 
glutamate neurotransmission.
Finally, drug models of psychoses have been developed through both 
studying drug-induced effects of acute doses and chronic use. As the repeated 
administration of recreational drugs is unethical, such latter research has relied upon 
recruiting participants who are already using the investigated drug in their everyday 
lives. Hence, drug models are limited as their conclusions and theories are in part 
based upon the findings of naturalistic drug studies, which have a host of common 
limitations, including poly-drug use, restricted study design and recruitment 
difficulties (see Curran, 2000 for review).
This author takes the position that drug models can be useful tools in the 
search for knowledge regarding the aetiology and maintenance of psychotic 
symptomatology, but that readers should be mindful that they are most helpful to 
this endeavour when viewed within the context of the above limitations. It is not 
proposed that drug-induced experiences which mimic psychotic symptomatology 
are exactly the same as idiopathic psychotic symptomatology, but rather that the 
striking similarity is of interest and warrants investigation.
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4. Ketamine and its association with the psychoses
4.1 Overview
Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor 
antagonist, which interferes with the action of excitatory amino acids (EAAs), 
including glutamate and aspartate (Anis, Berry, Burton & Lodge, 1983, cited in 
Curran & Monaghan, 2001). The EAAs are the most prevalent excitatory 
neurotransmitters in the brain and play an important role in cortico-cortical and 
cortical-subcortical interactions (Cotman & Monaghan, 1987, cited in Curran & 
Monaghan, 2001). Ketamine is available clinically as a racemic mixture of two 
enantiomers, the S-isomer and the R-isomer, which have different receptor binding 
profiles. The former has 2-4 times greater affinity for the NMDA receptor and 
clinical potency than the latter (0ye, Hustveit, Moberg, Pausen, & Skoglund, 1991; 
0ye, Paulsen, & Maurset, 1992, both cited in Abi-Saab, D’Souza, Moghaddam, & 
Krystal, 1998). Although both isomers bind to receptors other than the NMDA 
receptor (with less affinity), findings suggest the effects of subanaesthetic doses of 
ketamine are mediated by the NMDA receptors (Abi-Saab et al., 1998; Umbricht et 
al., 2000). This implies the ketamine model of the psychoses has high transmitter 
specificity.
Ketamine use began within clinical settings, for the purposes of anesthesia 
and analgesia. However its use was associated with bizarre post-operative
‘emergence phenomena’ comprising of vivid dreams, hallucination-like
experiences, delusions and confusional states (Siegel, 1978, cited in Curran & 
Monaghan, 2001). The ‘emergence phenomena’ resulted in ketamine’s withdrawal 
from use with adults, but ketamine is still used in ambulatory, veterinary and
pediatric anesthesia, and more recently in the treatment of chronic pain.
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Interestingly, the ‘emergence phenomena’ have made ketamine the drug of choice 
for some recreational drug users.
Recreational ketamine use (street names; K, Special K and Vitamin K), 
became popular in the UK club scene in the early 1990s. The effects of ketamine 
are dose-specific, therefore at lower doses users may feel euphoric, experience 
waves of energy, and possibly synaesthesia, whereas at higher doses users might 
become paralysed, experience hallucinations and alternate realities, and a feeling of 
dissociation, providing an 'out of body' experience known as the ‘K-hole’. These 
effects are short-lived, due to ketamine’s short half-life (Wieber, Gugler, 
Hengstmann, & Dengler, 1975, cited in Umbricht et al., 2000). In the past couple of 
years a surge in ketamine use has been observed (DrugScope, 2005). Indeed 
recently it was found that 0.8% of 16-24 year-olds had used ketamine in the last 
year (Murphy & Roe, 2007). Furthermore, surveys of club goers have found a much 
higher incidence of recreational ketamine use (43% of club goers surveyed; 
Mixmag, 2004). Although data on illicit drug use is not robust, it nevertheless 
provides an indication of rates of ketamine use in the dance club community. From 
January 2006, ketamine has been classified a class-C controlled drug in the UK.
4.2 Ketamine as a drug model o f the symptomatology characteristic ofpsychoses
Acute ketamine has been utilised to explore a ketamine model of psychoses. 
The model proposes glutamatergic dysfunction for symptomatology, and therefore 
for antipsychotic treatment. In contrast to amphetamine, which mimics only 
positive psychotic symptomatology (i.e. delusions and hallucinations), studies 
investigating ketamine-induced effects have found evidence of a full range of 
symptomatology (positive, negative and cognitive) characteristic of the psychoses. 
However these studies have never been reviewed.
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An important question researchers are beginning to pose is whether acute or 
chronic ketamine administration better models the symptomatology which is 
deemed characteristic of the pre-psychotic, acute or chronic states experienced by 
individuals diagnosed with psychoses. In this vein, some researchers have 
suggested that acute ketamine-induced effects better model the symptomatology 
characteristic of the period of time prior to the emergence of fully developed 
psychotic phenomenology (Corlett et al., 2006 & 2007; Pomarol-Clotet et al.,
2006), which some term the prodrome (McGorry et al., 1995, cited in Comblatt, 
Lencz, & Obuchowski, 2002). For the purposes of this review, the author 
differentiates between acute and chronic effects of ketamine. In addition, the author 
considers the degree of similarity between the type of symptomatology ketamine 
mimics and the symptomatology deemed characteristic of the different states 
experienced by individuals with diagnoses (i.e. pre-psychotic, acute, chronic), in 
order to consider which state acute and chronic ketamine models may most closely 
represent.
5. The functional psychoses
5.1 The continuum model
There is a growing movement within British Psychiatry and Psychology to 
leave behind what has historically been termed the ‘Kraepelinian dichotomy’ , in 
favour of a ‘dimensional’ conceptualisation of functional psychoses. Current 
diagnostic systems (DSM-IV: APA, 1994; ICD-10: WHO, 1992) attempt to 
distinguish between schizophrenia and bipolar disorder categorically. However
A differentiation held ‘true’ in Western Psychiatry since Emil Kraepelin (1919), which assumes 
schizophrenia and bipolar affective disorder are distinct entities with separate underlying 
neurobiological processes and interventions.
22
Murray et al. (2004) note that in clinical actuality precise symptomatic distinction 
between disorders is not possible, (with the category of schizoaffective disorders 
testifying to this). There is increasing recognition that individuals across 
categorically defined psychoses have both key first-rank Schneiderian3 (FRS), and 
mood symptomatology (Conus, Bdel-Baki, Harrigan, Lambert, & McGorry, 2004; 
Murray et al., 2004). Indeed, it has been suggested that FRSs should be considered 
symptoms of the psychoses rather than symptoms of schizophrenia specifically 
(Peralta & Cuesta, 1999, cited in Gonzalez-Pinto, 2003a). Evidence from genetic 
studies also indicates there is not a ‘neat’ biological distinction between 
schizophrenia and bipolar affective disorder (see Craddock & Owen, 2005 for key 
evidence). Thus, a more valid and reliable alternative to this categorical 
conceptualisation is the dimensional study of the symptomatology of the psychoses, 
(Andreasen & Olsen, 1982; Crow, 1980; Liddle & Barnes, 1990; Von Knorring & 
Lindstrom, 1995, all cited in Gonzalez-Pinto et al., 2003b).
In keeping with this movement, this review will not refer to specific 
diagnostic DSM-IV or ICD-10 classifications (except in section 5.2), but will take 
the position that psychotic and cognitive symptomatology may be present across 
the psychoses, to differing degrees. The review will refer to symptomatology 
deemed characteristic of the psychoses, and its relationship with ketamine, rather 
than specific categorical diagnoses, such as schizophrenia. This approach is in line 
with Abi-Saab et al. (1998) who suggest drug models may prove better at offering 
insight into the pathophysiology of psychotic symptomatology in general, rather 
than specific DSM-IV or ICD-10 diagnoses.
3 The main first-rank Schneiderian symptomatology (FRSS) consists o f delusions, hallucinations and 
formal thought disorder. For decades FRSS have been considered the core symptomatology o f the 
psychotic condition (Jaspers, 1963, cited in Gonzalez-Pinto et al., 2003a), where the term psychosis 
has been synonymous with ‘schizophrenia’.
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5.2 Categorisation o f symptomatology characteristic o f the psychoses
5.2.1 Why is categorisation important?
If ketamine is to qualify as a useful model of the symptomatology 
characteristic of the psychoses, it must induce its core symptomatology. Prior to the 
evaluation of the ketamine model of the psychoses, it is therefore necessary to 
consider the conceptualisation of this core symptomatology.
Over the years, many theorists have proposed various factor models of the 
psychoses, ranging from one to eight factors (see Serretti et al., 2001 for overview), 
which indicate symptomatology is not unidimensional. Serretti and Oliati (2004) 
note that recently, factorisation has also been introduced to understand other 
psychoses. The factor model deemed most useful for the purposes of this review is 
the five-factor model (Lindenmayer, Bemstein-Hyman, & Grochowski, 1994; 
Lindenmayer, Bemstein-Hyman, Grochowski, & Bark, 1995a; Lindenmayer, 
Grochowski, & Hyman, 1995b), which has demonstrated validity and reliability 
across different levels of chronicity, age groups and cultures. This model proposes 
symptomatology characteristic of the psychoses can be categorised into five 
separate, but coexisting components: negative and positive psychotic
symptomatology, manic symptomatology (excitement, poor impulse control, 
hostility, tension), depression / anxiety (anxiety, guilt feelings, depression, somatic 
concern, preoccupation), and cognitive symptomatology (conceptual 
disorganisation, disorientation, difficulty in abstract thinking, mannerisms and 
posturing, poor attention). The best replicated of these dimensions are the positive 
and negative psychotic components, and the manic and depression / anxiety 
components (Wolthaus et al., 2000), even in populations of individuals with 
heterogeneous psychoses (Serretti & Oliati, 2004; Ventura, Nuechterlein, Subotnik,
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Gutkind & Gilbert, 2000). However cognitive symptomatology is notoriously 
neglected, despite it being evident in all people with psychoses.
As positive and negative psychotic symptomatology have been recognised 
as core to the presentation of psychoses from the outset (e.g. Crow’s Type I and II 
schizophrenia, 1980; FRSs, Schneider, 1959), this review will specifically consider 
ketamine’s ability to model them. Further, as there is virtually irrefutable evidence 
that cognitive dysfunction (not secondary to medication, institutionalisation or 
symptomatology, and largely stable over time), which manifests years before the 
development of overt psychotic symptomatology, is a core component of the 
psychoses (Comblatt, Obuchowski, Roberts, Pollack & Erlenmeyer-Kimling, 1999; 
Erlenmeyer-Kimling et al., 2000; Walker, Diforio & Baum, 1999, all cited in Bilder 
et al., 2006), this review will also specifically consider ketamine’s ability to induce 
such deficits.
5.2.2 Positive psychotic symptomatology
Schneider (1959) advocated an arbitrary checklist of first-rank 
schizophrenic symptoms, which rapidly gained favour as they were ‘positive’ (i.e. 
reflecting an excess of ‘normal’ behavior), and were therefore definable and reliably 
rateable. These included delusions, hallucinations and formal thought disorder. 
Mackay (1980) argued that florid, positive symptoms occur in acute psychoses, 
often appearing at times of stress.
5.2.3 Negative psychotic symptomatology
In the early 20th Century, Kraeplin’s psychiatric disorder of dementia 
praecox isolated a fundamental set of symptomatology with a very poor prognosis 
and a chronic course. This set of symptomatology is now termed negative 
symptomatology (reflecting a loss of ‘normal’ behavior). Herbener and Harrow
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(2001) note that many studies have demonstrated the presence of negative 
symptomatology in individuals with heterogeneous psychoses. Although the main 
features of negative symptomatology are recognised as flat affect, poverty of speech 
(alogia), and anhedonia (Moller et al., 1994), there is still considerable diversity 
within the literature regarding its exact definition.
5.2.4 Cognitive symptomatology
There is irrefutable evidence that individuals who experience psychotic 
symptomatology also present with dysfunction across multiple cognitive domains, 
including learning and memory, executive functions, attention, language, spatial 
abilities, and general intelligence (Heinrichs & Zakzanis, 1998, cited in Murray et 
al., 2004). However neither ICD-10 nor DSM-IV criteria include a measure of 
cognitive dysfunction. Although there is debate regarding the onset of cognitive 
dysfunction, there is general agreement that this neurodevelopmental variance is 
present early in life, and that by the time of the first episode, deficits are large4. 
Cognitive impairments provide a superior predictor of a range of functional 
outcomes (e.g. ability to maintain social relationships, keep a job and function 
independantly), in comparison to psychotic symptomatology (Elvevag & Goldberg, 
2000, cited in Selva et al., 2007).
5.3 Different states experienced by individuals with psychoses
The psychoses literature has attempted to determine the pattern of positive 
and negative psychotic symptomatology, and cognitive dysfunction which best 
characterises and differentiates between a pre-psychotic, acute and chronic state 
experienced by individuals with idiopathic psychoses. Therefore, as well as 
considering they type of symptomatology mimicked by ketamine (i.e. positive,
4 Bilder et al. (2000) approximate neurodevelopmental deficits at first episode to equal 1.5 standard 
deviations, compared to healthy comparison groups.
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negative and cognitive), this review will also consider whether acute and chronic 
ketamine reliably induced symptomatology which appears characteristic of any of 
the above states. This endeavour is in line with Abi-Saab et al. (1998), who 
suggested ‘...different drug models might more accurately portray a subgroup of 
symptoms at different stages and / or specific phases of the illness’, (pg 105).
This endeavour is complex as the states described below are constructs 
created by medicine and science on the basis of characteristic patterns of 
symptomatology. Similar symptomatology is present within each state, and hence 
the states are not clearly separable categories. The subsections below (5.3.1 & 
5.3.2) will consider how each state has been defined (i.e. the symptomatology that 
is deemed characteristic of the state) in the literature, and will indicate how the 
literature proposes the states can most usefully be differentiated.
5.3.1 Pre-psychotic state
There is widespread recognition of a state prior to the emergence of fully- 
manifest psychotic symptomatology, often referred to as ‘the prodrome’ (McGorry 
et al., 1995, cited in Comblatt et al., 2002). Whether this state should be termed the 
‘prodromal state’ is a theoretical matter beyond the scope of this review. For the 
purposes of this review this state will be termed the ‘pre-psychotic’ state (in line 
with Mameros, Pillmann, Haring, Balzuweit, & Bloink, 2005), so as to be inclusive 
of the two most significant approaches used to define the prodrome; the ‘basic 
symptom’ (Huber, 1980; Klosterkotter, Hellmich, Steinmeyer & Schultze-Lutter, 
2001), and ‘ultra-high risk’ (Yung & McGorry, 1996; Yung et al., 1998) 
approaches. Indeed, these 2 approaches are increasingly being combined in the 
‘prodrome of psychoses’ literature, such as in the German Research Network on 
Schizophrenia studies (Hafner, Maurer & Ruhrmann, 2004, cited in Simon et al.,
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2007), and the European Prediction of Psychosis studies (Klosterkotter, Ruhrmann, 
Schultze-Lutter, Salokangas & Linszen, 2005, cited in Simon et al., 2007).
It is proposed that ‘basic symptoms’ describe the earliest, subtle, sub- 
clinical and self-experienced disturbances of thought processes, perception, 
motivation and affect, which initially occur during the pre-psychotic state. It has 
been argued the ‘ultra-high risk’ criteria capture unusual experiences occurring 
further into the development of fully-manifest psychotic symptomatology (Simon et 
al., 2007), and can include intermittent and attenuated positive symptomatology. 
Basic symptoms and unusual experiences captured by the ultra-high risk criteria are 
proposed to be characteristic of the pre-psychotic state alone. Although some basic 
symptoms may also be apparent during the chronic state, once idiopathic psychoses 
have been diagnosed (Gross, 1997), this latter state is characterised by negative 
psychotic symptomatology, a significant degree of cognitive impairment, and a 
history of fully-manifest positive psychotic symptomatology, not the presence of 
basic symptoms. Furthermore, it is argued that a much higher level of basic 
symptoms is experienced during the pre-psychotic state in comparison to the 
chronic state. As noted above, the states experienced by individuals with idiopathic 
psychoses are constructs which share symptomatology. Therefore, it is unsurprising 
that there may be some overlap of symptomatology between states. This review is 
not a critique of the state constructs, and so further consideration of this matter is 
beyond the scope of this paper.
The pre-psychotic state can last between 1-5 years (Yung et al., 2003), and 
is characterised by sub-clinical, attenuated positive and negative symptomatology, 
mood changes, cognitive dysfunction and functional impairments (Yung & 
McGorry, 1996). For example, Schultze-Lutter, Ruhrmann, Hoyer, Klosterkotter
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and Leweke (2007) found evidence for disturbances of attention, thought, 
perception, and motor action in a sample of outpatients without any diagnosis, who 
went on to develop psychotic symptomatology, in comparison to a clinical control 
group. Both prospective and retrospective studies have shown attenuated negative 
symptomatology is characteristic of the pre-psychotic state (e.g. Hafner, Loftier, 
Maurer, Hambrecht & Heiden, 1999; Klosterkotter, Gross, Huber & Steinmeyer, 
1997; Tsuang et al., 2000, all cited in Comblatt el al, 2002), very often developing 
over months and years before positive symptomatology is observed. Theorists 
believe a progressive pathway of deterioration exists, whereby initial non-specific, 
attenuated negative symptomatology and cognitive dysfunction are followed by the 
development of attenuated positive symptomatology, which gradually increase in 
intensity, until they reach a psychotic level (Comblatt et al., 2002). Indeed, it has 
been suggested that attenuated positive symptomatology is characteristic of those 
individuals closest to developing fully-manifest psychotic symptomatology (Simon 
et al., 2006). Furthermore, many studies have suggested a trend, which indicates 
that individuals with first-episode psychosis are significantly more cognitively 
impaired than individuals in a ‘pre-psychotic period’ (e.g. Keefe et al., 2006; 
Niendam et al., 2006).
Initially, sub-clinical symptomatology may only be perceptible by the 
individual (Gross, 1997). As the attenuated symptomatology becomes more 
pronounced they may also then be observed in behaviour (e.g. more frequent 
thought blocking can start to interfere with participation in conversations). The pre- 
psychotic symptomatology fluctuates in occurrence and severity, and is dependant 
on demands and stress (Gross, 1997). The symptomatology experienced during this 
state is proposed to be the early stages of the corresponding full-blown
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symptomatology of the psychoses (Klosterkotter, Ebel, Schultze-Lutter, F & 
Steinmeyer, 1996).
There is a growing interest in understanding the pre-psychotic state, and its 
ability to predict the development of psychotic symptomatology. Traditional 
treatment for the psychoses aims to reduce the duration of untreated active 
psychotic symptomatology, through the speedy provision of antipsychotic drugs 
following diagnosis. In contrast, current opinion is increasingly proposing the 
treatment of individuals in the pre-psychotic state, in the hope of attenuation, delay 
or even prevention of fully-manifest psychotic symptomatology. If ketamine were 
able to reliably model the construct of the pre-psychotic state as defined in the 
literature (which some authors have proposed), it may further understanding in this 
area. A caveat regarding this approach is the high ‘false-positive’ rate. Drake and 
Lewis (2005) estimate only 25 - 40% of those who present with brief or attenuated 
psychotic symptomatology progress to fully-manifest psychotic symptomatology 
within the year, whilst some never do.
5.3.2 Acute and chronic states
The presence of an acute, relatively short-lived, but potentially relapsing 
state characterised by positive psychotic symptomatology has been recognised 
since the beginning of the 20 Century. Crow (1980) provided one of the first 
attempts to theoretically differentiate this acute state from a chronic state of 
deterioration. He proposed two distinct syndromes; Type I, characterised by 
positive psychotic symptomatology, an acute course and good prognosis, and Type 
II, characterised by negative (Moller et al., 2002) and cognitive symptomatology, a 
chronic course, and poor outcome. Crow (1980) argued that these syndromes 
represented different dimensions of pathology, but can occur together.
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There is a large body of literature which suggests chronic states of psychotic 
symptomatology are associated with particularly evident cognitive deficits (Murray 
et al., 2004), however studies have also demonstrated cognitive deficits in 
individuals with acute states of psychotic symptomatology (Murphy et al., 1999; 
Qureshi & Frangou, 2002; Sweeney, Kmiec & Kupfer, 2000, all cited in Murray et 
al., 2004). In particular, memory and specific executive function deficits are 
characteristic of both acute and chronic states of psychotic symptomatology (Chan, 
Kwok, Chiu, Lam, Pang & Chow, 2000; Fossati, Amar, Raoux, Ergis & Allilaire,
1999). The literature shows a mixed picture regarding the temporal stability of 
cognitive deficits, with some studies (including longitudinal ones) providing 
evidence that the neuropsychological profile remains stable (see Goldberg et al., 
1993a; Nopoulos, Flashman, Flaum, Arndt & Andreasen, 1994, all cited in Gur, 
Ragland & Gur, 1997), whereas others indicate declining cognitive function over 
time (Sweeney, Haas & Li, 1992, cited in Gur et al., 1997). Studies clearly provide 
mixed results.
Critiques of this cognitive research include the proposition that psychotic 
symptomatology compromises cognitive functioning (e.g. emotional and 
motivational deficits can affect performance on cognitive tasks), for which many 
studies do not directly control. Nevertheless, Mortimer (1997) argued that the 
influence of psychotic symptomatology on cognition is not so clear, citing cross- 
sectional studies which found equivalent levels of cognitive impairment in different 
groups of people with psychotic symptomatology, with a wide range of ‘illness’ 
duration (Goldberg et al., 1993b; Heaton, Paulsen & McAdams, 1994; Hyde, 
Nawroz & Goldberg, 1994), and studies which demonstrated comparable levels of 
cognitive deficit in people with first-episode and chronic psychotic symptomatology
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(Hoff, Riordan, O’Donnell, Morris & De Lisi, 1992). Furthermore, first-onset 
psychosis typically coincides with an age when it adversely affects educational 
attainment, and individuals with a more chronic presentation of any psychoses will 
have received more antipsychotic medication, which may contribute to further 
cognitive dysfunction.
Currently, most authors agree on demarcating acute states of the psychoses 
from some form of chronic, mostly deteriorating state (Pillmann & Mameros, 
2003). The current British differentiation between acute and chronic states of 
psychotic symptomatology mainly rests upon the relative chronicity of the 
presentation. It is suggested that both states involve FRS delusions and / or 
hallucinations, however chronic states involve deterioration from a premorbid level 
of functioning and continuous signs of disturbance for more than 6 months (Van Os 
et al., 1995).
Recently, this distinction has been further delineated as the presence of 
‘acute and transient psychotic disorders’ (ATPD; ICD-10: WHO, 1992), and its 
DSM-IV equivalent, ‘brief psychotic disorder’ (BPD; DSM-IV: APA, 1994) have 
been proposed. These diagnoses refer to acute states with rapid onset and 
resolution, and an atypical course (Pillmann & Mameros, 2003). Despite potential 
relapse to the acute state, there is often full remission in between, with no transition 
to a chronic degenerative presentation. Nevertheless significant proportions do 
develop more chronic presentations (Kuruvilla, Thangadurai, Gopalakrishnan, 
Kurien & Jacob, 2006). Therefore it appears there may be a core group of 
individuals with ATPD, whilst others given this diagnosis are developing more 
chronic presentations. Interestingly, the positive symptomatology experienced by 
individuals diagnosed with ATPD differs to that experienced in other psychoses.
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For example, the former experience significantly fewer hallucinations and bizarre 
delusions (such as thought insertion, thought broadcasting, delusions of control), 
and much more rapidly changing delusions, in comparison to the latter (Mameros, 
Pillmann, F., Haring, A., Balzuweit, S., & Bloink, 2003).
For the purposes of this review, the term acute state will be used to refer to a 
period of time, characterised by positive psychotic symptomatology, with a 
relatively brief duration (in line with Van Os et al., 1995). This acute state may be 
(although is not necessarily), embedded within a more chronic state, characterised 
by cognitive and negative psychotic symptomatology.
6. Drug models of the psychoses
6.1 Historical models
6.1.1 The dopamine hypothesis o f the psychoses
Interest in the role of neurotransmitters in the cause and treatment of 
psychotic symptomatology developed in the 1950s. The classic dopamine (DA) 
hypothesis of the psychoses (Carlsson & Lindqvist 1963, cited in Kegeles et al.,
2000), which suggests that disturbed and hyperactive dopaminergic function is a 
central aspect of the pathogenesis of FRS positive symptomatology, is one of the 
earliest and most influential of the theories. The DA hypothesis was developed on 
the basis of several consistent observations within the literature (For summaries see 
Baumeister & Francis, 2002; Kahn & Davidson, 1995). Initially, it was observed 
that recreational use of amphetamine and cocaine (particularly after larger doses 
and / or prolonged use) produces a transient, psychotic-like state in healthy 
participants, dominated by positive symptomatology, such as auditory 
hallucinations and akathisia (Angrist, Sathananthan, Wilk & Gershon, 1974;
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Janowsky & Risch, 1979; Sherer, Kumor, Cone & Jaffe, 1988, all cited in Krystal et 
al., 2005). In a systematic review, Curran, Byrappa and McBride (2004) found that 
single, moderate doses of dopamine agonists resulted in brief increases in positive 
psychotic symptomatology in 50-70% of participants with pre-existing psychotic 
symptomatology, especially those with a history of positive symptomatology. It has 
been found that dopamine agonists increase dopaminergic transmission mainly due 
to increased DA release in the mesolimbic pathway (O’Connor, 1998).
The classic DA hypothesis was strengthened by the observation that drugs 
that blocked DA receptors (DA antagonists, which formed the basis of atypical 
antipsychotics such as haloperidol and chlorpromazine), effectively controlled 
positive psychotic symptomatology, whether naturally occurring or chemically 
induced, despite having limited or no efficacy with negative symptomatology 
(O’Connor, 1998). In addition, studies investigating DA’s metabolite, homovanillic 
acid, in plasma (pHVA), indicated that when participants with psychotic 
symptomatology discontinue atypical antipsychotics, an increase in pHVA level is 
observed, concurrent with a worsening of symptomatology. As atypical 
antipsychotics are especially effective at improving positive symptomatology, and 
as pHVA may primarily reflect striatal DA activity, increased DA activity in the 
striatum may be associated with the positive symptoms of psychosis (Kahn & 
Davidson, 1995).
Although this theory dominated for more than 3 decades, the DA hypothesis 
in its original form cannot account for all the core symptoms of psychosis, which 
include not only positive psychotic symptomatology, but also negative and 
cognitive symptomatology. Theorists therefore attempted to modify the DA 
hypothesis, on the basis of studies (Kahn & Davidson, 1995 for summary), which
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indicated negative and cognitive symptomatology may be associated with decreased 
DA function in the prefrontal cortex. It was hence proposed the psychoses may be 
characterised by chronic dopaminergic deficiency (associated with negative and 
cognitive symptomatology), which under environmental stress precipitates episodes 
of acute DA overactivity (associated with positive symptomatology), involving 
different DA receptor systems (Mackay, 1980).
Boeijinga, Soufflet, Santoro and Luthringer (2007) note the DA hypothesis 
is still unable to satisfactorily account for negative symptomatology, a chronic state 
of deterioration after repeated relapses, and cognitive dysfunction observed in the 
multitude of psychotic presentations. Further challenge to the DA hypothesis 
stemmed from the advent of atypical antipsychotics which do not act solely upon 
dopamine neurotransmitters, and are more efficacious than typical (older), DA 
specific antipsychotics. According to Mackay (1980), ‘It would be naive and 
counterproductive to suggest that (DA) is the only, or even the most important 
abnormality’, (p. 382).
6.1.2 The serotonin hypothesis o f  the psychoses
In 1954, it was first observed that Lysergic acid diethylamide (LSD) 
possessed hallucinogenic properties. As a result, a similarity was proposed between 
these properties and psychotic symptomatology. As LSD has a mainly serotonergic 
action (5-hydroxytryptamine, 5HT), it was proposed that its psychotropic effects 
were associated with a relative serotonin (5HT) dysfunction. In addition, controlled 
studies with individuals diagnosed with chronic psychoses demonstrated that a 
selective 5HT receptor antagonist (ritanserin), alleviated psychotic 
symptomatology, showing specificity for negative symptomatology. Such findings 
formed the basis of the serotonin hypothesis of psychosis, which proposed negative
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psychotic symptomatology could be explained serotonergically (Woolley & Shaw, 
1954, cited in Baumeister & Hawkins, 2004).
The original hypothesis was soon revised, due to numerous contradictory 
findings. By 1956, Woolley & Shaw proposed both a deficit and an excess of 5HT 
were equally plausible explanations of psychotic symptomatology (Baumeister & 
Hawkins, 2004). Further research provided varied findings (Iqbal & van Praag, 
1995 for review), and therefore the hypothesis was cast aside during the 1960s and 
1970s. The development o f ‘atypical’ antipsychotics (currently the antipsychotics of 
choice within British psychiatry, e.g. olanzapine, risperidone, clozapine), which 
have both serotonin and DA actions, renewed interest in the hypothesis, and more 
importantly has led to a combined 5HT / DA hypothesis of the psychoses.
6.2 The interaction o f dopamine and serotonin systems
Evidence strongly supports a 5HT / DA interaction (Iqbal & van Praag,
1995). For example, atypical antipsychotics have had a profound impact on the 
management of psychotic symptomatology, as 5HT antagonist action appears to 
augment the actions of DA receptor antagonists, thus demonstrating an improved 
efficacy in managing negative symptoms (Meltzer, 1992, as cited in Tamminga,
1998). Indeed, O’Connor (1998) notes that serotonin antagonism of DA activity in 
the prefrontal cortex may be the key to alleviating the negative psychotic 
symptomatology. Although atypical antipsychotics have the potential to attenuate 
both positive and negative symptomatology, up to 75% of individuals with 
psychotic symptomatology still experience significant active psychotic and 
cognitive symptomatology whilst undergoing atypical antipsychotic therapy 
(Tamminga, 1998). Therefore, it is evidence that the DA / 5HT interaction may not 
provide the whole picture.
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6.3 The glutamate hypothesis o f the psychoses
The glutamate hypothesis of the psychoses originated from observations that 
glutamate releasers (e.g. phencyclidine and ketamine), appear to induce 
symptomatology resembling that observed in the psychoses better than other 
compounds (Carpenter, 1999). Individuals with idiopathic psychoses report that 
experiences on PCP more closely resembled their individual acute psychotic 
symptomatology than any other psychoactive drugs (Ban, Lohrenz & Lehmann, 
1961; Luby, Cohen, Rosenbaum, Gottlieb & Kelley, 1959, both cited in Carpenter,
1999). Induced effects include perceptual changes and delusions, poverty of speech 
and thought, negative symptomatology, agitation and memory disturbance 
(Newcomer & Krystal, 2001 for review). Due to these effects, and the recognition 
that other drug models cannot account for the full range of symptomatology 
observed in the psychoses, the ability of PCP and ketamine to provide a more 
compelling drug model of the psychoses has been of increasing interest.
Initially, the anaesthetic phencyclidine (PCP) was investigated but due to its 
toxicity (Rothman & Olney, 1987, cited in Abi-Saab et al., 1998), researchers 
turned to its structural analogue, ketamine, which causes reactions similar to, but 
not as severe as those caused by PCP. The ‘clinical syndrome’ produced by PCP 
and ketamine led to the glutamatergic hypothesis of the psychoses, which proposes 
glutamatergic NMDA receptor hypofunction (which ketamine and PCP induce), 
may be responsible for the psychotic symptomatology and cognitive dysfunction 
observed in the psychoses (Bunney, Bunney & Carlsson, 1995; Coyle, 1996; Javitt 
& Zukin, 1991; Olney & Farber, 1995, all cited in Abi-Saab et al., 1998). 
Newcomer and Krystal (2001) suggest the mechanism itself might involve NMDA 
receptor dysfunction, or upstream / downstream effects which can be reproduced by
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blocking NMDA receptors. The glutamate hypothesis is currently one of the leading 
neurochemical theories of the psychoses.
Further evidence for the hypothesis comes from pharmacological, post­
mortem and clinical studies, which implicate the glutamatergic NMDA receptor in 
the pathophysiology of psychotic symptomatology (Javitt & Zukin 1991; Olney & 
Farber 1995, both cited in Boeijinga et al., 2007). For example, postmortem studies 
reveal NMDA receptor expression and function is altered in the brains of 
individuals with psychotic symptomatology (see Millan, 2005 for studies, cited in 
Large, 2007). Furthermore, PCP triggers acute psychotic symptomatology in 
stabilised individuals with chronic psychotic symptomatology, lasting up to several 
months (Stelzer, Simon, Kovacs & Rai, 1994, cited in Newcomer & Krystal, 2001), 
whereas LSD causes only a brief hallucinogenic state which does not last longer in 
individuals with psychotic symptomatology than in healthy controls (Domino & 
Luby, 1981, cited in Newcomer & Krystal, 2001). Some, but not all, genetic data 
suggests an association between NMDA receptor gene polymorphisms and 
psychotic symptomatology (Itokawa et al., 2003; Makino, Shibata, Ninomiya, 
Tashiro & Fukumaki, 2005, both cited in Large, 2007).
The above findings suggest the psychotic and cognitive symptomatology 
experienced by individuals with idiopathic psychoses cannot be fully explained by 
the DA hypothesis, or indeed the interaction between DA and serotonin systems. 
Furthermore, as atypical antipsychotics cannot attenuate or eliminate all psychotic 
symptomatology, glutamatergic NMDA receptors are increasingly important in the 
development of novel antipsychotic medication, as their dysfunction may be a 
central feature of the psychoses.
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6.4 The interaction o f glutamate and dopamine systems
It has been proposed that NMDA receptor antagonists induce 
psychotomimetic effects via an interaction with the DA system (Boeijinga et al., 
2007), however the neurobiology of this relationship remains unclear (Rabiner, 
2007 for review). It is both suggested that primary abnormalities in DA 
transmission might reduce glutamate release onto NMDA receptors (Olney & 
Farber, 1995, cited in Newcomer & Krystal, 2001), or NMDA receptor 
hypofunction may secondarily alter DA transmission (Adams & Moghaddam, 1998; 
Grace, 1991, both cited in Newcomer & Krystal, 2001). Kegeles et al. (2000) found 
evidence for the latter theory, with acute ketamine administration, which causes 
NMDA blockade, significantly increasing the effect of amphetamine on striatal 
dopamine release. This study was limited by its small sample and an apparent lack 
of randomisation.
7. A review of acute and chronic ketamine-induced effects
7.1 Methodological issues
There are several methodological limitations which constrain the 
interpretation of data from ketamine studies. Firstly, the majority of studies use a 
crossover design, which does not control for tachyphylaxis (i.e. a developed 
tolerance for ketamine, after repeated administration). Secondly, the majority of 
studies (certainly those conducted in the 1990s), investigating the psychotomimetic 
effects of ketamine utilised the Brief Psychiatric Rating Scale (BPRS: Overall, 
1974, cited in Newcomer et al., 1999a), which is not specific or selective for 
symptomatology characteristic of the psychoses. In addition, using less sensitive 
measures may have prevented the detection of more subtle ketamine-induced
39
effects. More recently authors have attempted to overcome this limitation (e.g. 
Pomarol-Clotet et al., 2006). Finally, prior to Newcomer et al.’s studies in 1999, 
ketamine plasma levels were not monitored, which limits the interpretations based 
upon this data.
7.2 Ketamine as a model o f  positive and negative psychotic symptomatology: Does 
the ketamine model o f the psychoses have clinical validity and specificity?
7.2.1 The effects o f acute ketamine in healthy participants
The majority of investigations into the effects of acute ketamine have been 
completed using challenge studies with healthy participants. Such studies involve 
the investigation of symptomatology through the transitory manipulation of NMDA 
receptor function with an acute, subanaesthetic dose of ketamine, in a controlled 
environment. Krystal et al. (1994) and Malhotra et al. (1996) were the first to use 
this methodology to explore acute ketamine-induced effects.
They found ketamine induced a ‘clinical syndrome’, characterised by 
positive and negative psychotic-like symptomatology (including thought disorder, 
blunted affect, emotional withdrawal), as well as perceptual alterations similar to 
dissociative states (e.g. altered body perception, depersonalisation, derealisation and 
distorted sensory perception). As the phenomenological profile resembled a range 
of psychotic symptomatology so closely, acute ketamine was proposed as a drug 
model of the psychoses. Therefore the acute ketamine model of the psychoses 
appeared to have good clinical validity. Initially, it appeared the model had limited 
clinical specificity, as clinical phenomena, not typical of the psychoses, were also 
noted (e.g. mood elevation and dissociation). With very limited data, the question of
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whether the acute ketamine model was reliable remained; could it consistently 
model symptomatology characteristic of the psychoses in further studies?
Using visual analog scales, Radant, Bowdle, Cowley, Kharasch and Roy- 
Byme (1998) observed dose-dependant effects of ketamine in 10 healthy young 
men in a randomised, single-blind, placebo-controlled crossover design. Findings 
indicated significant evidence of ideas of reference, hearing voices, perceptual 
alterations (including changed environmental perception, body perception, and 
passage of time), difficulties controlling thoughts, and feelings of unreality 
(evidence of dissociative effects). In a benchmark crossover study (utilised to 
minimise systematic bias between the groups), Newcomer et al. (1999a) also found 
dose-dependant, fully reversible and time-limited effects of ketamine. Results 
indicated that as time progressed from baseline to infusion, to post-washout, scores 
on both the negative subscale (blunted affect, emotional withdrawal, & motor 
retardation) and positive subscale (hallucinations, conceptual disorganisation & 
unusual thought content) of the abbreviated BPRS rapidly increased and then 
decreased after the infusion, within the high dose (0.27mg/kg: replication of higher 
dose in Krystal et al., 1994), and moderate dose (0.081 mg/kg) conditions, thus 
indicating the psychotomimetic properties of higher doses of ketamine. In addition, 
evidence of dose-dependant avolition, apathy, anhedonia, asociability and affective 
flattening were found on the Scale for the Assessment of Negative Symptoms 
(SANS: Andreasen, 1982). The design of this study was robust, and thus its 
findings can be taken as indicative of the model’s reliability. Hence it initially 
seemed that the acute ketamine model best represented the acute state experienced 
by individuals with idiopathic psychoses, as positive and negative psychotic 
symptomatology appeared to be reliably experienced when measured by the BPRS.
41
Prior to Newcomer et al. (1999a), ketamine challenge studies were 
confounded by a lack of steady-state infusion, limited dose conditions, and / or 
failure to measure plasma ketamine and metabolite levels during the study (which 
meant levels could be above or below that stated). Newcomer et al. (1999a) 
overcame these obstacles. Nevertheless, their study did have some limitations, 
including an exclusively young male cohort of participants, a relatively small 
sample size (increasing the probability of Type II error), and one dropout after 
randomisation.
Similarly designed crossover trials have since replicated Newcomer et al.’s 
(1999a) dose-dependant findings, (Anand et al., 2000; Boeijinga et al., 2007; 
Hetem, Danion, Diemunsch & Brandt, 2000; Morgan, Mofeez, Brandner, Bromley 
& Curran, 2004a), providing further evidence for the reliability of the ketamine 
model of the psychoses. Even low doses of ketamine (0.27 mg/kg over the first 10 
min, followed by 0.12 mg/kg over 50-min), have been found to significantly 
increase positive and negative psychotic-like symptomatology, in comparison to 
placebo (Parwani et al., 2005). This study also investigated levels of perceptual 
alteration following a low dose of ketamine. Qualitatively, they noted participants 
reported alterations in body perception (e.g. floating sensation, being pulled), self­
perception (i.e. reports of depersonalisation and a sense of unreality), environmental 
perception (e.g. things falling away from beneath them, objects appearing 
distorted), motor retardation (e.g. feeling heavy), and unusual thought content (e.g. 
jumbled thoughts). Interestingly, the perceptual alterations induced by acute 
ketamine (e.g. impaired body perception, environmental perception, time 
perception, and feelings of unreality), are characteristic of the pre-psychotic state 
rather than the acute state (Hamilton, 1985, cited in Anand et al., 2000).
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Adler, Goldberg, Malhotra, Pickar and Breier (1998) conducted a double­
blind, randomised, placebo-controlled crossover study which aimed to extend 
previous findings that acute ketamine appeared to induce thought disorder. Their 
study utilised a more valid measure of formal thought disorder (Scale for the 
Assessment of Thought, Language and Communication, TLC: Andreasen, 1978, 
cited in Adler et al., 1998), than had previously been used (i.e. BPRS). Findings 
indicated significant formal thought disorder during ketamine infusion, following a 
loading dose of 0.12mg/kg, in comparison to placebo. Using the Positive and 
Negative Syndrome Scale (PANSS: Kay, Opler & Lindenmayer, 1989), Krystal et 
al. (2005) also found evidence of several aspects of thought disorder (conceptual 
disorganisation, difficulties in abstract thinking and poor attention), with low dose 
ketamine administration (0.23mg/kg), in comparison to placebo. Other ketamine- 
induced effects included psychotic-like delusions, and negative psychotic-like 
symptomatology (blunted affect, emotional withdrawal, and motor retardation). 
Thus the picture developing thus far appeared to suggest acute ketamine best 
models the acute state.
Acute ketamine-induced speech disturbances (including disorganised 
speech), have also been found, resembling formal thought disorder observed in the 
psychoses (Abi-Saab et al., 1998; Krystal et al., 2003). For example, Covington et 
al. (2007) analysed speech samples from two prior experiments, (a between-groups 
study of individuals diagnosed with psychosis and comparable healthy controls, and 
a within-subjects challenge study with healthy participants), using software they 
developed. Results indicated acute ketamine resulted in significantly more 
repetitious speech in healthy participants, which was comparable to the significant 
level of repetitious speech detected in participants with idiopathic psychoses.
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Interestingly, repetitious speech was observed more frequently following acute 
ketamine, than in individuals with idiopathic psychoses. These results should be 
interpreted with caution, as the study used small-scale experiments, and was the 
first to utilise this novel computer speech analysis technique. Nevertheless, findings 
were in line with Adler et al. (1999), who also found a larger increase in 
repetitiousness following acute ketamine, than in individuals with idiopathic 
psychoses.
Diverse speech disturbances are core to the psychoses (McKenna & Oh, 
2005 for review), as they are proposed to form part of formal thought disorder, a 
FRS. The most marked disturbances tend to be failure to follow a discourse plan, 
repetition / perseveration, or drifting aimlessly, thus failing to convey the originally 
intended information. Evidence of such speech disturbances following acute 
ketamine use further add weight to the suggestion that acute ketamine best models 
the acute state.
The majority of earlier studies investigating acute ketamine-induced effects 
did not assess symptomatology in great detail, often relying on the BPRS (not 
specific for measuring psychotic symptomatology), to capture the participants’ 
presentation. Therefore, the validity of the conclusions based upon the findings of 
earlier studies (which predominantly utilised the BPRS) have more recently been 
called into question. As a result, Pomarol-Clotet et al. (2006) attempted to provide a 
more comprehensive account of ketamine’s effects, using measures other than the 
BPRS. Evidence of ideas, or even partially held delusions of reference were 
observed in approximately half their sample, supporting previous findings (see 
above). Self-reported experiences approximating dissociation (both 
depersonalisation and derealisation), were also described. Negative psychotic-like
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symptomatology was observed (poverty of speech and affect flattening), however 
the authors suggested this may be due to ketamine’s general depressant effect on the 
central nervous system, and recommended further study into this issue. The study 
failed to find evidence of formal thought disorder, which contradicts previous 
studies (Adler et al., 1998; Krystal et al., 1994, 2005). These results need to be 
interpreted with caution, due to the study’s phenomenological design preventing 
statistical comparisons between the effects of ketamine and placebo.
Interestingly, perceptual alterations (specifically of the body, time, and the 
environment), but not hallucinations were detected. These findings were in line with 
Stone, Erlandsson & Arstad (2006, cited in Stone & Pilowsky, 2006), who found 
wide ranging ketamine-induced perceptual alterations but no true hallucinations. 
Rather, several participants reported eidetic imagery, and most reported visual 
illusions. This highlights an important point regarding the clinical validity of the 
acute ketamine model of the psychoses. Although several studies have reported the 
presence of ketamine-induced ‘hallucinations’, this may in fact be a product of the 
measure utilised (BPRS), rather than a ‘true’ finding, as the BPRS rates perceptual 
alterations on the same scale as hallucinations. Whereas the former are frequently 
induced by acute ketamine, ketamine rarely induces auditory hallucinations, 
frequently associated with the psychoses, but does (at high doses), induce complex 
visual hallucinations, which are relatively uncommon in the psychoses (Honey et 
al., 2006). Any reported ketamine-induced auditory hallucinations appear to differ 
from true hallucinations (Honey et al., 2006). This methodological confound may 
have propagated the belief that ketamine routinely induces hallucinations (Lahti, 
Weiler, Michaelidis, Parwani & Tamminga, 2001).
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The dose-dependant visual and auditory perceptual distortions and (at higher 
doses) hallucinatory-like experiences are very similar (in form but not always in 
content), to attenuated positive psychotic symptomatology. The former are reported 
during the pre-psychotic state (Freedman & Chapman, 1973, cited in Abi-Saab, 
1998), whereas hallucinations form one of the main criteria for the acute state of 
psychoses, in idiopathic psychoses. Pomarol-Clotet et al.’s (2006) findings 
therefore appear to provide evidence of limited clinical validity if the acute 
ketamine model is proposed to reproduce the acute state, as hallucinatory 
experiences do not appear to be reliably replicated with doses of the drug 
administered in challenge studies. The model does appear to have superior clinical 
validity if deemed to represent the pre-psychotic state, as acute ketamine repeatedly 
induces perceptual alterations and ideas of reference (similar to delusions), both 
characteristic symptomatology of this state of the idiopathic psychoses.
Neither perceptual alterations nor hallucinations can be explained solely by 
changes in external sensory stimuli, which suggests an internal brain mechanism 
must be involved in the generation of these phenomena. Pereira and Johnson (2003) 
proposed the neurobiological genesis involves the NMDA receptor channel, which 
functions as a coincidence-detection mechanism for afferent and reentrant signals, 
supporting conscious perception, learning, and memory formation. The findings of 
ketamine challenge studies support this hypothesis. The detailed neurobiology of 
this genesis is beyond the scope of this review, and readers are directed to Pereira 
and Johnson (2003) for more information concerning the genesis of ketamine- 
induced perceptual distortions and hallucinatory-like experiences, and thus the 
potential genesis of idiopathic psychotic perceptual distortions and hallucinations. 
Interestingly, Drake and Lewis (2005) propose specific symptomatology
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experienced during the pre-psychotic state is predictive of an imminent transition to 
fully-manifest psychotic symptomatology. They noted these include ideas of 
reference, unusual thought content, (e.g. magical thinking), perceptual 
abnormalities, marked and rapid functional decline, and social withdrawal, all of 
which are induced by subanaesthetic doses of acute ketamine.
The paranoia induced by acute ketamine in healthy participants rarely 
reaches delusional proportions, presenting rather as ‘suspiciousness’ (Bowdle et al., 
1998; Malhotra et al., 1997a), evidenced by participants believing others are talking 
about them or researchers are against them, with intact awareness that this may be 
drug-induced (Abi-Saab et al., 1998), and ideas of reference (Bowdle et al., 1998; 
Krystal et al., 1994 & 1998; Radant et al., 1998). This attenuated positive psychotic 
symptomatology is observed in the pre-psychotic state, providing further evidence 
that acute ketamine may best model this state. Indeed, during this state, individuals 
with developing psychotic symptomatology report experiencing alterations in visual 
and auditory perception, and attentional changes, such that attention is drawn to 
non-salient, irrelevant environmental stimuli (Freedman, 1974; Freedman & 
Chapman, 1973; Hemsley, 1994; McGhie & Chapman, 1961, all cited in Corlett et 
al., 2006). Furthermore, the ability to form associations (between perceptions, 
thoughts, stimuli, and events), is heightened, so much so that associations are often 
formed where none exist (Miller, 1989 & 1993; Schneider, 1930, all cited in Corlett 
et al., 2007). It is suggested that attempts to account for these strange experiences 
result in the invention of bizarre, causal structures to explain them, which manifest 
clinically as delusions (Kapur, 2003; Kapur, Mizrahi & Li, 2005).
Many studies have indicated acute ketamine induces perceptual alterations, 
theoretically proposed to be involved in delusion formation. These include changes
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in the perception of one’s own body, time, auditory and visual stimuli, (Krystal et 
al., 1994; Newcomer et al., 1999a; Pomarol-Clotet et al., 2006; Radant et al., 1998; 
Stone et al., 2006). There is a paucity of research investigating the effects of 
ketamine on association formation, its effects on attention are mixed (see cognitive 
section below). Nevertheless, in a randomised, placebo-controlled crossover study, 
Corlett et al. (2006) found evidence of heightened association formation (measured 
by prediction error), following a low dose of ketamine. Furthermore, using a 
regression analysis, it was found that participants’ drug-naive responses to 
prediction error (suggested to provide an indication of subjects’ sensitivity to 
prediction error), were significantly predictive of subsequent perceptual alterations, 
as well as ideas and delusions of reference.
Thus, although earlier studies appeared to indicate that acute ketamine may 
best represent the acute state, more recently it has been suggested that this may have 
in part been the result of the measures utilised in these earlier studies (i.e. BPRS) 
confounding interpretations. Indeed acute ketamine does not appear to reliably 
induce fully-manifest core FRSs, namely hallucinations, delusions, and formal 
thought disorder, but rather reliably induces perceptual alterations (associated with 
hallucinations and delusions), ideas of reference, delusional ideas and unusual 
thought content. Therefore, more recently it has been argued that acute ketamine 
appears to model symptomatology characteristic of the pre-psychotic state, rather 
than the acute state. This matter is still unclear, and only further acute ketamine 
studies utilising more sensitive and specific measures will assist in determining 
which state acute ketamine best models, in terms of the psychotic symptomatology 
it induces.
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7.2.2 The effects o f acute ketamine in individuals with idiopathic psychotic 
symptomatology
Several investigations have also assessed the effects of acute ketamine in 
participants with idiopathic psychoses. However these studies are limited, partly 
due to ethical issues surrounding the administration of an agent which has the 
potential to exacerbate psychotic symptomatology and cognitive deficits both 
acutely and long-term (Carpenter, 1999 for review of ethical considerations). 
Nevertheless, the consistent finding that subanaesthetic, acute doses of ketamine 
induce a mild, dose-related, short-lived increase in positive psychotic 
symptomatology provides further evidence for the clinical validity and reliability of 
the ketamine model of the psychoses (Lahti, Koffel, LaPorte & Tamminga, 1995; 
Lahti et al., 2001; Malhotra et al., 1997a).
Lahti et al. were the first group to conduct ketamine challenge studies with 
individuals with idiopathic psychoses. Initially, Lahti et al. (1995) reported that 9 
stable in-patients with psychoses experienced a significant, but short-lived increase 
in total BPRS scores 20 minutes after a ketamine infusion of 0.3mg/kg and 
0.5mg/kg. This significant increase was mainly accounted for by a significant 
increase in their BPRS ‘psychosis’ subscale scores, indicating the presence of 
significant ketamine-induced positive symptomatology. Specifically, it was noted 
that the themes and content of the ketamine-induced positive psychotic 
symptomatology were very similar to symptomatology experienced by the 
participants during acute episodes of their psychoses. This was true for delusions, 
thought disorder, and hallucinations. For example, 2 participants with a history of 
extensive paranoid delusions reactivated part of these specific delusions with 
ketamine. Some participants with a history of thought disorder became disorganised
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following the administration of ketamine, in ways characteristic of their own 
presentation of thought disorder. Furthermore, visual hallucinations were frequent 
for all participants. Whereas some of these had the quality of previous 
symptomatology, other hallucinations had more of a ‘dream-like’ quality. 
Therefore, Lahti et al.’s (1995) findings appeared to indicate that an acute dose of 
ketamine causes the re-emergence of an acute state, in individuals with chronic, 
stable psychoses.
After a period of between 4-8 weeks, in which participants were free of 
antipsychotics, 6 of the original 9 participants consented to undertake the same 
challenge study. Interestingly, Lahti et al. (1995) found that when these participants 
were haloperidol-free, they did not experience a significant increase in their total 
BPRS scores, nor in their ‘psychosis’ BPRS subscale scores, despite the former 
scores showing a non-significant trend (p< 0.07) towards worsening mental state. 
This lack of significant findings may be due to a smaller sample size, a higher 
baseline level of psychotic symptomatology, and / or pharmacokinetic factors. 
Furthermore, when the authors compared the total BPRS scores of only the 6 
participants who completed both sets of challenge studies, no significant difference 
in scores was found.
In contrast, Malhotra et al. (1997a) completed a study which found acute 
ketamine (0.12mg/kg), significantly increased both positive and negative psychotic 
symptomatology (measured by BPRS), in comparison to placebo, in 13 
antipsychotic-free individuals with idiopathic psychoses and 16 healthy controls, 
with no differences between groups in terms of the size of these increases. Both 
groups also demonstrated significantly increased thought disturbance, withdrawal 
and motor retardation. Qualitative observations also indicated conceptual
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disorganisation. In line with Lahti et al.’s (1995) data, observations of participants 
with idiopathic psychoses indicated a re-activation of their individual psychotic 
symptomatology, following acute ketamine. In this respect, ketamine differs to 
amphetamine. The latter tends to induce new symptomatology, that is not typical of 
the individual’s previous psychotic presentation (Tamminga, Lahti, Medoff, Gao, & 
Holcomb, 2003, cited in Large, 2007). Auditory hallucinations were observed in 
50% of the diagnosed group with a history of hallucinations, and increased 
suspiciousness was observed in 75% of the diagnosed group with a history of 
paranoid symptoms. This pattern was not observed in controls. However the study 
was limited by a small sample size, a lack of ketamine plasma level monitoring, and 
the use of bolus administration rather than infusion (as in Lahti et al., 1995), which 
may not have been as accurate a technique. Indeed, the differences between this 
study’s findings and those of Lahti et al. (1995) may have been due to the differing 
methods of ketamine administration, and / or differences in study design, participant 
selection, and differing ketamine doses.
More recently, Lahti et al. (2001) conducted a placebo-controlled crossover 
study which further supported previous data. They found that 20 minutes after a 
ketamine bolus, 17 participants with active, but stable idiopathic psychotic 
symptomatology (resulting in a diagnosis of schizophrenia), experienced a 
significant increase in total BPRS scores, and BPRS ‘psychosis’ subscale scores, in 
comparison to placebo. Lahti et al. (2001) noted that the similarity between 
ketamine-induced symptomatology experienced by individuals with idiopathic 
psychoses and their own positive psychotic symptomatology suggested that 
ketamine provided a unique model of the psychoses.
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Taken together these results appear to speculate that an acute ketamine 
model may best represent the acute state. This is in line with the findings of earlier 
studies with healthy, drug-naive participants. However it is in contrast with the 
conclusions of later studies with healthy, drug-naive participants, which appear to 
suggest acute ketamine induces symptomatology characteristic of the pre-psychotic 
state. It may be that individuals with stable, chronic idiopathic symptomatology 
have a low threshold and / or an increased susceptibility for the emergence of fully- 
manifest psychotic symptomatology, as a result of previous experience of such 
symptomatology. Indeed, Krystal et al. (1999) note that individuals with idiopathic 
psychoses appear to exhibit an increased sensitivity to some, but not all the 
ketamine-induced effects observed in healthy participants. For example, they 
comment that hallucinatory experiences, but not delusional responses are even more 
prominent and developed in individuals with idiopathic psychoses, in comparison to 
healthy participants. Further investigation is required to elucidate this matter.
7.2.3 The effects o f acute and chronic ketamine in recreational users
The methodology of challenge studies only enables the investigation of 
acute effects of NMDA-antagonism through ketamine. This leaves a gap in the 
literature regarding the chronic effects of ketamine, despite suggestions that chronic 
ketamine use may provide a useful model of the chronic state (Ellison, 1995; 
Jentsch & Roth 1999, both cited in Uhlhaas, Phillips & Silverstein, 2007). 
Ketamine’s medicinal use as a one-off anaesthetic, as well as its range of cognitive 
and psychotic-like side-effects, ethically prohibits administering repeated doses to 
healthy participants under experimental conditions. Therefore, studies investigating 
the effects of chronic ketamine rely on recruiting from a population of individuals 
who use ketamine recreationally. This small body of research is subject to the many
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limitations of naturalistic drug research (e.g. poly-drug use interactions, pre-existing 
population differences, varying doses and purity of the drug).
Curran and Morgan (2000) were the first authors to use this naturalistic 
population to study the psychotomimetic effects of chronic ketamine. In terms of 
acute ketamine-induced effects observed in a sample of chronic ketamine users 
(termed acute-on-chronic use), findings indicated ketamine (approximately 2 mg/kg 
within 30 minutes of testing), induced significant psychotic-like symptomatology 
(measured by a state schizotypal symptomatology questionnaire developed by 
Curran & Morgan specifically for this study), in comparison to poly-drug controls. 
On this measure, magical ideation, perceptual distortions and thought disorder were 
found to be significantly increased. Subjectively rated effects of ketamine included 
perceptual alterations (including visual, auditory, temporal and body perception), 
lack of coordination and unsteadiness, out of body experiences, and altered reality. 
Pronounced dissociative states (depersonalisation, derealisation and amnesia, 
measured by an adapted version of the CADSS), were also observed, in comparison 
to controls. Three days after acute ketamine use, following abstinence from alcohol 
and other recreational drugs, despite generally lower scores on measures, ketamine 
users still experienced significantly more psychotic-like symptomatology and 
dissociation than controls, although other subjectively rated effects did not differ 
from controls.
These findings closely replicate the acute dissociative and psychotomimetic 
effects of ketamine in challenge studies with healthy, drug-naive participants, (see 
7.2.1). As the measures used in these studies were more specific for psychotic 
symptomatology than the BPRS, it was possible to determine that the 
psychotomimetic effects appear to be those characteristic of the pre-psychotic state
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(i.e. attenuated psychotic symptomatology). This therefore suggests that the acute 
ketamine model may best represent the acute state. Interpretation of the data gained 
for Day 3 is more complex. One possibility is that the symptomatology observed is 
due to long-term, chronic effects of ketamine. It is conceivable that residual effects 
of acute ketamine use on Day 0 gave rise to the symptomatology, or pre-existing 
group differences. This study was limited by a high dropout rate, and a lack of 
biometric confirmation of drug intake.
A further study of similar design (Curran & Monaghan, 2001), compared 
frequent (greater than twice a month), and infrequent (ketamine twice a month or 
less), users of ketamine. Results indicated very high levels of psychotic-like 
symptomatology (including perceptual alterations, unsteadiness and lack of 
coordination, bodily numbness, mental confusion), and dissociation following an 
acute dose of ketamine (acute-on-chronic) in both groups, yet no evidence of 
significant residual effects, 3 days later. These findings were supported by Morgan, 
Riccelli, Maitland and Curran (2004c). The lack of psychotic-like symptomatology 
3 days after acute ketamine administration (Curran & Monaghan, 2001; Morgan et 
al., 2004c), indicates the chronic ketamine model may not be a reliable nor valid 
model of the acute state. It is proposed that as chronic ketamine has not thus far 
been found to induce fully-manifest negative psychotic symptomatology, it may not 
be an appropriate model for the chronic state of the psychoses, despite its 
detrimental effects on cognition (see section 7.3). Rather, it may be that chronic 
ketamine users present with subtler psychotic-like symptomatology, which the 
behavioural measures utilised by Morgan et al. (2004c; 2006), are not sensitive or 
specific enough to detect. The author of this review hence suggests the chronic 
ketamine model may better represent the pre-psychotic state, which is characterised
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by attenuated positive and negative psychotic symptomatology. This proposition is 
supported by the findings of Uhlhaas et al. (2007), who observed higher levels of 
delusional ideation 3 days after ketamine use, in a sample of chronic ketamine 
users, and Morgan et al. (2004d) who found higher levels of schizotypal 
symptomatology and perceptual distortions in a sample of ketamine users who had 
substantially reduced their ketamine use, compared with poly-drug controls.
Recently, the processes involved in delusion formation have been 
investigated in chronic ketamine abusing participants (Uhlhaas et al., 2007). Results 
indicated significantly impaired contextual processing (measured by a contour 
integration task), and thus impaired perceptual organisation, following a non­
standardised, acute dose of ketamine (participants recruited in vivo at a party), in 
comparison to poly-drug controls, and no significant residual effects 3 days later. 
This finding supported Umbricht et al. (2000), who found acute ketamine induced 
deficits in perceptual organisation in both auditory and visual domains, in 20 
healthy, drug-naive participants.
Uhlhaas et al. (2007) argued that such impairments in perceptual 
organisation might, in part, account for the perceptual alterations observed in 
ketamine challenge studies, and thus may be related to delusion formation. Indeed, 
similar impairments in stimulus-driven contextual processing are observed in 
studies with individuals with idiopathic psychoses (Silverstein, Kovics, Corry & 
Valone, 2000; Uhlhaas, Phillips, Mitchell & Silverstein, 2006, both cited in Uhlhaas 
et al., 2007). Whilst some perceptual organisation deficits have been observed in 
chronic schizophrenia (Dakin, Carlin & Hemsley, 2005, cited in Uhlhaas et al., 
2007), it has been suggested that individuals in the pre-psychotic and acute 
psychotic stages experience marked deficits in visual perception, as found above
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(Uhlhaas, Phillips & Silverstein, 2005). It has also been proposed that NMDA 
receptors are involved in perceptual organisation (see Phillips & Silverstein, 2003). 
This provides further indication that an acute ketamine model may best represent 
either the pre-psychotic or acute state.
7.3 Ketamine as a model o f  cognitive symptomatology: Does the ketamine model o f 
the psychoses have clinical validity and cognitive specificity?
Abi-Saab et al. (1998) note ketamine-induced effects extend beyond 
psychotic-like symptomatology, to include other types of symptomatology 
associated with idiopathic psychoses. Indeed, there is a considerable body of 
evidence demonstrating cognitive dysfunction induced by NMDA receptor 
blockade, as a result of both acute and chronic ketamine administration. It has been 
proposed that such dysfunction is a consequence of ketamine inhibiting the 
induction of long-term potentiation, (LTP) a neuronal learning process (Harris, 
Ganong & Cotman, 1984, cited in Curran & Morgan, 2000). Indeed, NMDA 
receptors are densely localised throughout the cerebral cortex and the hippocampus, 
areas important for memory and cognition. Contrary to the historical proposition 
that cognitive deterioration observed in people with psychotic symptomatology is 
related to fixed structural abnormalities, it has been suggested that neurochemical 
dysfunction may be responsible for this process (Mortimer, 1997).
Despite a wealth of literature regarding the cognitive dysfunction 
experienced by individuals with idiopathic psychoses, there is still no agreement 
regarding the ‘neuropsychological profile’ of individuals who experience psychotic 
symptomatology. Memory dysfunction in various systems is considered as core 
symptomatology in individuals with idiopathic psychoses (Aleman, Hijman, de
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Haan & Kahn, 1999; Gold, Randolph, Carpenter, Goldberg & Weinberger 1992; 
Heinrichs & Zakzanis, 1998, all cited in Honey et al., 2005). Thus, in order for the 
ketamine model of psychoses to possess clinical validity, ketamine administration 
should reproduce similar memory system dysfunction.
Prior to reviewing the literature regarding cognitive deficits induced by 
ketamine, it is necessary to note caveats. Firstly, no one cognitive task taps any 
single cognitive process or memory system exclusively (Wheeler, Stuss & Tulving, 
1997, cited in Curran & Morgan, 2000). Studies have therefore based 
interpretations on the principal memory system thought to be tapped by the tasks 
employed. Secondly, the behavioural effects of ketamine may impair attention and 
executive functions, which are required for all memory tasks. Therefore, if these 
cognitive processes are not controlled for in studies, impaired performance on 
memory tasks may actually be due to deficits in attention and executive functioning, 
which will confound findings. Results from studies which are not mindful of these 
potential confounds have been interpreted with caution.
7.3.1 The effects o f acute ketamine in healthy participants
7.3.1.1 Declarative memory systems (episodic and semantic memory)
Early ketamine challenge studies consistently demonstrate transient deficits 
in various memory systems (Ghoneim, Hinrichs, Mewaldt & Peterson, 1985; 
Harris, Biersner, Edwards & Bailey, 1975; Krystal et al., 1994; Malhotra et al.,
1996). Specifically, declarative memory (consisting of episodic and semantic 
memory) is consistently impaired by acute ketamine in healthy participants. A large 
number of studies have shown acute ketamine (at a range of doses), induces verbal 
episodic memory impairment (Anand et al., 2000; Krystal et al., 1994). Disruption 
of episodic memory has been found in recognition tasks (Hetem et al. 2000), recall
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of passages of prose (Morgan et al., 2004a; Newcomer et al., 1999a); and recall of 
high- and low-frequency word lists (Hetem et al., 2000; Malhotra et al., 1996).
For example, Newcomer et al. (1999a) found dose-dependant effects of 
ketamine on immediate and delayed verbal episodic memory. The authors noted 
that after placebo, healthy participants’ total correct recall score (immediate -  
delayed recall scores), on a free recall task was 18.6% better than their performance 
after a high dose of ketamine (0.27mg/kg). Similarly, statistically significant 
differences were found between the low ketamine dose (0.0243mg/kg) and high 
ketamine dose conditions, on a non-verbal episodic memory task. This study was 
robust as it controlled for attention and working memory deficits. However a 
caveat; the sensitivity of different tasks could have contributed to the apparent 
selectivity of ketamine’s effect. These findings provide further evidence for the 
clinical validity of the acute ketamine model of the psychoses, as episodic memory 
dysfunction represents a core cognitive deficit in individuals with idiopathic 
psychoses.
Furthermore, Morgan et al. (2004a) gained similar findings, observing 
significant impairment in episodic memory in a group of 18 healthy participants 
(measured by a prose recall task), in comparison to placebo, following an acute, 
high dose of ketamine (0.8mg/kg), in the face of preserved attentional and executive 
performance. Interestingly, the high dose selectively impaired encoding of 
information into episodic memory, but not retrieval, indicating a dissociative effect 
on episodic memory, in that ketamine impairs encoding rather than retrieval.
Further robust research supports these early findings (Honey et al., 2005; 
Malhotra et al., 1996; Newcomer et al., 1999b; Parwani et al., 2005). For example, 
in a placebo-controlled crossover study Hetem et al. (2000) found ketamine
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infusion (steady-state of 0.5mg/kg), generated significant impairment in free recall 
and recognition of 2 lists of 40-words leamt during infusion, in 26 healthy 
participants, compared with placebo. No evidence of impairment was identified for 
free recall or recognition for words encoded prior to ketamine administration. 
Interestingly, individuals with idiopathic psychoses appear to experience 
impairments in encoding and retrieval of information, also utilising free recall and 
recognition tasks, as in ketamine challenge studies (Chan et al., 2000), although 
some suggest a retrieval-specific deficit in the psychoses (Calev, Venables & Monk, 
1983, cited in Chan et al., 2000).
Although participants within a pre-psychotic state do not show the same 
level of cognitive impairment as that observed in individuals with first-episode 
psychoses (Keefe et al., 2006; Pukrop et al., 2006, cited in Niendam et al., 2007), or 
multiple episodes of psychosis (Hawkins et al., 2004, cited in Niendam et al., 2007), 
it appears their most pronounced cognitive deficits are very similar to those 
experienced by individuals with fully-manifest psychotic symptomatology. One of 
the most reliably replicated deficits in participants deemed to be in the pre- 
psychotic state is impairment in verbal episodic memory (Eastvold, Heaton & 
Cadenhead, 2007; Niendam et al., 2006).
Evidence for acute ketamine-induced impairment in semantic memory has 
been found in some (Abel, Allin, Hemsley & Geyer, 2003, cited in Morgan et al., 
2006; Adler et al. 1998; Krystal et al., 1994), but not all (Krystal et al., 1999; 
Morgan et al., 2004a; Newcomer et al., 1999a) studies. This difference may be the 
result of methodological issues, however as these studies all accessed semantic 
memory using the category fluency task. The semantic memory system can more 
appropriately be studied using semantic priming tasks, which involve the
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facilitation of responding to a word (e.g. table), when it is preceded by a 
semantically related word (e.g. chair), as compared with an unrelated word (e.g. 
sheep).
Morgan et al. (2006) used a semantic priming task to assess semantic 
memory dysfunction, following acute ketamine administration in healthy 
participants. Findings indicated only a high dose of ketamine (200ng/ml of plasma), 
significantly impaired the controlled processes of semantic priming (expectancy and 
semantic matching), in comparison to placebo. Indeed, the high dose of ketamine 
caused ‘inverse priming,’ i.e. faster reaction times to unrelated rather than related 
words. The authors proposed this finding may be the result of a deficit in on-line 
contextual processing of semantic information, a process in which NMDA receptors 
have been implicated (Phillips & Silverstein 2003, cited in Morgan et al., 2006).
The above findings suggest that the acute ketamine model has some clinical 
validity and cognitive specificity for the cognitive symptomatology of the 
psychoses, as it has been proposed that early, prominent impairment in episodic and 
semantic memory systems is frequently observed within the psychoses (Green, 
1996, cited in Newcomer et al., 1999a; Mortimer, 1997). Indeed, several researchers 
have suggested semantic memory deficits are central to the cognitive impairment 
observed in the psychoses (e.g. Moritz et al., 2001, cited in Morgan et al., 2006; 
Rossell, Shapleske & David, 2000). Furthermore, it has been suggested that 
impairments in episodic memory are the most severe of all cognitive disturbances 
associated with the psychotic symptomatology (Heinrichs & Zakzanis 1998, cited in 
Hetem et al., 2000). Evidence that ketamine impairs episodic memory at levels 
equal to and below plasma concentrations associated with psychotic-like 
symptomatology (Honey et al., 2005; Newcomer et al., 1999a), suggests ketamine
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may best model either the pre-psychotic or chronic state, as both these states are 
characterised by cognitive impairment. Newcomer & Krystal (2001) argued that 
acute ketamine may best model memory impairment during the pre-psychotic state. 
As acute ketamine does not reliably induce fully-manifest negative psychotic 
symptomatology (see section 7.2.3), which is characteristic of the chronic state, 
this proposal appears well founded. They suggest that gradually increasing levels of 
NMDA receptor hypofunction may be associated with increasingly impaired 
cognition in the psychoses. Indeed, verbal episodic memory deficits are a consistent 
finding in neuropsychological research with individuals in the pre-psychotic state 
(Eastvold et al., 2007; Niendam et al., 2006; Pukrop et al., 2007). Interestingly, a 
significant impairment in verbal episodic memory has been found to be predictive 
of an imminent transition from a pre-psychotic state to fully-manifest psychotic 
symptomatology (Brewer et al., 2005; Lencz et al., 2006, both cited in Eastvold et 
al., 2007).
The type of ‘conscious state’ experienced when accessing verbal episodic 
memory also appears to be affected by ketamine. Morgan and Curran (2006) 
differentiate these types of ‘conscious state’ as remembering information about past 
episodes, independantly of self-reference (recognition memory), and the ability to 
remember contextual information about those episodes, such as who was present 
and who said what (source memory). Robust studies have found acute ketamine 
significantly impairs both abilities in healthy participants (Honey et al., 2005, 2006; 
Morgan, Mofeez, Brandner, Bromley & Curran, 2004b). A comparable study found 
no evidence of a selective impairment of source memory, as a result of a 60-minute 
ketamine infusion (Hetem et al., 2000).
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Honey et al.’s (2005) study showed acute ketamine administration at 
encoding significantly increased guessing bias (a tendency to guess words had been 
encoded under shallow, rather than intermediate or deep levels of processing), in 
comparison to placebo. The authors proposed this indicated a greater proportion of 
words were responded to on the basis of their familiarity, rather than ‘true’ 
recollection of encoding (i.e. source information), thus leading to increased use of 
the guessing strategy. However this study was limited by a small sample size and 
design insensitivities, which possibly resulted in subtle ketamine-induced effects 
being missed.
A further double-blind, placebo-controlled, randomised study by the same 
group found that following acute ketamine administration, healthy participants 
demonstrated impaired performance when deciding if they or an external agent (i.e. 
the experimenter), generated responses to specific words, if they had previously not 
been able to recall information from source memory about operations performed on 
the word (Honey et al., 2006). This is a particularly intriguing finding, as it is at 
odds with source memory deficits experienced by individuals with idiopathic 
psychoses, whose core deficit is an increased tendency to externalise. Indeed, it is 
suggested that such dysfunction is central to some of the positive psychotic 
symptomatology of the psychoses, including auditory hallucinations, passivity 
phenomena, thought insertion, and delusions of control (Brebion, Gorman, Amador, 
Malaspina & Sharif, 2002; Frith, 1987; Frith & Done, 1989, all cited in Honey et 
al., 2006), and their response to treatment (Keefe, Poe, McEvoy & Vaughan, 2003, 
cited in Honey et al., 2006).
When administered at encoding, the effects of acute ketamine are generally 
consistent with studies which report source memory dysfunction, in individuals
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with idiopathic psychotic symptomatology (Brebion et al., 2000, 2002; Keefe, 
Arnold, Bayen & Harvey, 1999; Keefe, Arnold, Bayen, McEvoy & Wilson, 2002; 
Morrison & Haddock, 1997; Vinogradov et al., 1997, all cited in Honey et al., 
2005). It has been suggested that this observed source memory dysfunction best fits 
with cognitive impairment within the acute state, because individuals with more 
chronic presentations display a selective impairment in source memory, with intact 
recognition memory (Hetem et al., 2000).
The acute ketamine model may lack cognitive specificity in this area, as 
source accuracy was not measurably impaired as a consequence of ketamine, which 
conflicts with findings with individuals with psychotic symptomatology (Honey et 
al., 2005). Furthermore, the increased tendency to internalise in agency source 
monitoring tasks is at odds with the pattern of source memory deficits in individuals 
with idiopathic psychoses. Honey et al. (2006) argued that this latter finding may 
simply indicate the acute ketamine model better represents cognitive deficits 
associated with paranoia / suspiciousness and delusions of reference (the type of 
positive psychotic-like symptomatology induced by ketamine), rather than the 
source monitoring deficits experienced by individuals with idiopathic passivity 
phenomena and auditory hallucinations (which are not typically induced by 
ketamine). They therefore conclude that ‘in short, ketamine may mimic some 
aspects of the psychopathology of schizophrenia but not others’, pg 421. They 
propose that as acute ketamine appears to induce subtler cognitive symptomatology 
than that experienced by individuals with fully-manifest psychotic symptomology, 
it may best model the pre-psychotic state.
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7.3.1.2 Executive functioning and working memory
Poor executive functioning is repeatedly observed in individuals with 
idiopathic psychoses, even in cases where there is no general cognitive deterioration 
(Hughes et al., 2003; Liddle & Morris, 1991, cited in Mortimer 1997). Whilst some 
studies have indicated acute ketamine impairs executive functioning (Adler et al., 
1998; Hetem et al., 2000; Krystal et al., 1994), others have not (Harbome, Watson, 
Healy & Groves, 1996, cited in Morgan & Curran, 2006; Morgan et al., 2004b; 
Newcomer et al., 1999a; Radant et al., 1998), and most have gained mixed results 
(Honey et al., 2003; Krystal et al., 2000; Morgan et al., 2004a). The basis for these 
differences is not clear. Nevertheless it is clear that individuals both in the pre- 
psychotic state and with fully-manifest psychoses do experience notable deficits in 
verbal executive functions (Eastvold et al., 2007; Gschwandtner et al., 2003; 
Hawkins et al., 2004; Hoff et al., 1992, all cited in Niendam et al., 2007; Pukrop et 
al., 2007; Simon et al., 2006), even though the deficits experienced by the former 
are less prominent than those experienced by the latter (Hawkins et al., 2004, cited 
in Niendam et al., 2007; Keefe et al., 2006; Pukrop et al., 2006).
A more consistent finding is that of a specific working memory (WM - an 
element of executive function), deficit in healthy participants, following acute 
ketamine. Morgan and Curran (2006) note the main observed trend within studies is 
that acute ketamine affects manipulation rather than maintenance of information in 
WM. For example, forward digit span and performance on the spatial delayed 
response task (both measures of the maintenance of material in working memory), 
have been found to be intact following ketamine administration (Abel et al., 2003; 
Ghoneim et al., 1985; Newcomer et al., 1999a; Rowland et al., 2005). Intact 
backwards digit span (measure of the manipulation of information in working
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memory), has been observed in some (Ghoneim et al., 1985; Rowland et al., 2005) 
but not other (Abel et al., 2003) studies. In an RCT, Honey et al. (2003) also found 
that a low dose of ketamine (lOOng/ml), significantly impaired performance on a 
WM task, specifically impairing the manipulation of information in WM, in the 
presence of intact maintenance processes. Interestingly, WM deficits in psychoses 
appear to be characterised by greater impairment in manipulation, rather than 
maintenance (Kim, Glahn, Nuechterlein & Cannon, 2004; Perry et al., 2001, both 
cited in Fletcher & Honey, 2006), suggesting the acute ketamine model has clinical 
validity in this domain.
The N-back task has also been used to investigate verbal WM dysfunction, 
following ketamine. This task involves an attentional component (0-back), in which 
participants simply respond to a number/letter, and two other components with 
increasing WM load. Robust studies have demonstrated significant ketamine- 
induced impairment on the WM components of this task, with intact 0-back 
(attentional) ability (Adler et al., 1998; Morgan et al., 2004b; Newcomer et al., 
1999b).
It has been proposed that the cognitive dysfunction observed above, at 
subdissociative levels of ketamine, are not representative of either the deficits in 
the acute or chronic state because in the chronic state, such subtle cognitive 
effects may be swamped by the extent of cognitive impairment present, and in 
the acute state the extent of psychotic symptomatology could potentially be 
masking such subtle patterns of cognitive impairment (Honey et al., 2003). They 
therefore argue that the patterns of cognitive impairment observed in acute 
ketamine challenge studies may more appropriately represent precursors to the 
full cognitive impairment apparent in individuals with idiopathic psychoses.
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This author therefore suggests that the cognitive dysfunction outlined above 
mimics the very earliest changes (i.e. during pre-psychotic state), present in 
those with idiopathic psychoses.
Many studies have found that individuals considered as being within a pre- 
psychotic state display deficits in WM and executive functions (Eastvold et al., 
2007; Simon et al., 2006; Wood et al., 2003, cited in Pukrop et al., 2007). These 
earlier studies were limited by a significant proportion of ‘false-positives’ (i.e. 
participants deemed to be in the pre-psychotic state, but who do not develop 
psychoses). Nevertheless, Pukrop et al. (2007), whose study overcame this 
limitation, found significant impairments in WM and verbal executive function 
when ‘true-positives’ (i.e. participants deemed to be in the pre-psychotic state, who 
did develop psychoses) were compared to healthy controls. Indeed, Simon et al. 
(2007) concluded that the most pronounced cognitive deficits experienced by 
individuals in the pre-psychotic state are impairments in executive function and 
WM. Furthermore, significant impairment in spatial working memory has been 
found to be predictive of an imminent transition to fully-manifest psychotic 
symptomatology (Brewer et al., 2005; Lencz et al., 2006, cited in Eastvold et al., 
2007).
Indeed, based upon the pattern of WM and episodic memory impairment 
following acute ketamine, Fletcher and Honey (2006) argue that acute ketamine 
shows promise in mimicking characteristic cognitive impairment associated with 
the pre-psychotic state, and therefore appears to have good clinical validity and 
promising clinical reliability. However the cognitive specificity of the acute 
ketamine model is not that strong, as evidence of procedural memory impairment 
(Morgan et al., 2004b) and preserved executive functions (for review see Morgan &
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Curran, 2006) contrast with the presentation of individuals with psychotic 
symptomatology (Perlstein, Carter, Noll & Cohen, 2001, cited in Morgan et al., 
2004b), and in a pre-psychotic state (Niendam et al., 2006; Pukrop et al., 2007).
7.2.1.3 Attentional processes
There is limited evidence for ketamine-induced attentional deficits as a 
result of an acute dose in healthy participants. Whereas some studies have found 
ketamine is associated with deficits in sustained attention (Krystal et al., 1994; 
Malhotra et al., 1996; Umbricht et al., 2000), others have indicated no impairment 
(Heekeren et al., 2007; Krystal et al., 1999; Newcomer et al., 1999a; Radant et al., 
1998), whilst others have found mixed results (Oranje et al., 2000). It therefore 
appears the acute ketamine model is not particularly reliable in replicating the loss 
of the selective function of attention experienced by those with idiopathic psychotic 
symptomatology (Baribeau-Braun, Picton & Gosselin, 1983; McGhie & Chapman, 
1961, both cited in Oranje et al., 2000), including those in the pre-psychotic state 
(Pukrop et al., 2007).
These findings also bring into question the cognitive specificity of the acute 
ketamine model as in a review, Gur et al. (1997) noted attentional dysfunction is a 
primary deficit experienced by people with idiopathic psychoses.
7.3.2 The effects o f acute ketamine in individuals with idiopathic psychotic 
symptomatology
Limited ketamine challenge studies investigating cognitive dysfunction have 
been conducted with individuals with idiopathic psychoses. Malhotra et al. (1997a) 
found ketamine caused significantly impaired free recall and recognition memory, 
with intact attentional function, in a group of 13 antipsychotic-free individuals with 
a psychoses diagnosis, in comparison to placebo. Interestingly, episodic memory
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was significantly more impaired in participants with a psychoses diagnosis, in 
comparison to healthy controls, following ketamine. However an early study by 
LaPorte, Lahti, Koffel and Tamminga (1996) found no evidence of episodic 
memory impairment or WM deficits in a very small sample of 7 participants with a 
psychoses diagnosis, following 0.5mg/kg of ketamine. The authors suggested this 
lack of significant ketamine-induced cognitive deficits may have been the direct 
result of the design of the study, which was unusual and had several limitations. 
Ketamine (or placebo), was administered after the learning procedure. Hence, the 
study’s findings suggest ketamine-induced episodic memory impairment is specific 
to encoding, rather than retrieval of information.
7.3.3 The effects o f acute and chronic ketamine in recreational users
A major limitation of the above research into ketamine-induced cognitive 
dysfunction is its focus on ketamine’s acute effects. As a result, theorists have 
begun to investigate cognitive dysfunction in recreational ketamine users, in order 
to further our understanding of the chronic effects of ketamine, paralleling 
investigations into chronic psychotic-like symptomatology. Early anecdotal 
evidence suggested ketamine users experience memory deficits and attentional 
dysfunction (Jansen, 1990; Siegel, 1978, both cited in Curran & Morgan, 2000).
A few studies have examined the effects of ketamine on the cognition of 
recreational users, on the night of drug use (acute-on-chronic effects), and then 3 
days later (chronic effects), following abstinence from alcohol and other 
recreational drugs. Firstly, Curran and Morgan (2000) found on the night of drug 
use (Day 0), acute ketamine induced a broad spectrum of cognitive impairments 
(episodic, semantic, working memory and focused attention), in comparison to 
poly-drug controls. These findings replicated data from previous challenge studies
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with healthy volunteers (see above). However working memory was measured 
utilising the serial sevens task, therefore findings from this task may have been 
confounded by numeracy skills and working memory abilities prior to any ketamine 
use.
Three days later, when compared to polydrug using controls, ketamine users 
still presented with significantly impaired episodic and semantic memory. The 
authors noted however that a lack of practice on the specific cognitive task, due to 
acute amnesic effects of ketamine on Day 0 was possibly responsible for the 
former, but not the latter impairment in memory. Errors made in the category 
fluency task (which taps semantic memory), included rhyming (e.g. for the category 
“fruit” one ketamine user began “melons, Helens ...”) and semantic errors (e.g. 
another began “oranges, juice, vitamins, goodness ...”). Such errors are similar to 
those reported in acute schizophrenia (McKenna, Mortimer & Hodges, 1992, cited 
in Curran & Morgan, 2000).
It could however be argued that the cognitive dysfunction observed on Day 
3 was not due to chronic effects of ketamine, but rather was the result of pre­
existing group differences in cognitive functioning. Curran and Monaghan (2001) 
conducted a further study (with similar design), to investigate this possibility. They 
compared two groups of ketamine users, frequent and infrequent, the former 
differing to the latter on the basis of more frequent intake, and larger doses of 
ketamine. At Day 0 (acute-on-chronic effects), both frequent and infrequent 
ketamine users were significantly impaired on tasks tapping episodic, semantic and 
working memory and focused attention. Three days later, frequent ketamine users 
still experienced impaired episodic and semantic memory systems, whereas 
infrequent users were performing at significantly higher levels on all previously
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impaired cognitive tasks. These findings suggest that the patterns of memory 
impairment on Day 3 are a consequence of the chronic use of ketamine. This 
conclusion is strengthened by the observation that an acute dose of ketamine does 
not cause residual cognitive impairments 3 days later, in healthy participants 
(Morgan et al., 2004a).
The above studies indicated episodic memory impairment as a result of both 
acute and chronic ketamine use. As in ketamine challenge studies, the type of 
‘conscious state’ experienced when accessing verbal episodic memory also appears 
to be affected by chronic ketamine use. Morgan et al. (2004c) were the first group 
to examined source and recognition memory in chronic ketamine users. They found 
on the night of drug use (acute-on-chronic effects), both source and recognition 
memory were impaired in ketamine users, which supports most findings in healthy 
participants (Honey et al., 2005, 2006; Morgan et al., 2004b). Three days later 
(chronic effects of ketamine), source memory was selectively impaired alongside 
intact recognition. This pattern of impairment has been suggested to fit more closely 
with a chronic state than the findings from acute ketamine challenge studies (Huron 
et al., 1995, cited in Hetem et al., 2000). Interestingly, an acute dose of ketamine on 
Day 0 (acute-on-chronic), induced a similar degree of source memory impairment 
to healthy participants infused with a high level of ketamine, whereas chronic 
effects of ketamine 3 days later induced a source memory impairment similar to 
healthy participants infused with a low dose of ketamine (Morgan et al., 2004b).
In a robust study, Morgan et al. (2006) found chronic ketamine use 
significantly impaired the controlled processes of semantic priming, specifically for 
low but not high frequency words, in comparison to poly-drug controls. As with 
healthy participants observed in this study, this effect was characterised by
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‘inversed priming’. The authors suggested the priming impairment for low- 
frequency words might be indicative of degradation in the semantic store. These 
results indicate a chronic ketamine model may be more appropriate than an acute 
model for representing the pattern of impaired semantic priming observed in 
individuals with more idiopathic psychoses, where a degradation of the semantic 
store has also been suggested (Rossell, Bullmore, Williams & David, 2001; Rossell 
& David, 2006, both cited in Morgan & Curran, 2006).
8. Treatment implications
8.1 Clinical specificity
In order for drug models of the psychoses to be utilised ethically and 
successfully in the development of pharmacological treatments for idiopathic 
psychoses, it is imperative for them to possess good clinical specificity. If the drug 
model is not specific, then the development of treatments based on its 
neurobiological methods of action will likely prove fruitless, or worse potentially 
harmful. Although current opinion in the pre-psychotic state and first-episode 
literature suggests that the early identification of attenuated or fully-manifest 
psychotic symptomatology and subsequent early intervention could provide the best 
outcome for individuals, it is vital to be mindful of the high rate of individuals 
identified as experiencing pre-psychotic symptomatology and cognitive 
dysfunction, who do not develop a subsequent psychoses (i.e. false-positives). For 
early intervention to succeed, an accurate definition of the pre-psychotic state is 
essential (Simon et al., 2007). This issue raises ethical concerns about the 
pharmacologic treatment of individuals who are identified as in a pre-psychotic 
state, who may never actually develop a psychoses (Corcoran, Malaspina &
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Hercher, 2005; Haroun, Dunn, Haroun & Cadenhead, 2006; McGorry, Yung & 
Phillips, 2001, all cited in Eastvold et al., 2007) who at baseline assessment, using 
current criteria, are indistinguishable from those who do go on to develop psychotic 
symptomatology. Improved predictive accuracy for distinguishing individuals at 
imminent risk for developing psychoses is required for the earliest possible 
interventions to be disseminated ethically. If the acute and / or chronic ketamine 
model does appear to best mimic the symptomatology characteristic of the pre- 
psychotic state, it may play a pivotal role in the development of a more robust 
definition of the pre-psychotic state, with far greater predictive accuracy.
As a drug model of the psychoses, ketamine appears to have reasonable 
clinical specificity. Both acute and chronic ketamine intake are able to model a 
variety of psychotic-like and cognitive symptomatology, potentially associated with 
the psychoses. Whereas the acute ketamine model appears to induce psychotic-like 
symptomatology which is characteristic of either the pre-psychotic or acute states, 
it currently appears that the chronic ketamine model may best induce psychotic-like 
symptomatology characteristic of the pre-psychotic state (however research into the 
chronic effects of ketamine is sparse).
The majority of studies demonstrate subanaesthetic doses of acute ketamine 
also frequently induce significant dissociation (Anand et al., 2000; Curran & 
Morgan, 2000; Krystal et al., 1994; Malhotra et al., 1996; Pomarol-Clotet et al., 
2006; Uhlhaas et al., 2007) and euphoria (Anand et al., 2000; Krystal et al., 2005). 
The former type of symptomatology is not specific to the psychoses, and is present 
in several other DSM-IV diagnoses, such as various anxiety disorders and post- 
traumatic stress disorder. Although it could be argued that the latter experience does 
not fall within a factor of psychotic-like symptomatology, it may well be akin to the
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elevated and expansive mood experienced within the ‘manic symptomatology’ 
factor (Lindenmayer, Bemstein-Hyman & Grochowski, 1994; Lindenmayer, 
Grochowski & Hyman, 1995a; Lindenmayer, Bemstein-Hyman, Grochowski & 
Bark, 1995b). Interestingly, ketamine-induced euphoria can be observed in the 
presence of dysphoria, predominantly due to tension or anxiety, (e.g. Krystal et al.,
2005), which is in line with the controversial proposal that depressive 
symptomatology may co-exist with manic symptomatology (Cassidy, Forest, Murry 
& Carrol, 1998; Dilsaver, Chen, Shoaib & Swann, 1999, both cited in Gonzalez- 
Pinto et al., 2003b). Finally, although there are several aspects of cognitive 
disruption (Honey et al., 2005), and altered sensorimotor functioning (Oranje et al., 
2000; Weiler, Thaker, Lahti & Tamminga, 2000) which may differentiate ketamine- 
induced symptomatology from that of idiopathic psychoses, overall the ketamine 
model still appears to have reasonable clinical specificity.
8.2 Pharmacologic interventions
Despite not having complete clinical specificity, the ketamine model does 
appear to have good clinical validity. Therefore, based on the hypothesis that 
NMDA receptor hypofunction contributes to the pathophysiology of the psychoses, 
pharmacological treatments that facilitate NMDA receptor function have been 
developed (Tuominen, Tiihonen & Wahlbeck, 2005 for review). For example, a 
recent RCT investigated the efficacy of an oral selective agonist for mGlu2 and 
mGlu3 receptors, termed LY210023 (Patil et al., 2007) in a cohort of 118 drug-free 
participants, with high levels of psychotic symptomatology. Results indicated that 
LY210023 was safe and well tolerated by participants. They found both LY210023 
(40mg twice daily), and olanzapine (15mg once daily), displayed a rapid onset of 
efficacy, as after week 1, both groups scored significantly lower on the PANSS than
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placebo. This improvement was maintained until the end of the trial (4 weeks later). 
Furthermore, the LY210023 group showed significantly less psychotic 
symptomatology on both the positive and negative sub-scales of the PANS S. In 
addition, LY210023 participants did not show increased prolactin levels, worsening 
extrapyramidal symptoms or weight gain, unlike individuals using more commonly 
prescribed antipsychotics. The authors suggested their findings supported a 
potential alternative antipsychotic monotherapy for psychoses. However a high 
level of dropout limited this study.
Generally, clinical trials of glutamate agonists have generated mixed results 
(for review see D’Souza, Chamey & Krystal, 1995, cited in Abi-Saab et al., 1998), 
and thus despite glutamate transmission dysfunction being implicated in psychoses, 
there still remains an absence of treatments acting on these pathways. Interestingly, 
lamotrigine (300mg administered 2 hours prior to a ketamine infusion) has been 
found to significantly decrease ketamine-induced psychotic-like positive and 
negative symptomatology, dissociation, semantic memory deficits and elevated 
mood (Anand et al., 2000). A recent paper suggested lamotrigine might be usefully 
utilised as an adjunct to conventional and atypical antipsychotic treatment of 
psychotic symptomatology, in particular positive symptomatology (Kremer et al., 
2004, as cited in Patil et al., 2007).
The efficacy of current antipsychotic medication for attenuating acute 
ketamine-induced symptomatology in clinical populations has also been 
investigated. These few studies indicate that single doses of haloperidol (Krystal et 
al., 1999; Lahti et al., 1995), or olanzapine (Anand et al., 2000; Lahti, Holcomb, 
Gao & Tamminga, 1999), do not significantly attenuate ketamine-induced 
psychotic-like symptomatology, despite evidence that haloperidol can reduce
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ketamine-induced impairment of executive function in healthy participants (Krystal 
et al., 1999). A caveat to be mindful of here is that individuals with idiopathic 
psychoses frequently require weeks or even months of drug treatment for symptom 
resolution to be achieved. Clozapine is one of the most effective drug treatments for 
psychotic symptomatology (Davis & Chen, 2004, cited in Large, 2007) and 
therefore has been used in the validation of all drug models of psychoses. This 
atypical antipsychotic significantly blunts ketamine-induced positive 
symptomatology (Malhotra et al., 1997b), which again provides evidence for the 
validity of the ketamine model.
9. Chronic ketamine use - risk factor for psychotic symptomatology?
This review has thus far focused upon the ‘idiopathic hypothesis’ of the 
psychoses, which proposes psychotic symptomatology is precipitated by gradually 
evolving, endogenous receptor dysfunction. The ‘exogenous hypothesis’ of 
psychoses will now be considered briefly. This hypothesis suggests the 
consumption of external pharmacological agents, in this case glutamate antagonists 
(PCP or ketamine), may constitute a risk factor for the development of psychotic 
symptomatology, through mechanisms that are extrinsic to the pathophysiology of 
‘naturally occurring’ psychoses. To the author’s knowledge, there is no published 
data concerning the rates of subsequent psychoses in chronic ketamine users. 
Although it has been noted that PCP induces symptomatology virtually 
indistinguishable from that observed in idiopathic psychoses, such that chronic PCP 
users may be misdiagnosed as experiencing a psychoses (Pearlson, 1981; Smith, 
Wesson, Buxton, Seymour & Kramer, 1978, both cited in Abi-Saab et al., 1998), 
such findings have not been reported for ketamine use.
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Ketamine has been found to mimic relapse to an acute state in individuals 
with well-controlled, stable chronic psychoses (Lahti et al., 1995, 2001; Malhotra et 
al., 1997a). However induced symptomatology is mild and short lived. Interestingly 
it does appear that there are qualitative differences in the symptomology re­
experienced by individuals with idiopathic psychoses when given an acute dose of 
ketamine, and symptomatology experienced by healthy participants when given the 
same acute dose of ketamine. Typically, lower doses of ketamine have been found 
to induce illusions, perceptual alterations, thought disorder and suspiciousness in 
drug-naive, healthy participants, rather than fully-manifest hallucinations. This is in 
contrast to individuals with idiopathic psychoses, who experience ketamine-induced 
fully-manifest psychotic symptomatology, including hallucinations. Furthermore, 
the hallucinatory experiences induced by high doses of ketamine in drug-naive, 
healthy participants are mainly visual in form (Vollenweider, Leenders, Oye, Hell 
& Angst, 1997). Complex visual hallucinations are relatively uncommon in 
individuals with idiopathic psychoses. In contrast, there is a higher rate of 
ketamine-induced auditory hallucinations (e.g. 50% of the sample with a history of 
auditory hallucinations; Malhotra et al., 1997a) experienced by those with 
idiopathic psychoses, in comparison to healthy participants. This form of 
hallucinatory experience is much more common to idiopathic psychoses 
presentations. It has been proposed this may be due to a reduction in threshold, as 
the result of increased sensitivity for psychotic symptomatology, therefore making 
the re-activation of previously experienced psychotic symptomatology more likely.
It is therefore tentatively hypothesised that these findings suggest acute 
ketamine induces fully-manifest psychotic symptomatology. Due to the short 
duration of this psychotic symptomatology, and as only specific aspects of the
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psychoses are replicated, it is argued that acute ketamine does not cause transition 
to an acute state. However participants in the above studies were only provided 
with between 1 to 3, low doses of ketamine, so caution should be used in applying 
these data to recreational use. It is therefore apparent that a gap in the literature 
exists with regard to the effects of chronic ketamine use, and subsequent rates of 
ketamine-induced psychoses.
10. Conclusions -  how useful a model of the psychoses is ketamine?
10.1 Clinical validity and reliability
10.1.1 Acute ketamine model o f the psychoses
In summary, the acute ketamine model appears to have good clinical 
validity and reliability for the pre-psychotic state. Challenge studies with healthy 
participants, participants with idiopathic psychoses and acute-on-chronic studies 
with self-administering ketamine users have found ketamine induces a dose- 
dependant ‘clinical syndrome’, characterised by subtle positive and negative 
psychotic-like symptomatology (including unusual thought content, blunted affect, 
emotional withdrawal), as well as dissociative effects (non-core symptomatology 
sometimes observed in psychoses). Attenuated negative symptomatology associated 
with the psychoses has not been reported using other drug models. Acute ketamine 
does not appear to reliably induce ‘true’ delusions or hallucinations, but rather 
causes perceptual alterations and suspiciousness. It is proposed these perceptual 
alterations best model the processes involved in delusion and hallucination 
formation, and therefore are indicative of pre-psychotic processes. Honey et al.
(2006) propose that as ketamine appears to induce subtler symptomatology than that
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experienced by individuals with fully-manifest psychotic symptomology, it may 
best model the pre-psychotic state.
Furthermore, it has been proposed that the cognitive deficits induced by 
acute ketamine may better reflect the cognitive disturbances seen in the pre- 
psychotic state (Fletcher & Honey, 2006), in which cognitive symptomatology is 
subtler. Evidence that ketamine impairs episodic memory at levels equal to and 
below plasma concentrations associated with psychotic-like symptomatology 
(Honey et al., 2005; Newcomer et al., 1999a) also suggests ketamine may best 
model the pre-psychotic state.
10.1.2 Chronic ketamine model o f the psychoses
It currently unclear which state of the psychoses the chronic ketamine model 
best represents, the pre-psychotic or the chronic state. The lack of psychotic-like 
symptomatology 3 days after acute ketamine administration observed in the 
majority of chronic ketamine studies (e.g. Curran & Monaghan, 2001; Morgan et 
al., 2004c), indicates the chronic ketamine model is probably not a reliable nor 
valid model of the acute state. It is proposed that as chronic ketamine has not thus 
far been found to induce fully-manifest negative psychotic symptomatology, it is 
not an appropriate model for the chronic state of the psychoses either, despite its 
detrimental effects on cognition. Rather, it is proposed that chronic ketamine may 
best mimic the attenuated psychotic symptomatology characteristic of the pre- 
psychotic state. This hypothesis is supported by the findings of Uhlhaas et al.
(2007), and Morgan et al. (2004d), however further investigation is needed into this 
matter as so few chronic ketamine studies have been completed. At this stage, it is 
not possible to differentiate between these possibilities, as research has not
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investigated the presence of subtle, pre-psychotic symptomatology in chronic 
ketamine users.
Chronic ketamine has been proposed to best model the semantic and 
episodic memory impairments associated with the psychoses (Morgan & Curran,
2006). However it is unclear which state chronic ketamine-induced cognitive 
impairments most resemble. The finding that chronic ketamine use specifically 
impairs source memory, in the presence of intact recognition memory is suggested 
to fit more closely with a chronic state (Huron et al., 1995, cited in Hetem et al.,
2000), but the picture is an unclear one, as there is simply not enough available 
research evidence yet in the literature to make an informed decision. Further 
research is thus required to investigate the chronic effects of ketamine on cognition.
10.2 Contextual validity 
Ketamine has a relatively short plasma half-life of 2-4 hours (Copeland & 
Dillon, 2005), therefore its acute effects are short lived, and fully reversible. 
Recreational users usually administer ketamine intranasally, which has an estimated 
duration of effect of up to 1 hour (Siegel, 1978). In a session, ketamine users will 
frequently self-administer several sequential doses to maintain psychotropic effects 
over time. The short half-life of ketamine would mean it would be eliminated from 
the body within 24 hours (Curran & Monaghan, 2001). This is not the case with 
psychotic and cognitive symptomatology characteristic of the acute and chronic 
states of psychoses, where symptomatology may be present for weeks, months and 
even years. It thus appears the acute ketamine model has much less contextual 
validity than the chronic model, in which ketamine-induced effects also take a 
chronic course. It may be that the acute ketamine model better mimics the pre-
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psychotic state, as within this state symptomatology can be transitory and relatively 
short in duration (Yung & McGorry, 1996).
Furthermore, both healthy participants and recreational ketamine users are 
reliably able to report the subjective effects of ketamine, whereas it is 
controversially reported that frequently those with idiopathic psychoses ‘lack 
insight’ into their symptomatology. Indeed, the DSM-IV-TR states that ‘a majority 
of individuals with schizophrenia lack insight regarding the fact that they have a 
psychotic illness’. This further suggests the ketamine model has limited contextual 
validity.
10.3 Clinical and cognitive specificity
All drug models of the psychoses have only partial specificity, inducing 
some but not all aspects of symptomatology. Therefore, it is unlikely that acute or 
even chronic administration of a pharmacological agent would reproduce all the 
symptomatology, specifically related to the psychoses, which arise through a 
complex interplay of genetic, developmental, and environmental factors.
The ketamine model appears to have limited clinical specificity. For 
example, complex visual hallucinations have been reported at high doses of acute 
ketamine (Vollenweider et al., 1997), which are relatively uncommon in idiopathic 
psychoses. However auditory hallucinations, which are common to the psychoses, 
are not usually elicited by ketamine. Furthermore, acute ketamine is subjectively 
rewarding (Morgan et al., 2004a), induces euphoria, and disruption of some aspects 
of sensorimotor function (see above), which are not typically associated with the 
psychoses. In addition, it has been suggested that the acute ketamine model may 
have limited clinical specificity for negative symptomatology, as it is confounded
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by the presence of significant levels of sedation (Abi-Saab et al., 1998). Further 
studies are required to address this problem.
The cognitive specificity of the acute ketamine model is also limited, as 
evidence of procedural memory impairment (Morgan et al., 2004b) and preserved 
executive functions (Morgan & Curran, 2006 for review) contrast with the 
presentation of individuals with psychotic symptomatology (Perlstein et al., 2001, 
cited in Morgan et al., 2004b), and those in a pre-psychotic state (Eastvold et al., 
2007; Niendam et al., 2006; Pukrop et al., 2007). In addition, the accuracy of source 
memory does not appear to be measurably impaired by acute ketamine, which 
contrasts with findings with individuals with psychotic symptomatology (Honey et 
al., 2005). Finally, the cognitive specificity of the ketamine model is brought into 
question as although attentional dysfunction is a primary deficit experienced by 
people with idiopathic psychoses (Gur et al., 1997), mixed findings have been 
gathered regarding ketamine-induced attention impairments.
10.4 Transmitter specificity
It has been demonstrated that ketamine has high transmitter specificity (Abi- 
Saab et al., 1998 for review), and thus antagonism at the NMDA receptor is thought 
to account for ketamine-induced effects observed in the studies above.
10.5 Experimental specificity
The vast majority of the studies reported in this review were randomised, 
placebo-controlled, crossover studies, and thus their findings are deemed relatively 
robust. However the ketamine challenge studies mostly had a crossover design, 
which is limited by tachyphylaxis (i.e. a developed tolerance for ketamine, after 
repeated administration). This suggests that acute ketamine studies in the main may 
be underestimating the level of symptomatology experienced by individuals infused
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with acute ketamine. This confound may in part explain the difficulty with 
determining whether the acute ketamine model best mimics symptomatology 
characteristic of the pre-psychotic or acute states. Furthermore, the experimenters in 
the majority of acute ketamine challenge studies were not blind to the condition 
participants were undertaking. It is impossible to blind experimenters in chronic 
ketamine studies. The ketamine literature is therefore potentially confounded by 
bias, which could be introduced as a result of experimenters knowing the 
participants’ level of ketamine infusion or recreational consumption.
11. Ideas for future research
As any useful literature review should, this paper has reliably indicated 
direction for future research needs. In particular, it is evident that research 
investigating the chronic ketamine model of the psychoses is limited, and requires 
pursuing. Specifically, studies involving the recreational ketamine population are in 
their infancy, and require further development.
It is unclear whether the chronic ketamine model best mimics 
symptomatology characteristic of the pre-psychotic or chronic state. This author 
has proposed that chronic ketamine users may in fact present with subtle, attenuated 
psychotic-like symptomatology, which is undetected by the behavioural measures 
utilised by the few chronic ketamine studies which have been published. Indeed, it 
is hypothesised that chronic administration may give rise to ketamine-induced 
attenuated positive and negative psychotic symptomatology and cognitive 
dysfunction characteristic of the pre-psychotic state.
In order to investigate this hypothesis it would be necessary to utilise a 
robust and sensitive measure of the earliest signs of developing psychoses. This
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would be a novel approach to research conducted with the ketamine using 
population. Given a suitable sample size, it would thus be possible to determine 
whether ketamine users experience pre-psychotic symptomatology, and if so 
explore the degree to which such symptomatology is experienced, and the meaning 
afforded such symptomatology. Potential measures that could be utilised to assess 
pre-psychotic symptomatology in the recreational ketamine population include the 
Schizophrenia Prediction Instrument -  Adult version (SPIA: Klosterkotter et al.,
2001), and the Scale of Prodromal Symptoms (SOPS; McGlashan, Miller, Woods, 
Hoffman & Davidson, 2001) and its companion interview manual, the Structured 
Interview for Prodromal Syndromes (SIPS; Miller et al., 2003). The former has 
been developed from a hierarchical cluster analysis of the BSABS (Gross, Huber, 
Klosterkotter & Linz, 1987), and includes 10 ‘basic symptoms’ that were recently 
reported by Klosterkotter et al. (2001). The latter measures (usually used in 
combination), are proposed to assess for the later pre-psychotic symptomatology, 
just prior to the emergence of fully-manifest psychotic symptomatology, and are 
based upon Yung et al.’s (2005) pre-psychotic state criteria. In order to further 
evaluate the clinical validity and reliability and cognitive specificity of the chronic 
ketamine model of the psychoses, it would be necessary to conduct further studies 
investigating the cognitive profile of recreational ketamine users, to determine if 
previous findings could be replicated.
A factor to consider in such studies would be the frequency with which 
ketamine is being administered recreationally. It may be possible to compare 
cohorts of recreational ketamine users who take ketamine at differing frequencies, 
to explore any potential significant differences.
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Part 2: Empirical Paper
Chronic ketamine use and pre-psychotic 
symptomatology
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Abstract
Background: Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) 
receptor antagonist, with psychotomimetic properties. An acute dose of ketamine 
induces psychotic-like symptomatology, dissociative effects and pronounced 
cognitive dysfunction, thus ketamine is used as a ‘model’ of the psychoses. 
Recreational use of ketamine is rapidly increasing but there is limited research on 
ketamine’s chronic effects.
Aims: Researchers have suggested that ketamine may better model the psychotic 
symptomatology and cognitive dysfunction associated with the pre-psychotic state 
(prodrome), however this has not been systematically investigated. The present 
study aimed to determine the extent to which the chronic effects of ketamine 
overlap with the symptomatology characteristic of the pre-psychotic state.
Participants: Sixty-one participants, 35 men and 26 women aged 18 to 46 years, 
completed the study.
Design: A between subjects design was used to compare three groups: 21 frequent 
ketamine users (who used ketamine daily), 20 infrequent ketamine users (who used 
ketamine a maximum of once or twice a week), and 20 control participants (who 
reported no illicit drug use). Participants completed an interview (Schizophrenia 
Prediction Instrument -  Adult Version: SPI-A), self-report questionnaires 
(including O-LIFE; Peter’s Delusion Inventory, PDI; Dissociative Experiences 
Scale, DES) and a battery of cognitive tasks tapping episodic memory, working 
memory and executive functioning.
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Results: Both ketamine groups reported higher levels of psychotic-like 
symptomatology on the clinical index of symptomatology (SPI-A) and the general 
population index of psychotic-like markers (O-LIFE). On the former index a 
‘frequency’ effect was observed: frequent users were found to experience more 
psychotic-like symptomatology (i.e. basic symptoms) than infrequent users. 
Frequent ketamine users were also found to score higher on measures of 
dissociation, and both groups of ketamine users experienced higher delusional 
ideation compared with controls. Furthermore, both groups of ketamine users 
demonstrated impaired episodic and working memory compared to controls. Group 
differences were also found in verbal fluency.
Conclusion: The findings lend support to the ketamine model of the psychoses, and 
suggest that glutamatergic disturbances may contribute to the pre-psychotic state 
because symptomatology proposed to be characteristic of the pre-psychotic state 
was observed in chronic ketamine users. These findings have important clinical 
implications for the growing numbers of ketamine users in this country and 
elsewhere.
Key words: chronic effects, basic symptoms, ketamine, pre-psychotic
symptomatology, psychoses, psychosis proneness; schizotypy
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INTRODUCTION
“I t’s so much like a party in your own head that eventually you are isolated and in 
a world o f your own. Your brain ‘fr  aggies there’s disconnection and loose ends in 
your mind, like its full o f live wires. ” (infrequent user 5)
“I get very distracted by spiritual interactions. I  don Y think ketamine causes these 
experiences, but rather it is a catalyst for these experiences, for spiritual activity. 
The spirits are breaking the boundary o f this world and the other side. It (ketamine) 
helps you to tune in, like tuning a radio dial. People need to understand that. ” 
(frequent user 2)
Ketamine -  an overview
Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, 
which interferes with the action of excitatory amino acids (EAAs), including 
glutamate and aspartate (Anis, Berry, Burton & Lodge, 1983). The EAAs are the 
most prevalent excitatory neurotransmitters in the brain and play an important role 
in cortico-cortical and cortical-subcortical interactions (Cotman & Monaghan, 
1987). Ketamine use began within clinical settings, for the purposes of anesthesia 
and analgesia. As a result of the bizarre post-operative ‘emergence phenomena’ it 
induced (vivid dreams, hallucination-like experiences, delusions and confusional 
states: Siegel, 1978), it was withdrawn from anaesthetic use with adults. 
Interestingly, these ‘emergence phenomena’ have made ketamine the drug of choice 
for an increasing number of recreational drug users.
Recreational ketamine use (street names; K, Special K and Vitamin K), became 
popular in the UK club scene in the early 1990s. In the past few years a surge in
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ketamine use has been observed (DrugScope, 2005). Indeed recently it was found 
that 0.8% of 16-24 year-olds had used ketamine in the last year (The British Crime 
Survey: Murphy & Roe, 2007). Furthermore, surveys of club goers have found a 
much higher incidence of recreational ketamine use (43% of club goers surveyed: 
Mixmag, 2004). In January 2006, ketamine was classified a class-C controlled drug 
in the UK.
Ketamine use and psychotic-like symptomatology and cognitive dysfunction
The acute effects of ketamine in healthy volunteers have been widely investigated. 
Findings indicate that acute ketamine has dose-specific effects, reliably inducing 
unusual thought processes and speech disturbances (mimicking formal thought 
disorder), blunted affect, emotional withdrawal, perceptual alterations, dissociation 
and cognitive impairment, such as deficits in episodic, semantic and working 
memory (Anand et al., 2000; Boeijinga, Soufflet, Santoro & Luthringer, 2007; 
Covington et al., 2007; Hetem, Danion, Diemunsch & Brandt, 2000; Krystal et al., 
1994; Malhotra et al., 1996; Morgan, Mofeez, Brandner, Bromley & Curran, 2004a; 
Newcomer et al., 1999; Pomarol-Clotet et al., 2006). The psychotomimetic effects 
of acute ketamine appear to include symptomatology deemed core to the psychoses 
(i.e. positive and negative psychotic-like symptomatology, and marked cognitive 
impairment). These studies support a ‘ketamine model’ of the psychoses, which has 
led to the glutamatergic hypothesis of the psychoses (Olney & Farber, 1995). This 
hypothesis proposes that glutamatergic NMDA receptor hypofunction (which 
ketamine induces), may contribute to the psychotic symptomatology and cognitive 
dysfunction observed in the psychoses.
125
However there is a paucity of research investigating the chronic effects of ketamine, 
and to this author’s knowledge there are only 8 published studies (Curran & 
Monaghan, 2001; Curran & Morgan, 2000; Morgan et al., 2006; Morgan, 
Monaghan & Curran, 2004b; Morgan, Riccelli, Maitland & Curran, 2004c; 
Muetzelfeldt et al., 2008; Narendran et al., 2005; Uhlhaas, Millard, Muetzelfeldt, 
Curran & Morgan, 2007). The increasing number of recreational ketamine users in 
the UK and worldwide, and the growing evidence of ketamine-induced psychotic- 
like experiences requires this gap in our knowledge to be addressed. Ketamine’s 
medicinal use as a one-off anaesthetic, as well as its range of cognitive and 
psychotic-like side effects ethically prohibit administering repeated doses to healthy 
participants under experimental conditions. Therefore, the only window on chronic 
effects is through individuals who use ketamine recreationally.
Curran and Morgan (2000) were the first authors to use this naturalistic population 
to study the psychotomimetic effects of chronic ketamine. They found ketamine 
users experienced higher levels of psychotic-like symptomatology, including 
magical ideation, perceptual distortions, unusual thought content and dissociation 
than poly-drug controls, three days after an acute dose of ketamine (following 
abstinence from alcohol and other recreational drugs). They also noted significantly 
impaired episodic and semantic memory. Their findings closely replicated the acute 
dissociative and psychotomimetic effects of ketamine in challenge studies with 
healthy, drug-naive participants. Similarly, Uhlhaas et al. (2007) found higher 
levels of delusional ideation 3 days after ketamine use, and Morgan et al. (2004b) 
found higher levels of schizotypal symptomatology and perceptual distortions in a
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sample of ketamine users who had substantially reduced their ketamine use, 
compared with poly-drug controls.
However other studies have found no evidence of psychotic-like or dissociative 
symptomatology in ketamine users, in comparison to poly-drug controls (Morgan et 
al., 2004c, 2006). Nevertheless, these studies did find evidence of cognitive deficits, 
including episodic memory dysfunction, with selective source memory (memory for 
contextual information about episodes) impairment alongside intact recognition. 
Furthermore, Curran and Monaghan (2001) found no differences in psychotic-like 
symptomatology between frequent and infrequent ketamine users, yet did find 
frequent users exhibited impaired episodic and semantic memory, 3 days after acute 
ketamine use.
The findings of these chronic ketamine studies are clearly mixed. It could be argued 
this is because the psychotic-like symptomatology and cognitive dysfunction 
observed are not due to chronic effects of ketamine, but rather were the result of 
pre-existing group differences. However Curran and Monaghan’s (2001) findings 
provide support against this interpretation because three days after acute ketamine 
use, frequent ketamine users still experienced impaired episodic and semantic 
memory, whereas infrequent users performed at significantly higher levels on all 
previously impaired cognitive tasks. This conclusion is strengthened by the 
observation that an acute dose of ketamine does not cause residual cognitive 
impairments 3 days later, in healthy participants (Morgan et al., 2004a).
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If it is taken that ketamine does have chronic effects, why has an absence of 
psychotic-like symptomatology been observed in several studies when users are 
drug free (Curran & Monaghan, 2001; Morgan et al., 2004c, 2006)? Differences 
across studies may have been the result of the varying frequency with which 
ketamine was taken by users, and the differing amounts taken. This interpretation of 
findings lacks evidence, as groups of ketamine users who used with very similar 
frequency (e.g. 3.1 & 4.4 times per month) showed differing symptomatology 
(Curran & Morgan, 2000; Morgan et al., 2006 respectively). A key problem is that 
the measures utilised to assess psychotic-like symptomatology in previous studies 
(namely the Schizotypal Symptomatology Questionnaire: SSQ, and Subjective 
Effects Scales: SES) may not have been sensitive or specific enough to detect the 
chronic phenomenological effects of ketamine, resulting in mixed findings. Indeed, 
it may be that the symptomatology induced by chronic ketamine use (i.e. unusual 
thought patterns, perceptual distortions and delusional ideation) more closely 
represents attenuated positive and negative psychotic symptomatology, deemed 
characteristic of the ‘pre-psychotic’ state (e.g. Corlett et al., 2006; Schultze-Lutter, 
Ruhrmann, Hoyer, Klosterkotter & Leweke, 2007a).
The pre-psychotic state
There is widespread recognition of a state experienced by those diagnosed with 
idiopathic psychoses, prior to the emergence of fully manifest psychotic 
symptomatology, often referred to as ‘the prodrome’ (McGorry et al., 1995, cited in 
Comblatt, Lencz & Obuchowski, 2002). For the purposes of this paper this state 
will be termed the ‘pre-psychotic’ state (in line with Mameros, Pillmann, Haring, 
Balzuweit & Bloink, 2005), so as to be inclusive of the two most significant
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approaches used to define the prodrome: the ‘basic symptom’ (Huber, Gross, 
Schuttler & Linz, 1980; Klosterkotter, Hellmich, Steinmeyer & Schultze-Lutter, 
2001), and ‘ultra-high risk’ (Yung et al., 1998; Yung & McGorry, 1996) 
approaches. Indeed, these two approaches are increasingly being combined in the 
‘prodrome of psychoses’ literature, such as in the German Research Network on 
Schizophrenia studies (Hafner, Maurer & Ruhrmann, 2004), and the European 
Prediction of Psychosis studies (Klosterkotter, Ruhrmann, Schultze-Lutter, 
Salokangas & Linszen, 2005).
Basic symptoms describe the earliest, most subtle, sub-clinical and self-experienced 
disturbances of thought processes, perception, motivation and affect, which initially 
occur during the pre-psychotic state. Basic symptoms are thought to be central to 
the behavioural disturbances and functional disability experienced during the pre- 
psychotic period and fully manifest psychoses. However whereas psychotic 
symptomatology is externally observable by others on the basis of behaviour and 
expression, it is proposed that during the pre-psychotic period, basic symptoms are 
often only perceived by the person affected.
Gross (1997) suggests the basic symptom construct can be subdivided into 2 
groups: level 1 (nonspecific) and level 2 (characteristic) basic symptoms, with the 
former developing prior to the latter. She explains that level 2 symptoms consist of 
cognitive thought disturbances (e.g. thought blocking, disturbance of expressive 
speech), perceptual disturbances (e.g. hypersensitivity to light and visual stimuli), 
and action symptoms (i.e. subjectively experienced disorder of movement and 
action, such as loss of automatic skills), and notes that cognitive thought
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disturbances have been found to be indicative of a forthcoming transition to fully- 
manifest psychotic symptomatology. Furthermore, the presence of basic symptoms 
does not necessarily indicate that an individual will develop a psychotic disorder in 
years to come, as some individuals demonstrate patterns of spontaneous remission.
It is proposed that although some basic symptoms are intermittently present during 
the acute and chronic states experienced by individuals with psychoses (Gross, 
1997), these state are characterised by different symptomatology. The acute state is 
deemed to be characterised by positive psychotic symptomatology, and the chronic 
state is deemed to be characterised by negative psychotic symptomatology, a 
significant degree of cognitive impairment, and a history of fully-manifest positive 
psychotic symptomatology. Furthermore, it is argued that a much higher level of 
basic symptoms is experienced during the pre-psychotic state in comparison to the 
acute and chronic states.
Aims and hypotheses
No study has yet investigated the possibility that chronic ketamine induces 
attenuated positive (and potentially negative) psychotic symptomatology, deemed 
characteristic of the pre-psychotic state. If chronic ketamine use does mimic 
symptomatology characteristic of the pre-psychotic state, then attenuated negative 
symptomatology should be observed (e.g. Hafner, Loffler, Maurer, Hambrecht & 
Heiden, 1999; Klosterkotter, Gross, Huber & Steinmeyer, 1997; Tsuang et al., 
2000, all cited in Comblatt el al, 2002). This study therefore aimed to inform the 
ketamine model, and thus the glutamate hypothesis of the psychoses, which 
proposes glutamatergic NMDA-receptor hypofunction (which ketamine induces),
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may be responsible for the psychotic symptomatology and cognitive dysfunction 
observed in the psychoses (Javitt & Zukin, 1991; Olney & Farber, 1995; Coyle, 
1996, all cited in Abi-Saab, D'Souza, Moghaddam & Krystal, 1998). It also aimed 
to expand the literature regarding the potential long-term effects of ketamine use, so 
as to inform the ketamine using population.
The current study intended to explore the presence of basic symptoms in a sample 
of frequent and infrequent ketamine users in comparison with healthy controls. The 
use of an assessment tool which examines basic symptoms ensured a high level of 
sensitivity and selectivity for pre-psychotic symptomatology, which other chronic 
ketamine studies have not used. Given the previous research on chronic ketamine 
use, the central focus of this study was on the psychotomimetic effects of ketamine. 
Although dissociation is not a symptom specific to the psychoses, it occurs under 
ketamine use. Therefore, a measure of dissociation was included. A standard scale 
was also used to monitor mood. Effects on cognition were also of interest, given the 
cognitive deficits widely observed during the pre-psychotic state. Cognitive 
assessments were selected so as to examine cognitive systems reliably observed as 
impaired in participants deemed to be in the pre-psychotic state, including verbal 
episodic memory, verbal executive functioning and working memory (Niendam et 
al., 2006, 2007; Eastvold, Heaton, & Cadenhead, 2007; Pukrop et al., 2007).
On the basis of previous acute and chronic ketamine studies, the following 
predictions were made:
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Subjective effects
1) It is predicted that ketamine users will display higher levels of psychotic-like 
symptomatology, psychotic proneness and delusional ideation in comparison to 
controls (Curran & Morgan, 2000; Morgan et al., 2004b; Uhlhaas et al., 2007). It is 
also hypothesised that frequent ketamine users will show higher levels than 
infrequent users.
2) Based upon Curran and Morgan (2001), Morgan et al. (2004b, 2004c) and 
Morgan et al. (2006), it is hypothesised there will be no group differences in level 
of dissociative symptomatology.
Cognitive effects
1) Executive functioning: Ketamine users will show more deficits in category 
fluency compared with controls, but no difference in verbal fluency (Curran & 
Morgan, 2000; Morgan et al., 2004d). Category fluency will be more impaired in 
frequent ketamine users compared with infrequent users (Curran & Monaghan, 
2001).
2) Episodic memory: Prose recall will be more impaired in frequent compared with 
infrequent ketamine users, who in turn will be more impaired than controls (Curran 
& Morgan, 2000; Curran & Monaghan, 2001).
3) Working memory: As no study with recreational ketamine users has used digit 
span as a measure of working memory, this aspect of the present research is 
exploratory. It is tentatively hypothesised that if chronic ketamine use provides a 
model of the psychoses, then manipulation rather than maintenance of information 
in working memory will be selectively impaired (Morgan & Curran, 2006), as is the
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general finding with individuals with psychoses (Kim, Glahn, Nuechterlein & 
Cannon, 2004; Perry et al., 2001).
METHOD 
Power calculation
The power calculation was based upon prose recall results (means and SD) reported 
by Curran and Monaghan (2001), who compared frequent ketamine users with 
infrequent ketamine users. Statistical power analyses using a programme located at 
http://www.dssresearch.com estimated a sample of 18 participants per group, in 
order to gain statistically significant findings at a power level of 0.90, with an alpha 
level of 1%. This number of participants is in line with previous ketamine studies 
completed by the Curran & Morgan UCL consortium.
Participants and Design
A between-subjects design was utilised to compare frequent ketamine users, 
infrequent ketamine users and controls who reported no illicit drug use. Participants 
were recruited through advertisement and via snowball sampling (Solowij, Hall & 
Lee, 1992). Participants were paid for their participation and all completed a 
written, informed consent form. The inclusion criteria were: aged 18-50 years, 
native English speakers or fluent in English as a second language. Infrequent 
ketamine use was defined as use of ketamine between 3-12 days in a month; 
frequent ketamine use as every day.
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Joint thesis
This thesis was part of a joint project, completed alongside 2 fellow trainee clinical 
psychologists, Suzanna Hunt (UCL: Prodromal symptoms in daily skunk users) and 
Lisa Monaghan (Royal Holloway: Chronic Cocaine use and prodromal symptoms of 
schizophrenia). See Appendix 1 for details of the contribution made by each trainee.
Ethics
The study was approved by the UCL Graduate School Ethics Committee (See 
Appendix 2).
Procedure
On the testing day participants were again provided with a volunteer information 
sheet to read (See Appendix 3) and were then asked to give written, informed 
consent (See Appendix 4 for consent form). Then they gave details of their current 
and historical drug use and only ketamine using participants answered further 
questions specifically about their ketamine use.
Assessments
Tests were selected to assess a range of human memory functions, dissociative and 
psychotogenic symptoms, and mood effects. Tests were administered in the 
following order: DES, The Spot-the-Word Test, Short O-LIFE, BDI, prose recall 
immediate, phonological fluency, semantic fluency, prose recall delayed, PDI, LES, 
Digit Span. Prose recall was delayed by 15 minutes. This delay was filled with the 
fluency tasks listed above and another cognitive assessment not reported in this 
paper. Order of testing was the same for each participant.
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Semi-structured Interview - Symptomatology Assessment
Schizophrenia Prediction Instrument -  Adult Version (SPI-A; Schultze-Lutter, 
Klosterkotter & Addington, unpublished). Pre-psychotic symptomatology was 
assessed using the SPI-A. This assessment was chosen in order to provide a clinical 
index of symptomatology. Interrater reliability was established through the 
development of a semi-structured interview schedule (See Appendix 5), based upon 
the SPI-A manual (Schultze-Lutter et al., unpublished). The trainee clinical 
psychologists who developed the interview schedule (SD, SH, and LM) practised 
completing the schedule with each other and piloted the schedule with drug users, in 
order to improve reliability. Furthermore, SPI-A item self-rating cards were 
developed for participants, to improve rating reliability (See Appendix 6). However 
formal assessment of interrater reliability was not conducted.
The SPI-A was developed from a hierarchical cluster analysis of the Bonn Scale for 
the Assessment of Basic Symptoms (BSABS; Gross, Huber, Klosterkotter & Linz, 
1987). It comprises 7 subscales (A-F, & O):
A) Affective-Dynamic Disturbances (experiences associated with changes in mood 
and emotional responsiveness).
B) Cognitive-Attentional Impediments (experiences such as reduced concentration 
and attention, and increased distraction).
C) Cognitive disturbances (experiences associated with unusual thought processes 
and language disruption).
D) Disturbances in Experiencing Self & Surroundings (experiences such as 
emotional confusion, thought pressure and unstable ideas of reference).
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E) Body Perception Disturbances (experiences associated with strange or unusual 
bodily sensations).
F) Perception Disturbances (experiences associated with visual and acoustic 
perceptual alteration).
O) Optional Extras (a range of items chosen from a potential list of 11 items to 
include pre-psychotic symptomatology suggested to be that most predictive of 
transition to fully-manifest psychotic symptomatology by Klosterkotter et al., 
2001).
Sample items from these subscales of the SPI-A include:
A: Impaired tolerance to certain social everyday situations, and Decrease in positive 
emotional responsiveness towards others.
B: Feeling overly distracted by stimuli, and Slowed-down thinking.
C: Thought interference, Thought blockages and Disturbances in expressive speech. 
D: Decreased ability to discriminate between different kinds of emotions and 
Unstable ideas of reference.
E: Bodily sensations of numbness and stiffness and Bodily sensations of being 
electrified.
F: Hypersensitivity to light / optic stimuli and Hypersensitivity to sounds / noise.
O: Thought perseveration, Decreased ability to discriminate between ideas and 
perception, pure fantasy and true memories, Captivation of attention by details of 
the visual field, Derealisation and Motor blockages.
In total, it featured 34 main items (within subscales A-F), and 5 Optional Extra 
items. Each item could be rated a score between 0 (absent) and 6 (extreme). Three
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SPI-A subscales contained 5 items (A, D, O), and four subscales contained 6 items 
(B, C, E, F). Total SPI-A subscale scores were calculated by summing the 
individual scores for each subscale, and then summing the subscale scores. The 
maximum total SPI-A score was 234 points. Prior to undertaking the SPI-A 
interview, ketamine users were instructed to rate only subjective day-to-day 
experiences (i.e. chronic effects of ketamine), not intoxicated experiences resulting 
from acute effects of the drug. Participants were also informed to only rate 
experiences that had developed since they started using ketamine and experiences 
that had changed since starting ketamine. An SPI-A score sheet was created for 
recording results (Appendix 7).
Subjective rating scales
Dissociative Experiences Scale (DES: Bernstein & Putnam, 1986). This 
subjectively rated, 28-item measure is designed to index trait dissociation ranging 
from everyday experiences (e.g. riding in a car and not remembering all the trip), to 
more pathological experiences (e.g. standing outside your body watching yourself). 
It was decided to assess dissociation as it is commonly observed in the psychoses, 
despite not being necessary or specific for a DSM or ICD diagnosis of psychotic 
disorder. Acute ketamine studies have indicated that acute ketamine reliably induces 
dissociation, and it was therefore deemed useful to look at whether such 
symptomatology was present in chronic ketamine users. Sample items include:
- Some people find that sometimes they are listening to someone talk and they 
suddenly realise they did not hear part or all of what was said.
- Some people are told that they sometimes do not recognise friends or family.
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- Some people have the experience of feeling that other people, objects, and the 
world around them are not real.
- Some people sometime find that they hear voices inside their hear that tell them to 
do things or comment on things that they are doing.
For each of the 28 items, the respondent is able to score a percentage value of how 
much they agree with each statement. These percentage values start at 0% and finish 
at 100%, and are fixed at increments of 10%. A total score reflecting current 
dissociation is obtained by summing across all items. Therefore, the maximum total 
DES score is 2800.
The Spot-the-Word Test: Version B (Baddeley, Emslie & Nimmo-Smith, 1993). This 
test was used to estimate premorbid verbal intelligence. It was required as it is well 
documented that intelligence impacts upon performance on cognitive tasks. It was 
therefore desirable to have such a measure so that groups of participants could be 
matched for premorbid intelligence, and the relationship between scores on 
cognitive tasks and premorbid intelligence could be determined for the sample of 
participants in this study.
Participants were required to choose the real word from 60 pairs of words / non­
words (e.g. slank-chariot, sterile-palth, grottle-strumpet, chalper-camera) by ticking 
the item in each pair they believed to be the real word. A total score reflecting 
premorbid IQ is obtained by summing all correctly identified words, therefore the 
maximum total score was 60. This task has been shown to give a measure of IQ that
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is correlated 0.69 with the National Adult Reading Test (NART; Crawford, Dreary, 
Starr & Whalley, 2001).
Short Oxford-Liverpool Inventory o f Feelings and Experiences Questionnaire 
(Mason, Claridge & Jackson, 2005). This is a self-report measure consisting of 43 
items, and is based upon an analysis of what is probably the largest single dataset of 
schizotypal measures (Claridge et al., 1996). The measure is utilised to determine 
the level of ‘psychosis proneness’ in non-clinical samples of individuals. Psychosis 
proneness (Claridge, 1987) is a construct which indicates that certain individuals in 
the general population have similar experiences to the positive symptomatology of 
the psychoses, while remaining functioning members of society. This is in line with 
the dimensional conceptualisation of functional psychoses, which suggests that 
psychotic symptomatology is the severe expression of a disposition to the 
psychoses, which is present throughout the general population. This assessment was 
chosen in order to provide a general population index of psychotic-like markers. 
The O-LIFE has high internal consistency (Mason et al., 1995) and test-retest 
reliability (Burch, Steel & Hemsley, 1998).
Sample items of included in the Short O-LIFE include:
- Are you easily confused if too much happens at the same time?
- Do you think you could learn to read other’s minds if you wanted to?
- Can some people make you aware of them just by thinking about you?
- Have you ever felt the urge to injure yourself?
- Are your thoughts sometimes so strong that you can almost hear them?
- Do you feel very close to your friends?
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For each item the participant responds either yes or no. To score the items, a value 
of 1 is given to yes responses, and a value of 0 to no responses, for the majority of 
items. For items 4, 9, 17, 27, 30, 37, 39, 41 (reverse items) scoring is reversed. To 
obtain the total O-LIFE score, all item scores are summed. The Short O-LIFE 
consists of four subscales. These are attained by grouping scores for specific items, 
as follows:
1) Unusual Experiences subscale (representative of positive psychotic-like 
symptomatology akin to hallucinatory and delusional experiences): 12 items (3, 5, 
6, 8, 10, 13, 19, 23,26, 29, 34,35).
2) Cognitive Disorganisation subscale (conceptualised as disorganised psychotic- 
like symptomatology relating to thought disorder-like experiences and attentional 
difficulties): 11 items (1, 7, 12, 16, 20, 24, 31, 33, 36, 38, 42).
3) Introvertive Anhedonia subscale (representative of negative psychotic-like 
symptomatology, and concerned with the inability to derive pleasure from 
experiences): 10 items (4, 11, 15, 17, 22, 25, 27, 30, 32, 41).
4) Impulsive Nonconformity subscale (index of impulsivity and risk-taking 
behaviour): 10 items (2, 9, 14, 18, 21, 28, 37, 39, 40, 43).
The first three factors are comparable to the three factor model of the psychoses 
proposed by Liddle (1987); Unusual Experiences, Cognitive Disorganisation, 
Introvertive Anhedonia. The fourth factor, Impulsive Nonconformity, is based on 
Eysenck’s Psychoticism scale (Eysenck & Eysenck, 1975) and is the least well 
related to psychosis proneness. Subscale scores are obtained by summing the scores 
for items within that subscale.
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The Beck Depression Inventory (BDI-II: Beck, Steer, & Brown, 1996). The BDI-II 
is a 21-item self-report instrument intended to assess the existence and severity of 
symptoms of depression as listed in the Diagnostic and Statistical Manual of Mental 
Disorders Fourth Edition (DSM-IV: APA, 1994). A measure of symptoms of 
depression was required as it is well documented that low mood impacts upon 
performance on cognitive tasks. It was therefore desirable to have such a measure so 
that the relationship between mood and scores on cognitive tasks could be 
determined for the sample of participants in this study.
The instrument requires participants to rate themselves on measures of sadness, 
pessimism, past failure, loss of pleasure, guilty feelings, punishment, self-dislike, 
self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, 
indecisiveness, worthlessness, loss of energy, changes in sleeping pattern, 
irritability, changes in appetite, concentration difficulty, tiredness and/or fatigue, 
and loss of interest in sex. For each item participants have a choice of 4 optional 
Likert-scale responses, scored from 0 (item is not applicable) to 3 (severe). For 
example for the first item sadness response options are:
(0) I do not feel sad
(1) I feel sad much of the time
(2) I am sad all the time
(3) I am so sad or unhappy that I can’t stand it
A total score reflecting severity of depression is obtained by summing across all 
BDI items, so that the maximum total score is 63. In addition, the Inventory entails 
two subscales: the Cognitive subscale (8 items: pessimism, past failures, guilty
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feelings, punishment, self-dislike, self-criticalness, suicidal thoughts or wishes, and 
worthlessness) and the Somatic subscale (13 items: sadness, loss of pleasure, crying, 
agitation, loss of interest, indecisiveness, loss of energy, changes in sleep pattern, 
irritability, change in appetite, concentration difficulty, tiredness and/or fatigue, and 
loss of interest in sex). The total subscale scores are calculated by adding individual 
item scores specific to that subscale.
Peters Delusion Inventory (Peters, Joseph & Garety, 1999). This self-report 
inventory is designed to assess delusional ideation in the general population. A 
measure of delusional ideation was required because the study aimed to investigate 
the ability of chronic ketamine to model symptomatology characteristic of the pre- 
psychotic state, in which delusional ideation is observed. The PDI is a 21-item 
measure, which includes items such as:
- Do you ever feel as if things in magazines or on TV were written especially for 
you?
- Do you ever feel as if you were being persecuted in some way?
- Do you ever feel that you are a very special or unusual person?
- Do you ever feel as if the world is about to end?
Participants answer ‘yes’ if they have experienced the thought or belief described. A 
total PDI score is then calculated by summing the number of ‘yes’ responses. 
Furthermore, if participants answer yes to an item, they then also rate the degree of 
distress this thought or belief induces (on a 1-5 Likert-scale where 1= not at all 
distressing, and 5= very distressing), and their level of preoccupation with (on a 1-5 
Likert-scale where 1= hardly ever think about it, and 5= all the time), and
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conviction in (on a 1-5 Likert-scale where 1= don’t believe it’s true, and 5= 
absolutely true) the thought or belief the experience. A total ‘Distress’ score is 
calculated by summing the distress ratings and dividing this score by the number of 
items to which the participant responded yes. A total ‘Preoccupation’ score is 
calculated by summing the preoccupation ratings and dividing this score by the 
number of items to which the participant responded yes. A total ‘Conviction’ score 
is calculated by summing the conviction ratings and dividing this score by the 
number of items to which the participant responded yes.
The Life Experiences Survey (LES: Sarason, Johnson & Siegel, 1978). This 
questionnaire assesses the number of significant life experiences (both positive and 
negative) encountered by participants in the 12-month period prior to testing, and 
their severity. This measure was chosen as it is widely recognised that stressful life 
events can precipitate the development of fully-manifest psychotic symptomatology, 
and changes in mood. It was therefore deemed necessary to explore whether life 
events in the preceding 12 months were significantly related to SPI-A and BDI-II 
scores.
The participant responds by rating the severity of relevant life events, from a list of 
43 items, using a seven point Likert scale (where -3= ‘Extremely negative’, and 
+3= ‘Extremely positive’).
Sample items from the survey include:
- Marriage
- Death of a spouse
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- Major change in distance form family (increased or decreased)
- Major personal illness or injury
There are 3 open-ended items at the end of the questionnaire for the participant to 
include and rate the severity of additional life experiences which may have occurred 
in the last 12 months, but which are not in the main body of the survey.
Four scores can be derived from the LES:
1) Number of negative life events: sum the total number of negative life events 
responded to.
2) Number of positive life events: sum the total number of positive life events 
responded to.
3) Mean rating of negative life events: sum the severity scores for all the 
negative life events (removing any negative signs), and divide this total by the 
number of negative life events responded to.
4) Mean rating of positive life events: sum the severity scores for all the positive 
life events (removing any negative signs), and divide this total by the number of 
positive life events responded to.
Cognitive Tasks
Cognitive tasks were selected so as to examine cognitive systems reliably observed 
as impaired in participants deemed to be in the pre-psychotic state, including verbal 
episodic memory, verbal executive functioning and working memory (Niendam et 
al., 2006, 2007; Eastvold, Heaton, & Cadenhead, 2007; Pukrop et al., 2007).
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Episodic Memory
Prose recall
Prose recall was chosen to measure episodic memory because there is much 
previous research with acute ketamine users utilising this measure so findings could 
be directly compared, and it has been found to provide the best laboratory test 
predictor of everyday memory performance (Sunderland, Watts, Baddeley & Harris, 
1986). Participants were played a taped passage of prose from the Rivermead 
Behavioural Memory Battery (RBMB: Wilson, Cockbum & Baddeley, 1985), and 
were then required to verbally recall it (i) immediately and (ii) after a 15-minute 
delay, filled with other cognitive assessments. Recall was scored in terms of ‘idea 
units’ recalled, with one point for each exact synonym and half a point for 
incomplete recall or a close synonym (maximum score is 21).
Executive functioning
Fluency
Phonological and semantic fluency tasks were chosen as simple and quick measures 
of frontal lobe function and to tap retrieval from semantic memory. In phonological 
fluency, participants were given a single letter prompt (i.e. F) and required to 
generate as many words beginning with that letter in 60 seconds (excluding proper 
nouns and many words beginning with the same prefix). In semantic fluency, 
participants were provided with a super-ordinate category member (i.e. musical 
instruments) and asked to generate as many members of that category as possible 
again in 60 seconds. The number of correct exemplars and number of errors were 
recorded for both fluency tasks. Verbal and category fluency total scores were
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calculated by summing the number of correct responses. Error scores were 
calculated by summing the total number of errors for each task separately.
Working Memory
Digit Span Forwards (Version A)
Digit span was used to measure working memory because it is a quick measure that 
would not fatigue participants greatly, given the previous amount of work they had 
undertaken. It was also chosen because it provided a way to differentiate the ability 
to maintain information in working memory from the ability to manipulate 
information, a pattern of impairment reliably observed in the psychoses literature 
(Fletcher & Honey, 2006).
Participants were presented with number strings of increasing length, which they 
had to memorise and immediately verbally repeat (e.g. 8-2-9, 3-8-4-7-5-1-6). Digit 
span forwards total score was calculated by summing the number of number strings 
the participant recalled correctly. This task taps the phonological loop component of 
working memory (Baddeley, 2000), which is involved in rehearsal and temporary 
maintenance of auditory verbal information.
Digit Span Backwards (Version A)
Participants were again presented with number strings of increasing length, which 
they had to memorise, and immediately verbally repeat in reverse order. Digit span 
backwards total score was calculated by summing the number of number strings the 
participant recalled correctly. This task taps the central executive component of 
working memory (Baddeley, 2000), which is suggested to be a limited-capacity
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supervisory attentional mechanism (Shallice, 1982), responsible for the maintenance 
and manipulation of information.
Statistical Analyses
All statistical analyses were performed using Statistical Package for Social Sciences 
(SPPS Version 11.5). Group differences were examined using one-way ANOVAs 
and, where data were nonparametric, the Kruskall-Wallis test. Bonferroni post hoc 
tests and Bonferroni corrected Mann-Whitney U tests were used to explore simple 
effects where a significant effect of group was revealed. Independant samples t-tests 
and, where data were nonparametric, Mann-Whitney U tests were used to compare 
ketamine groups on ketamine use variables and general drug use variables. Chi- 
squared tests were used to explore dichotomous data. The prose recall immediate 
and delayed data were analysed using 3X2 repeated measures analyses of variance 
(RMANOVA) with delay (immediate, delayed) as the within-subjects factor and 
group (control, infrequent ketamine, frequent ketamine) as the between-subject 
factor. Post-hoc comparisons (simple effects) were again Bonferroni corrected.
Correlations (one-tailed) were conducted using Spearman’s rank order correlation, 
and all correlations conducted were hypothesis driven. Correlations were only 
conducted on measures showing significant group differences to minimise the 
chance of Type I errors. Correlations were conducted within each of the two 
ketamine groups for degree of ketamine use and SPI-A total and subscale scores, 
and DES total scores. Within each of the two ketamine groups SPI-A total and 
subscale scores were also correlated with BDI, Digit Span backwards, and BDI total 
scores were correlated with negative life events on the LES. Where no significant
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differences between frequent and infrequent ketamine users were obtained, 
correlations were conducted across both ketamine groups. To minimise Type I error, 
the a-level for correlations was set at 0.01.
RESULTS
1. Demographics & reported drug use (Tables 1,2 & 3)
There were 61 participants in total: 20 infrequent ketamine users (ten females), 21 
frequent ketamine users (nine females), and 20 non-drug using control participants 
(seven females). The respective numbers of individuals of different ethnicity in the 
infrequent / frequent ketamine user groups, and non-drug using control participants 
were; Asian (0/0/3), Black British (0/0/1), White British (13/13/13), White Other 
(4/8/2), Other -  mixed race (3/0/1). Two participants were Italian by birth, and one 
Eastern European. There were no significant group differences in gender or ethnic 
background (comparing White British with Other ethnic background). The highest 
level of educational qualification attained by infrequent / frequent ketamine user 
groups, and non-drug using control participants respectively were; GCSEs (2/7/4), 
College diploma / NVQ (1/6/0), AS/A levels (3/3/7), Undergraduate degree 
(11/3/7), Diploma of higher education (3/2/0), Masters (0/0/2). The current 
employment status of infrequent / frequent ketamine user groups, and non-drug 
using control participants respectively was: Unemployed (4/8/2), Employed 
(12/10/18), Student (4/3/0).
The three groups did not differ in age but did differ in pre-morbid IQ (j2 = 7, P = 
0.03), although Bonferroni corrected Mann-Whitney U tests showed no differences 
between any 2 groups.
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Groups differed in BDI total score (j2 = 23.19, P < 0.001), BDI Somatic subscale 
score (j2 = 23.38, P < 0.001), and BDI Cognitive subscale score (j2 = 18.2, P < 
0.001). Frequent ketamine users scored higher on all 3 BDI scales than both 
infrequent ketamine users (BDI Overall & Somatic: P < 0.001; BDI Cognitive: P = 
0.002) and controls (P < 0.001). In the frequent ketamine user group, 14 individuals 
were found to have clinically significant levels of depression (BDI depression 
category: 6 ‘mild’, 3 ‘moderate’, 5 ‘severe’).
There were no differences in the number of positive life experiences encountered by 
participants in the year prior to testing. However differences were found between 
groups for the degree of positivity of the positive experiences encountered (F(2, 57) 
= 6.43, P = 0.003), reflecting positive life experiences of frequent ketamine users 
being rated as significantly less positive than those of the controls (P = 0.002). 
There was a statistically significant difference identified in the number of negative 
life experiences encountered by participants in the year prior to testing (%2 = 20.42, 
P < 0.001), due to the frequent ketamine users experiencing more negative events 
than both infrequent ketamine users and controls (both P < 0.001). Group 
differences were found for the degree of negativity of the negative life experiences 
encountered (F(2, 57) = 5.5, P = 0.007), reflecting higher negativity ratings by 
frequent ketamine users compared with controls (P = 0.005).
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Table 1. Group means (sd) for demographics.
Controls Infrequent 
Ketamine users
Frequent 
Ketamine users
Age (yrs) 28.05 (7.39) 25.05 (4.35) 24.80 (7.49)
Spot the word test score 48.95 (5.53) 48.50 (3.46) 44.48 (6.30)
(no. correct)
BDI total 5.50 (8.09) 7.20 (4.80) b 19.14 (10.65) 8
BDI Somatic 3.70 (5.03) 4.85 (3.25) b 12.67 (6.44)8
BDI Cognitive 1.80 (3.50) 2.35 (1.84) b 6.48 (4.75) 8
Number of positive life
events (LES) 4.50 (2.72) 4.35 (2.70) 3.90 (2.61)
Number of negative life
events (LES) 1.65 (2.18) 2.35 (2.48) b 7.00 (4.47) 8
Mean rating of positive
life event (LES) 2.37 (0.70) 1.86 (0.65) 1.52 (0.88)c
Mean rating of negative 0.97 (1.08) 1.34 (0.96) 1.93 (0.71)8
life event (LES)
a = F > C ,  b = F >  InF, c = F < C (using Bonferroni corrected p values)
There were no differences in the number of years of regular ketamine use but, as 
expected, frequent ketamine users were found to ingest ketamine significantly more 
often than infrequent ketamine users, used significantly higher amounts in a typical 
session and rated themselves as significantly more concerned about their ketamine 
use on the Severity of Dependence scale (Table 2).
Table 2. Mean (sd) of ketamine use variables in the infrequent (n = 20) and
frequent ketamine users (n = 21).
Infrequent 
ketamine users
Frequent 
ketamine users
t39 P
Years o f regular ketamine use 5.33 (3.36) 5.62 (3.39) -0.28 0.78
Number o f days used 5.60(2.41) 30.00 (0)*** -45.19 <0.001
ketamine in typical month
Amount ketamine used in a 1.44(1.54) 3.30 (2.07)** -3.24 0.002
typical session (g)
Severity o f ketamine 1.60(1.79) 7.86 (3.8)*** -6.80 <0.001
dependence score
* P <  0.05, ** P <  0.01, *** P < 0.001
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In terms of frequency of mixing ketamine with other recreational drugs, in the 
infrequent / frequent ketamine user groups, respective numbers of ‘Sometimes 
mixed’ were 7/7, ‘Often mixed’ were 4/5, ‘Always mixed’ were 6/4.
Table 3. Mean (sd) of other drug use in the infrequent (n = 20) and frequent
ketamine users (n = 21).
% regular drug use Years of drug; use No. of days used per month
Infrequent K Frequent K Infrequent K Frequent K Infrequent K Frequent K
Alcohol 75% 66.7% 9.23 (4.04) 8.96 (4.73) 13.53 (8.67) 19.07 (9.68)
Tobacco 90% 76.2% 10.58(5.34) 10.81 (7.43) 26.61 (8.02) 29.25 (1.73)
Cannabis 60% 47.6% 8.54 (6.07) 10.25 (8.26) 8.67 (7.71) 18.33(12.11)
MDMA 35% 14.3% 5.21 (3.81) 5.00(1.73) 2.86 (2.27) 5.00 (4.58)
Amphetamine 10% 9.5% 11.50(4.95) 4.50(2.12) 4.00 (0) 10.00 (7.07)
LSD/Hallgn 15% 9.5% 4.83 (6.25) 9.00 (5.66) 2.67(1.15) 5.50 (0.71)
Cocaine 35% 33.3% 7.00 (2.83) 7.29 (3.30) 4.71 (1.80) 10.00(4.28)
Benzodiazepine: 5% 38.1% 2.00 (0) 1.78(1.46) 6.00 (0) 13.13 (7.12)
There were no significant differences in the numbers in each ketamine user group 
who rated themselves as regular users or not of alcohol, tobacco, cannabis and 
cocaine. For these recreational drugs, there were no differences in years used, days 
per month or the amount taken.
The control group reported regular use of alcohol (75% of participants; 12.8 ± 6.38 
days used in a typical month) and tobacco (25% of participants; 30 ± 0 days used in 
a typical month). Subjective reports of general drug use were verified with 
urinanalysis for 56 participants across the groups (urinanalysis unattained: 2 
frequent and 3 infrequent ketamine users).
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2. Subjective effects
SPI-A (Table 4)
There was a significant main effect of group on SPI-A total scores and all SPI-A 
subscale scores (A-F and O). These main effects reflected a dose-dependant effect, 
where frequent ketamine users scored higher than infrequent users, who in turn 
scored higher than controls for SPI-A total score and all subscale scores, apart from 
subscale D (Figure 1 and Table 5). For subscale D, the scores of the infrequent 
ketamine users did not differ from controls.
Table 4. Mean (sd) of SPI-A total and subscale scores (A-F & O) in the infrequent 
ketamine user (n = 20), frequent ketamine user (n = 21) and control (n = 20) groups.
Group
Controls Infrequent Frequent
Ketamine Ketamine
SPI-A Total &
Subscales_________
SPI-A Total Score 10.05(12.28) 32.70(17.10) 92.67 (27.86)1
SPI-A: A 1.70(4.18) 4.00(4.79) 17.48 (6 .68)a
SPI-A: B 1.40(1.96) 8.20(7.14) 16.19 (5 .76)a
SPI-A: C 2.35(2.89) 7.85 (4.31) 18.67 (5 .65 )a
SPI-A: D 1.90(2.63) 2.35 (2 .76)c 9.52 (6 .55)b
SPI-A: E 0.20(0.89) 2.05(2.80) 5.76 (4 .57)a
SPI-A: F 1.15 (2.66) 4.30(3.33) 12.19 (7 .72)a
SPI-A: O 1.35(1.87) 5.45(4.15) 12.76 (4 .61)a
a = F > InF > C, b = F > C, c = F > InF (using Bonferroni corrected p values)
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Table 5. Mean (sd) of SPI-A total and subscale scores (A-F & 0) in the infrequent 
ketamine user (n = 20), frequent ketamine user {n = 21) and control (n = 20) groups.
Statistical values
Group Main F > InF F > C InF > C
Effect
SPI-A Total & 
Subscales
SPI-A Total Score r2 = 45.99*** U =  11.5*** U = 1.0*** U = 50.0***
SPI-A: Affective (A) *2 = 110.0*** U = 20.5*** U = 10.5*** U =  110.0*
SPI-A: Cognitive- 
Attentional (B)
*2 = 36.49*** U = 77.5** U = 3.0*** U = 65.0***
SPI-A: Cognitive 
Disturbances (C)
*2 = 42.64*** U = 32.5*** U = 2.0*** U = 55.0***
SPI-A: Self and 
Surroundings (D)
*2 = 22.25*** U = 62.5*** U = 54.0***
SPI-A: Body 
Perception (E)
*2 = 30.38*** U = 93.5** U =  18.5*** U = 119.0**
SPI-A: Perceptual 
Disturbances (F)
*2 = 24.85*** U = 88.0** U = 49.5*** U =  90.5**
SPI-A: Optional 
Extras (O)
*2 = 38.36*** U = 51.5*** U = 3.0*** U = 75.0***
* P <  0.05, ** P <  0.01, *** P < 0.001 (Bonferroni corrected p values)
Figure 1. SPI-A mean scores for all subscales, for the frequent ketamine, infrequent 
ketamine and control groups, (note: maximum scores for subscales A, D, O = 30 & 
for subscales B, C, E, F = 36).
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O-LIFE (Table 6)
Table 6. Mean (sd) of O-LIFE total and subscale scores (A-F & O) in the 
infrequent (n = 20), frequent ketamine users (n -  21) and controls (n = 20).
____________________ Group_____________
Controls Infrequent Frequent
  Ketamine Ketamine
OLIFE Total &
Subscales______________
Total score 9.50(7.18) 17.65 (6.51)
Unusual Experiences 2.40 (2.33) 5.20 (2.89)
Cognitive Distortions 3.70(2.70) 6.40(3.22)
Introvertive Anhedonia 4.60(1.60) 1.05(1.10)
Impulsive Nonconformity 4.50 (1.19) 5.05 (2.11)
a = F > C & InF > C , b = F < C  & InF < C (using Bonferroni corrected p values)
There was a main effect of group (F2,58 = 10.6, P <0.001) for OLIFE total score. 
This reflects higher OLIFE total scores in frequent (P < 0.001) and infrequent 
ketamine users (P = 0.005), compared with controls. However there were no 
significant differences between the two ketamine groups for OLIFE total score. 
There were main effects of group on three OLIFE subscale scores: Unusual 
Experiences (F2,58 = 10.92, P<0.001), Cognitive Disorganisation (F2,58 = 5.5, P = 
0.007), and OLIFE Introvertive Anhedonia (F2,58 = 28.59, P <0.001). Bonferroni 
corrected post hoc tests on Unusual Experiences & Cognitive Distortions subscales 
revealed higher scores for frequent and infrequent ketamine users compared with 
controls (UE: P <0.001 & P = 0.01 respectively; CD: P = 0.009 & P = 0.035 
respectively), however the two ketamine groups did not differ. Controls attained 
higher scores on the Introvertive Anhedonia subscale than both frequent and 
infrequent ketamine users (P <0.001 & P <0.001 respectively), but the two 
ketamine groups did not differ significantly.
20.29 (9 .30)a 
6.67 (3 .51)a 
6.86 (3 .79)a 
2.14 (1 .77)b 
4.52(1.83)
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Delusional ideation & Dissociation (Table 7)
Table 7. Group means (sd) for delusional ideation & dissociation.
Controls Infrequent 
Ketamine users
Frequent 
Ketamine users
PDI ‘Yes’ score 3.28 (2.59) 7.35 (3.53) c 9.80 (5.50)a
PDI ‘Distress’ score 2.54(1.65) 1.85 (0.56) 2.36 (0.94)
PDI ‘Preoccupation’ 2.01 (1.33) 2.24 (0.56) 2.55 (0.98)
score
PDI ‘Conviction’ 3.09(1.75) 3.06 (0.55) 3.00 (0.89)
score
DES score 291.50 (225.98) 492.00 (357.91)b 1028.10 (491.87)a
a = F > C ,  b = F >  InF, c = F < C (using Bonferroni corrected p values)
Kruskal-Wallis tests indicated highly significant group differences in the number of 
‘Yes’ items responded to on the PDI (%! = 18.2, P < 0.001). This was due to both 
frequent ketamine users and infrequent ketamine users responding ‘Yes’ to more 
PDI items than controls (Frequent: U = 54.5, P < 0.001; Infrequent: U = 61, P < 
0.001). No differences emerged in the PDI Preoccupation, Distress and Conviction 
scores.
There were also group differences in DES score {yl = 23.74, P < 0.001), reflecting 
higher scores of frequent ketamine users than infrequent ketamine users (U = 84, P 
= 0.001) and controls (U = 36, P < 0.001).
3. Cognitive Assessments (Table 8)
Episodic memory
RMANOVA showed highly significant main effects of group (F(2,58) = 6.7, P = 
0.002), and delay on prose recall scores (F(i,58) = 50.12, P < 0.001), but no 
interaction. As seen in Table 7, controls had higher recall scores than both frequent
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(P = 0.008) and infrequent ketamine users (P = 0.007); overall immediate recall 
was better than delayed recall (Figure 2).
Table 8. Mean (sd) scores on cognitive tasks of infrequent ketamine users (n = 20), 
frequent ketamine users ( n -  21) and controls (n = 20).
Group
Controls Infrequent K
users
Prose recall immediate 
Prose recall delayed
Digit span forwards 
Digit span backwards
Verbal fluency total 
Category fluency total
8.40 (3.06) 
7.35 (3.3)
10.30(2.34) 
7.45 (2.82)
19.10(7.63) 
18.95 (7.01)
5.48 (2.99) b 
4.68 (2.95) b
9.25 (2.61) 
5.15 (1.98) b
14.65 (2.98) 
17.35 (3.03)
Frequent K
users
5.71 (2.38) 
4.60 (2.1)a
8.57 (2.44)
4.71 (2.08)
13.14(4.07) 
14.71 (4.56)
a = F < C, b = InF < C (using Bonferroni corrected p values)
Pre-morbid IQ (assessed by ‘spot the word’ test) was a significant covariate for 
prose recall scores (p = 0.004), however covarying prose recall for pre-morbid IQ 
did not affect the outcome of the analysis and group differences remained highly 
significant (F(2,57) = 5.67, p = 0.006). BDI total score was not a significant covariate 
for prose recall scores.
Working memory
There were no group differences in digit span forwards. Significant group 
differences in digit span backwards (F(2,58) = 43.76, P = 0.001) reflected higher 
scores for controls, compared with both frequent (P = 0.001) and infrequent (P = 
0.008) ketamine users. Frequent and infrequent ketamine users did not differ from 
one another (Figure 3).
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Executive functioning
Verbal fluency: Group differences were found for verbal fluency total score (%2 = 
7.3, P = 0.026). No specific differences emerged between any 2 groups (Figure 4). 
Errors were at floor level.
Category fluency: There was no group effect identified for category fluency total 
score (Figure 4) and errors were again at floor level.
Figure 2. Immediate and delayed prose recall mean scores for control, infrequent 
ketamine and frequent ketamine groups. Bars represent standard errors.
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Figure 3. Digit span forwards and backwards mean scores for control, infrequent 
ketamine and frequent ketamine groups. Bars represent standard errors.
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4. Correlations
When ketamine users were grouped together a significant negative correlation was 
found between years of ketamine use and OLIFE total score (r = -0.38, P = 0.007). 
Amount of ketamine used in a typical session correlated negatively with Digit Span 
backwards (r = -0.37, P = 0.009).
For infrequent ketamine users significant correlations were found between amount 
of ketamine used in a typical session and SPI-A subscale C score (r = 0.50, P = 
0 .012).
* *
A
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For frequent ketamine users only, significant correlations were found between BDI 
totals and SPI-A total scores (r -  0.66, P = 0.001), subscale A scores (r = 0.63, P = 
0.001) and subscale B scores (r = 0.55, P = 0.005).
To investigate whether impaired performance on cognitive tests was related to 
cognitive difficulties assessed by the SPI-A subscales B and C, these variables were 
correlated. A significant negative correlation was found between SPI-A subscale C 
scores and Digit Span backwards scores for frequent ketamine users (r = -0.49, P = 
0.01), and a trend in this direction was observed for infrequent ketamine users (r = - 
0.45, P = 0.023).
To explore whether levels of depression were related to negative life experiences, 
BDI and number of negative life experiences were correlated. A positive correlation 
was found between BDI total and number of negative life events for infrequent 
ketamine users only (r = 0.55, P = 0.006).
No significant correlations emerged between cannabis use variables and specific 
subjective or cognitive measures.
DISCUSSION
To the best of our knowledge, this is the first study to investigate symptomatology 
deemed characteristic of the pre-psychotic state in recreational ketamine users. 
Furthermore, it is the first study of daily users of the drug. The three groups studied 
were well matched for demographics, and the two ketamine groups were well 
matched for other drug use.
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Summary of main findings
There were five main findings of the study:
a) Frequent ketamine users demonstrated a higher level of pre-psychotic 
symptomatology than infrequent ketamine users, with both groups demonstrating 
higher levels than controls. Furthermore, both groups of ketamine users experienced 
a higher level of psychotic proneness and delusional ideation compared with 
controls, but did not differ from one another on these measures.
b) Contrary to prediction, frequent ketamine users experienced higher levels of 
dissociation compared with infrequent ketamine users and controls.
c) In line with hypotheses, both groups of ketamine users demonstrated marked 
deficits on prose recall immediate and delayed tasks.
d) No specific differences emerged between any 2 groups on the verbal and 
category fluency tasks.
e) Both groups of ketamine users showed selective impairment in the manipulation 
but not maintenance of information in working memory.
Who were the ketamine participants?
The two ketamine groups had both used the drug for 5-6 years, but clearly differed 
in their level of use, with frequent users ingesting ketamine daily and infrequent 
users once or twice a week. On average, frequent users consumed 3.3g per session, 
a significantly higher amount than infrequent users, who consumed an average of 
1.4g per session (‘sessions’ were reported to last between 12-72 hours). Although 
infrequent users reported consuming less than half the amount of ketamine reported 
by frequent users, both average amounts consumed are sufficient to induce marked 
psychotic-like symptomatology in healthy, drug-naive volunteers (Krystal et al.,
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1994; Malhotra et al., 1996; Morgan et al., 2004a; Newcomer et al., 1999a). The 
anaesthesia literature reports that an intravenous dose of 2mg/kg of body weight 
usually produces surgical anesthesia within 30 seconds after injection, with the 
anesthetic effect usually lasting five to ten minutes. Although the bioavailability of 
intra-nasally consumed ketamine is only 50%, it is apparent that both frequent and 
infrequent ketamine users had developed a tolerance for the drug as they were not 
experiencing periods of unconsciousness. In addition, although it is not known 
whether people may become dependant upon ketamine, the few single case reports 
of ketamine addiction in the literature (Hurt & Ritchie, 1994; Moore & Bostwick, 
1999), and a recent larger scale study (Muetzelfeldt et al., 2008), indicate that 
ketamine dependency is a distinct possibility within the cohort of ketamine users. 
Indeed, this study found that frequent ketamine users rated themselves as 
significantly more concerned about their ketamine use on the Severity of 
Dependence scale (SDS), suggesting evidence of a higher level of dependence 
amongst frequent users. SDS norms for ketamine users are not available.
Subjective effects
Symptomatology characteristic o f the pre-psychotic state
A ‘frequency’ effect was observed in the SPI-A data; frequent ketamine users 
reported higher overall levels of pre-psychotic symptomatology compared with 
infrequent users, who in turn reported higher overall levels than controls. This 
pattern was observed for all subscales of the SPI-A, except D (self and 
surroundings), where infrequent ketamine users scored in line with controls. In 
discussing these findings, I shall use some quotes from participants as illustrations.
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Chronic ketamine use therefore appears to induce affective-dynamic disturbances 
(SPI-A subscale A). This category of pre-psychotic symptomatology is associated 
with changes in mood and emotional responsiveness, and in one’s ability to tolerate 
stress. Most ketamine users reported more variable and extreme moods since 
starting ketamine, often stating they became annoyed or irritated much more easily, 
although some noted their mood had generally improved. For example, ketamine 
users said:
“My mood is more erratic. I  have more ups and more downs. The frequency o f 
highs and lows are more. ” (infrequent user 2)
“I ’m more moody and more intolerant. I  get more snappy, frowning a lot, and more 
annoyed easily. ” (frequent user 2)
Ketamine users also reported being more ambivalent towards people and pursuits, 
often stating they were more withdrawn and could not be bothered with things as 
much as before they used ketamine. For example, ketamine users said:
“I ’m much more happy to sit back and watch life pass me by. ” (frequent user 3)
“I ’m more withdrawn, I  just can’t be bothered anymore. ” (frequent user 16)
“You lose a lot o f motivation and goal-direction in your life. You ’re satisfied 
with what you ’re doing -  which is absolutely nothing. ” (frequent user 9)
These findings suggest chronic ketamine use mimics the attenuated negative 
symptomatology characteristic of the pre-psychotic state (e.g. Hafner et al., 1999; 
Klosterkotter et al., 1997; Tsuang et al., 2000), which very often develops months 
and years before fully-manifest positive symptomatology is observed. Interestingly,
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it appears that chronic ketamine users were still able to derive pleasure from 
experiences (a loss of this ability would indicate an attenuated negative symptom), 
as both groups of ketamine users had lower scores on the Introvertive Anhedonia 
factor of the OLIFE than controls.
Related to the reported changes in mood and motivation, frequent users differed 
significantly in their levels of depression (BDI-II total scores), compared with 
infrequent users and controls. Indeed, of these frequent users fourteen (67%) had 
clinically significant levels of depression. BDI total score and SPI-A total score 
were significantly correlated, sharing 44% of the variance. This finding can be 
interpreted in two ways. Firstly, pre-psychotic symptoms may have been picked up 
by the BDI (e.g. problems concentrating, emotional withdrawal). Secondly, 
depressive symptoms may have been picked up by the SPI-A (e.g. affective 
changes) and may thus be responsible for group differences in levels of pre- 
psychotic symptomatology. The former interpretation is more probable for three 
reasons. Primarily, although it was not possible to covary for BDI total scores due to 
the non-parametric distribution of the SPI-A data, the variance shared between the 
variables was below 45%, indicating the SPI-A total scores were representing 
something other than just depressive symptomatology. In addition, a level of 
depressive-like symptomatology is in line with predictions that chronic ketamine 
use induces psychotic-like experiences, as this would include attenuated negative 
symptomatology. Finally, ketamine users were asked to provide accounts of 
changes since starting the drug, which would suggest the depressive-like 
symptomatology reported was not previously present or had significantly worsened. 
Although a higher number of negative life events in the year prior to testing could
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account for this change, a lack of correlation for frequent ketamine users between 
BDI and number of negative life events (LES) does not appear to support this.
Chronic ketamine use also seemed associated with cognitive-attentional 
impediments and general cognitive disturbances (SPI-A subscales B & C 
respectively). Both groups of ketamine users experienced thought disorder-like 
experiences and attentional difficulties as assessed by the Cognitive Disorganisation 
factor of the OLIFE. Cognitive-attentional impediments refer to pre-psychotic 
symptomatology associated with reduced concentration and attention, and increased 
distraction (e.g. Comblatt et al., 2002; Schultze-Lutter et al., 2007a), and ‘slowed- 
down’ thinking. Ketamine users often cited ‘random thoughts’ or ‘random (external) 
stimuli’ (e.g. patterns, colours) as the cause of the attentional changes, which 
mimics the pre-psychotic state where attention is drawn to what appears to the 
observer ‘non-salient, irrelevant’ environmental stimuli (Freedman & Chapman, 
1973; Freedman, 1974; Hemsley, 1994; McGhie & Chapman, 1961, all cited in 
Corlett et al., 2006).
The cognitive disturbances seemingly induced by chronic ketamine were associated 
with formal thought disorder and indecisiveness. Formal thought disorder is 
characterised by unusual thought processes (including difficulties organising or 
connecting thoughts logically moment-to-moment) and the manifestation of this, 
termed schizophasia (includes impaired access to the lexicon, word approximation, 
and moving away from the intended conversational topic). Indeed, both frequent 
and infrequent ketamine users provided accounts of losing one’s trail of thought,
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either gradually or through sudden thought blockages, and an increased frequency 
of ‘out of the blue’ intrusive thoughts. For example:
“Intrusive thoughts occur -  death, how the world is going. For example, I  imagine 
how I will feel when my parents die. And then I think, where did that come from -  
out o f the blue, but its full on ” (infrequent user 2)
"My thoughts tend to fade away as I  go off on tangents, unless they are going at a 
rapid pace, then they will suddenly disappear. I  try to think about what I  was 
saying, but this stresses me out, so I ’ll start new thoughts. ” (infrequent user 3)
“I get a (thought) block, then other mad, crazy thoughts come. ” (frequent user 3)
These difficulties resemble thought disturbances experienced by individuals in a 
pre-psychotic state (Schultze-Lutter et al., 2007a). Many ketamine users also 
reported subsequent difficulties with expressive speech, with infrequent users 
tending toward milder impairments. One frequent user noted her speech could 
sometimes approximate ‘jibberish’, indicating a loss of voluntary control over 
speech generation, which Chaika (1990) argues is the fundamental impairment 
underpinning language difficulties observed in the psychoses. Although the 
language difficulties reported by ketamine users appear to reflect attenuated positive 
psychotic symptomatology, the unusual thought processes reported were not 
appraised negatively. Indeed, some ketamine users stated they actively enjoyed and 
encouraged losing their train of thought or ‘going blank’.
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“My mind goes blank, but in a comfortable way. I ’m not bothered about thinking in 
that space o f time. It becomes a relaxed state when it happens. Sometimes it’s good 
to go with it, and just let go. ” (frequent user 11)
Only frequent users of ketamine showed disturbances in experiencing self and 
surroundings (SPI-A subscale D). Frequent users reported making connections 
between environmental stimuli or events and themselves, believing in some way 
they were the focus of the stimulus or event. Some frequent users stated they were 
aware the connections were not really present but enjoyed forming them. This is 
reminiscent of the concept of the ‘happy schizotype’ (McCreery & Claridge, 1995), 
which refers to particular groups of individuals in the general population (e.g. 
individuals who believe in the paranormal, members of specific new religious 
movements) who show similar positive psychotic-like symptomatology to that 
found in an exaggerated form in the idiopathic psychoses, but who are not distressed 
by these experiences. Other frequent users stated the formed highly improbable 
connections, but seemed less certain about dismissing them. For example:
“This happens all the time. I  was on the tube, deciding whether to get off at 
Leicester Square or Holborn, and someone on the tube said Leicester Square, and I 
thought that was meant for me. ” (infrequent user 7)
“I  try to connect things in my mind and somehow they do connect. I  always think 
that something that happens has a hidden purpose that may not be showing at the 
time. ” (infrequent user 18)
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“It feels like everything revolves around you -  it’s a bit egotistical. I  could be doing 
something minor, like kick a can across the floor and think someone might make a 
face or something unrelated, but I  think they're related, (frequent user 1)
“When I  hear sirens, I  can think they're coming to get me. " (frequent user 18)
These higher subscale D scores appear similar to the unstable ideas of reference 
observed in the pre-psychotic state, which involves a heightened ability to form 
associations (between perceptions, thoughts, stimuli and events), so much so that 
associations are often formed where none exist (Corlett, Honey & Fletcher, 2007; 
Schneider, 1930).
Body perception disturbances and more general perceptual disturbances (SPI-A 
subscale E & F respectively) also seem to emerge as a result of chronic ketamine 
use. Ketamine users consistently reported medically-unexplainable brief feelings of 
itching, twitching and ‘pins and needles’ in their bodies. In the pre-psychotic 
literature such unusual body sensations are reliably observed (Klosterkotter et al., 
1997, 2001). Furthermore, ketamine users reported increased sensitivity to light and 
/ or noise, visual distortions (e.g. flashes, stars, flames), and changes in perceived 
acoustic stimuli, such as brief periods of muffled hearing or sounds seeming louder. 
Periods of muffled hearing have been linked with subsequent derealisation within 
the psychoses (Schultze-Lutter et al., unpublished). Bodily depersonalisation (a 
marked anomalous experience during the pre-psychotic state; Klosterkotter et al., 
1997, 2001) was very occasionally noted by ketamine users (e.g. an arm or foot 
feeling separated from the rest of one’s body), with only two frequent ketamine 
users describing brief‘out-of-body’ experiences when ‘sober’.
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Such perceptual alterations are repeatedly observed in individuals deemed within 
the pre-psychotic state (Freedman & Chapman, 1973; Freedman, 1974; Hemsley, 
1994). Indeed, it is proposed that attempts to account for alterations in visual and 
auditory perception coupled with attentional changes (noted in SPI-A subscale B) 
and a heightened ability to form associations (noted for frequent ketamine users 
only in SPI-A subscale D) result in the invention of bizarre, causal structures to 
explain them, which manifest clinically as delusions (Kapur, 2003; Kapur, Mizrahi 
& Li, 2005). The finding that ketamine users scored higher than controls on 
delusional ideation (assessed by the PDI) and the Unusual Experiences factor of the 
OLIFE (which assesses hallucinatory and delusional experiences) supports this.
Finally, chronic ketamine use was found to induce basic symptoms grouped within 
the SPI-A ‘Optional’ subscale. These included feelings that the world around them 
was unreal, distant and ‘somehow weird’ (derealisation) and uncontrollable 
perseverative focus on thoughts and images. The latter fits with the main theme of 
the Schneiderian first-rank symptoms of the psychoses (Mellor, 1970; Schneider, 
1959); loss of control over one’s train of thought. Interestingly, the ‘Optional 
symptoms’ were all appraised as fun and enjoyable (with the exception of motor 
blockages), and in some cases were ‘encouraged’. A possible explanation of this is 
offered below.
Another interpretation of the SPI-A findings is that they reflect pre-existing 
differences between ketamine users and controls. However, this seems unlikely for 
three reasons. Firstly, participants were instructed to only rate themselves on 
variables where they had noticed changes since they started taking ketamine, which
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is suggestive of ketamine-induced change. Secondly, previous studies support the 
existence of chronic ketamine-induced psychotic-like symptomatology in users 
(Curran & Monaghan, 2001; Morgan et al., 2004b). Finally, if pre-existing 
differences were responsible for our findings it would be hypothesised that no 
difference would be observed between ketamine user groups, however this was not 
the case. Although ketamine groups experienced similar levels of psychosis 
proneness on the OLIFE (despite both groups scoring higher than controls), this 
measure is not a clinical index of symptomatology and was not specific for basic 
symptoms. Therefore the OLIFE could not differentiate subtle ketamine-induced 
differences in clinical symptomatology. Furthermore, the negative correlation of 
years of ketamine use with OLIFE total scores may reflect a tolerance to ketamine’s 
psychoactive effects rather than providing evidence for pre-existing differences 
between ketamine users and controls.
It is also highly improbable that group differences in pre-psychotic symptomatology 
were the reflection of other recreational drugs, as the ketamine groups did not differ 
in general drug use, apart from ketamine. The finding that cannabis use did not 
correlate with SPI-A or OLIFE scores in either ketamine group further strengthens 
this proposition.
Schultze-Lutter, Klosterkotter, Picker, Steinmeyer and Ruhrmann (2007b) 
investigated the ability of the SPI-A to predict the pre-psychotic state. They noted 2 
partially overlapping basic symptom ‘risk criteria’ for defining the ‘prodrome’, 
based on data of the prospective Cologne Early Recognition (CER) study 
(Klosterkotter et al., 2001; Schultze-Lutter et al., 2006). The first risk criteria
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specified an SPI-A score of 3 or above, and one of ten specific cognitive-perceptive 
basic symptoms (See Schultze-Lutter et al., 2007b). If these criteria are applied to 
ketamine users who took part in this study, 95% of infrequent users and 100% of 
frequent users would be deemed to be experiencing symptomatology at a level 
similar to individuals deemed within the pre-psychotic state.
Dissociation
Contrary to our hypothesis, frequent ketamine users reported more dissociative 
experiences in comparison to infrequent ketamine users and controls (who did not 
differ from one another). This finding is unlikely to be due to pre-existing 
differences between groups because only frequent ketamine users experienced 
higher levels of dissociation compared with controls. Rather, this finding is 
probably due to the daily use of ketamine in the frequent user group, a far higher 
frequency of ketamine use than previous studies have explored. Nevertheless, even 
at lower frequencies of ketamine use one study has shown chronic effects of 
ketamine on dissociative symptomatology (Curran & Morgan, 2000), and most 
acute ketamine challenge studies demonstrate significant dissociation (Anand et al., 
2000; Krystal et al., 1994; Malhotra et al., 1996; Pomarol-Clotet et al., 2006).
Cognitive effects
Episodic memory
Both groups of ketamine users recalled less of a passage of prose than controls 
immediately and after a delay. Although no single memory task taps a single 
memory system, prose recall loads significantly upon episodic memory, and no 
deficits were identified in digit span forwards (working memory). In addition,
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neither levels of depression nor pre-morbid IQ affected the differences identified. 
This pattern of prose recall impairment fits with impairment in verbal episodic 
memory observed in participants in the pre-psychotic state (Eastvold et al., 2007; 
Niendam et al., 2006). Interestingly, a significant impairment in verbal episodic 
memory has been found to be predictive of an imminent transition from a pre- 
psychotic state to fully-manifest psychotic symptomatology (Brewer et al., 2005; 
Lencz et al., 2006, both cited in Eastvold et al., 2007).
The prose recall task has been found to be the best laboratory test predictor of 
everyday memory performance (Sunderland, Watts, Baddeley & Harris, 1986) and 
therefore the findings of this study indicate that both frequent and infrequent 
ketamine users would experience memory problems in everyday life. This fits with 
SPI-A data which indicated ketamine users experienced disturbances in immediate 
recall and difficulties holding things in memory for less than half an hour (SPI-A 
subscales B & C). These findings also support the observation of episodic memory 
impairments as a result of both acute and chronic ketamine use in previous studies 
(e.g. Curran & Morgan, 2000; Curran & Monaghan, 2001), and Morgan et al.’s 
(2006) conclusion that chronically, ketamine appears to have more marked effects 
on episodic memory than other cognitive domains.
It is suggested these findings may have implications for the reliability of the data 
gathered through the SPI-A and the questionnaires. If all ketamine users were 
experiencing memory problems in everyday life, it is indeed probable that reports of 
subjective effects were influenced by these memory difficulties. It is argued that any 
impairment in episodic memory would have resulted in ketamine users under-
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reporting symptomatology, as they had not initially encoded or had lost the storage 
of a memory trace. Therefore, if findings have been affected by everyday memory 
problems, the true picture of symptomatology may indeed be greater than that 
reported.
Working memory (WM)
The pattern of effects found on the digit span backwards task paralleled that on 
prose recall, with both groups of ketamine users performing significantly worse than 
controls, but similarly to one another. However there were no group differences 
identified in the digit span forwards task. It is not possible to compare digit span 
performance in this cohort of ketamine users with previous cohorts as the task has 
not been previously been used with this population. The findings suggest a specific 
deficit in the manipulation of information in WM, rather than maintenance. The 
finding of a negative correlation between digit span backwards scores and SPI-A 
subscale C scores (cognitive disturbances) for frequent ketamine users, and a trend 
in this direction for infrequent users may indicate that the more thought disordered 
users have the most difficulty with the manipulation of information in WM.
A selective impairment in manipulation of information in working memory is in line 
with deficits revealed following acute ketamine administration in healthy volunteers 
(Honey et al., 2003). This study is the first to show that chronic ketamine also 
impairs the manipulation but not the maintenance of information in working 
memory. This mimics the cognitive profile observed in the psychoses (Kim et al., 
2004; Perry et al., 2001), including within the pre-psychotic state (Pukrop et al.,
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2007; Simon et al., 2007), thus providing support for the ketamine model of the 
psychoses.
Executive functioning
Although group differences were found for the verbal fluency task, it was not clear 
where these lay. Contrary to prediction, there were no group differences in the 
category fluency task. Although the limited literature has provided mixed findings 
for the impairment of verbal fluency in ketamine users, an absence of impairment in 
category fluency is unusual (Curran & Morgan, 2000; Curran & Monaghan, 2001; 
Morgan et al., 2004b). It is therefore necessary to consider the context of the 
category fluency task. A factor which could not have been foreseen prior to testing 
was ‘expert’ knowledge ketamine users often reported regarding the category 
chosen: musical instruments. Whilst only anecdotal evidence, ketamine users 
frequently commented that the category fluency task was ‘easy’ as they had studied 
for music qualifications, or worked in the music industry or were involved in music 
in some other way. Therefore, the use of this specific category may have masked 
impairment of executive functioning. Alternatively, chronic ketamine use may not 
impair executive functioning, as was evidenced by Morgan et al. (2004b), who 
found performance on verbal fluency and category fluency was the same in 
ketamine users as in controls.
What other factors may account for the cognitive findings besides regular use o f 
ketamine?
Another interpretation of the cognitive findings is that there were baseline 
differences between groups. Although it is not possible to rule out this
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interpretation, there are three reasons why such differences are unlikely. Firstly, the 
groups were well matched for demographic variables and general drug use, which 
could impact upon cognitive scores. Secondly, although groups differed in 
premorbid IQ (with no specific differences between any 2 groups), no correlations 
were found between pre-morbid IQ and cognitive task scores. Finally, the high 
densities of NMDA receptors in the cerebral cortex and the hippocampus, areas 
important for higher executive functions and memory weakens this interpretation 
further.
Methodological considerations
The present study has methodological limitations endemic to most research with 
recreational drug users (Curran, 2000). For example, although the groups were well 
matched for demographic variables, they may have been a heterogeneous sample 
and differed in other ways, e.g. familial history of drug dependence. Recreational 
drug research is also complicated by difficulties recruiting participants (e.g. because 
of the illegal status of the drug), which may impact upon the representativeness of 
study samples.
In addition, it could be argued that the high levels of depressive symptomatology 
observed in frequent ketamine users may have confounded findings. Although it 
could be argued that exclusion criteria for participants should have included ‘BDI 
score of over 13’, it is suggested this would have resulted in an unrepresentative 
sample. It is well known that drug misuse is associated with comorbid depression 
(Sanderson et al., 1990, cited in Abraham & Fava, 1999), with drug use cited either 
as a cause of depression or a form of self-medication for pre-existing depressive
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symptomatology (Abraham & Fava, 1999). The association between the two is 
complex and beyond the scope of this discussion. Nevertheless, it may be useful to 
complete a future study which attempts to exclude individuals with significant 
levels of depressive symptomatology.
Although urinanalysis was completed, this was undertaken to verify general drug 
use, rather than ketamine use. Nevertheless, the subjective effects reported by 
participants painted an unique ‘ketamine profile’ (derealisation, ‘out of body’ 
experiences, bodily numbness, confusion and perceptual distortions), which strongly 
supports the assumption that ketamine was actually taken. Doses of ketamine used 
were based solely upon self-report data which may have introduced bias into the 
results as retrospective reporting can be inaccurate.
It was also noted that participants could at times forget instructions to rate only 
subjective day-to-day experiences (i.e. chronic effects of ketamine), and could 
sometimes get carried away describing the acute effects of ketamine. This was a 
particular difficulty with frequent ketamine users, and understandably so, as some of 
these individuals were ingesting ketamine several times daily and noted they rarely 
deemed themselves to be ‘sober’. The rating of acute effects of ketamine on the SPI- 
A was of most concern. However as this measure is a semi-structured interview it 
was possible for interviewers to repeatedly check out whether participants were 
recalling chronic or acute effects, to limit the impact of this reporting bias. 
Nevertheless, it is recognised that this issue will have impacted upon the results of 
the study, as retrospective reporting is never completely accurate.
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Finally, it is impossible to rule out pre-existing differences between ketamine users 
and controls without a prospective study. For the reasons explained above it is 
argued that this interpretation of the findings is unlikely.
This study also had several strengths. Firstly, all groups were well matched for 
demographic variables, thus minimising the chance that significant differences were 
the result of pre-existing differences between groups. Secondly, both ketamine 
groups were well matched for other drug use and years of ketamine use, thus 
minimising the likelihood that significant differences were the result of other drugs 
used, or the duration of ketamine use. Thirdly, the self-reported use of other drugs 
was objectively corroborated using urine samples. Finally, using the SPI-A (a semi­
structured interview approach) enabled the chronic effects of ketamine use to be 
teased apart from acute effects. This would have been impossible had a self-report 
questionnaire been utilised.
Scientific and Clinical Implications
The results of this study indicate that ketamine use is associated with attenuated 
positive and negative psychotic-like symptomatology, with frequent users 
experiencing a higher level than infrequent users. In addition, they suggest that 
chronic ketamine use has selective detrimental effects on episodic and working 
memory. These findings have wide reaching clinical and scientific implications.
Firstly, the ketamine using population should be informed of the risks associated 
with long-term use of this drug. Longer-term ketamine users are likely to experience 
chronic effects of ketamine, which appear to be attenuated forms of experiences
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sought out through acute use of the drug, and mimic symptomatology deemed 
characteristic of the pre-psychotic state. This is indeed a concerning observation 
given the rapidly increasing population of ketamine abusers in the UK and 
worldwide. Currently, there is a paucity of research into the effects of chronic 
ketamine use, and it is vital this omission be addressed. Although only anecdotal 
evidence, one frequent ketamine user interviewed reported experiencing what he 
described as a ‘drug-induced’ psychosis (not psychiatrically diagnosed or treated), 
which lasted several days and was extremely distressing. This raises the issue of 
ketamine’s possible role in transition from attenuated psychotic-like 
symptomatology to fully manifest psychoses. It will thus be important to conduct 
longitudinal studies in which the potential progression of symptomatology is 
investigated and, following the cessation of ketamine use, the possibility of 
symptom remittance.
The second finding of clinical importance is the high levels of depression revealed 
amongst frequent ketamine users. This finding is interesting as acute ketamine has 
been reported to have prolonged antidepressant qualities in individuals with 
treatment resistant depression (e.g. Berman et al., 2000; Zarate et al., 2006). An 
explanation of this disparity may be that whereas acute ketamine appears to have 
anti-depressant qualities, chronic ketamine (at higher doses) may have depressant 
qualities. The latter hypothesis is speculative as the causal relationship between 
high levels of depressive symptomatology and chronic ketamine use is currently 
unclear. Indeed, it may be that chronic ketamine users experience higher levels of 
depression because of previous negative life events (although negative life events 
assessed in this study were not found to be associated with level of depression), the
177
chronic physical health difficulties induced by ketamine, or lifestyle, amongst other 
factors. Further studies are required to explore the relationship between depressive 
symptomatology, past life events, lifestyle and chronic ketamine use. However, if 
chronic ketamine use is shown to reliably induce depression, then this will have 
clinical implications for the ketamine using population.
Drug models of the psychoses have long been utilised to investigate psychotic 
symptomatology, and subsequently in the development of antipsychotic 
medications. Acute ketamine has been utilised widely to develop a ketamine model 
of the psychoses, which proposes glutamatergic dysfunction for symptomatology, 
and therefore as a target for antipsychotic treatment. However, the investigation of 
chronic ketamine as a model of the psychoses has been limited. The current study 
reinforces Honey et al.’s (2006) argument that as ketamine appears to induce subtler 
symptomatology than that experienced by individuals with fully-manifest psychotic 
symptomology, it may best model the pre-psychotic state. Specifically, this study 
indicates that chronic ketamine use provides a very useful model of pre-psychotic 
symptomatology, with good clinical and contextual validity (Fletcher & Honey,
2006). The clinical specificity of the model is questionable as frequent ketamine 
users experienced significant dissociation, which is not specific to the psychoses.
The findings of this study require replication, although currently they appear to 
provide evidence for a chronic ketamine model of the pre-psychotic state, indicating 
that chronic ketamine use may prove useful in the exploration of this state of 
idiopathic psychoses. This model argues that chronic NMDA antagonism and thus 
glutamate dysfunction appear to be an aspect of the pre-psychotic state. Exploration
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of this state utilising chronic ketamine as a model may improve the reliability of 
early recognition. Furthermore, new drugs using the glutamate pathway may prove 
useful in the prevention of fully-manifest psychotic symptomatology (Patil et al.,
2007).
Conclusion
The current study investigated levels of pre-psychotic symptomatology in chronic 
ketamine users employing a measure of basic symptoms, a novel area of 
investigation. It found a frequency effect of ketamine for symptomatology deemed 
characteristic of the pre-psychotic state, and a general effect of ketamine (both 
frequent and infrequent use) on a measure of psychosis proneness. For infrequent 
users only, amount of ketamine use was positively correlated with SPI-A subscale C 
scores, suggesting ketamine may most notably be related to cognitive disturbances. 
In support of this, both frequent and infrequent ketamine users were found to be 
similarly impaired in tasks tapping episodic and working memory. The findings 
lend support to the NMDA receptor hypofunction model of the psychoses, and 
suggest that glutamatergic disturbances may contribute to symptomatology deemed 
characteristic of the pre-psychotic state.
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Part 3: Critical Appraisal
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Overview
This critique presents an opportunity to reflect upon the process of completing my 
DClinPsy thesis. I have focused on the following areas: the benefits of working as 
part of a research group, matters to consider when conducting research with the 
ketamine using population, clinically relevant observations, and the issue of socially 
constructed concepts in the field of research into the functional psychoses.
Reflections on working as part of a research group
Although it had not been my intent to undertake a joint thesis, by the end of the first 
year I found myself planning the design of my study as part of a comprehensive 
research group, consisting of 3 UCL supervisors (Professor Val Curran, Dr Oliver 
Mason and Dr Celia Morgan), and 2 other trainee clinical psychologists (Suzanna 
Hunt, UCL and Lisa Monaghan, Royal Holloway). This arrangement was of benefit 
from the outset.
My experience of research prior to doctoral training had been an isolating one. 
Previous research supervision had taken a didactic form, where I had muddled 
through the various stages of the research (i.e. design, data collection, analysis, etc), 
feeding back my plans to supervisors, yet never quite knowing whether my methods 
were ‘correct’. Suddenly I found myself in a collaborative research context, which I 
very much valued. For example, there were many discussions at the outset of the 
research process regarding the design of the 3 studies to be completed by each 
trainee. These discussions involved agreeing on how each trainee would share 
participants, which developed my ability to in practice think about a number of 
study designs which would control for confounding factors, and select the most
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appropriate. Through these discussions we were able to learn from one other, and 
bounce ideas and hypotheses off one another, a novel and enjoyable experience for 
me. I learnt how multiple perspectives and backgrounds are as valuable in the 
research process as they can be in clinical practice, as they introduce difference to 
your thinking. Furthermore, I began to realise that not only was I undertaking an 
extremely interesting piece of work, but I was also (finally) going to learn, in 
practice, how research ‘should’ be done.
The group context provided me with the containment I had never had during 
previous research I had undertaken. As an individual who enjoys and values joint 
working, I began to enjoy the research process and even have fun -  something I 
never thought possible! For example, the otherwise daunting and potentially dull 
task of creating a semi-structured interview for the SPI-A (to improve inter-rater 
reliability across trainees) became a lively debate about the best way to structure 
questions, rate responses and record information. The task itself was divided 
between the 3 trainees, thus lightening the load, and providing opportunity for 
different interpretations of the SPI-A manual to be identified and then resolved. 
From keeping each other going during data collection, which at times could be very 
tiring and take much time out of our evenings and weekends, to thrashing out ideas 
for the interpretation of our individual data sets, and how best to write these up, I 
have not been able to fault working in a group context, and would highly 
recommend it. My thanks to you all for making it such an enjoyable experience, 
which has moved me from a position of recognising the importance of, but 
reluctantly undertaking research to seeking out research opportunities in my future 
career.
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Reflections on conducting research with the ketamine using population
Research with chronic ketamine users is constrained by the common limitations of 
naturalistic drug studies, including poly-drug use, restricted study design and 
recruitment difficulties. I will reflect upon each in turn, and then consider further 
issues which are more specific to completing research with ketamine users.
Poly-drug use in the ketamine using population
Given that ketamine is illicit and has potential neurotoxicity, ethical approval will 
understandably not be granted to repeatedly administer ketamine to drug-naive 
participants, as in acute challenge studies. Therefore, the only feasible way of 
studying the effects of chronic ketamine is to work alongside the naturalistic 
population of ketamine users. It has been argued that studies should only recruit 
people who use just ketamine (Narendran et al., 2005). However it would be 
extremely difficult to recruit such users, and even if a sample of sufficient size was 
collected, findings would not be generalisable to the general ketamine using 
population who are predominantly poly-drug users. A potential constraint with 
using this cohort of participants is therefore that their individual poly-drug profiles 
are unique, with unknown interactions and subsequent effects. A strength of my 
study design was that I attempted to control for this confounding factor by matching 
frequent and infrequent ketamine users for current poly-drug use. However this 
does not take into account historical drug use and interactions. Drug histories 
themselves can be problematic, as they are limited by several biases, such as social 
desirability and memory inaccuracies (especially as verbal episodic memory was 
found to be impaired in all ketamine users).
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Furthermore, as ketamine and the majority of substances in the poly-drug history 
are illegal, it is not possible to be accurate about what drug was actually taken, or 
the real dose (Curran, 2000). Dosages of illicit substances differ widely. Another 
strength of my study was the verification of current drug use using urinanalysis. 
However this only provided information regarding drug use in the last few hours or 
days. Due to ketamine’s short half-life, urinanalysis was not conducted to verify 
ketamine use. Although hair analysis could have been completed to overcome these 
limitations, it was too costly.
Hence, it is evident that although I attempted to control for both current and 
historical poly-drug use through my study design, this limitations was still 
problematic and could have impacted upon the findings I gathered.
Study design
Ketamine users and researchers were not blind to the participants’ drug histories 
and current ketamine use, and therefore knew their group allocation. Although it 
has been suggested that this is straightforward to overcome by having one person 
obtain drug histories and another administer the tests (Curran, 2000), it is argued 
that even if such a design had been employed, it would have been evident from the 
answers given in the SPI-A which group participants were allocated to. Therefore, it 
was decided not to utilise a more sophisticated study design than between-subjects 
(e.g. single-blind). Nevertheless, this common limitation of naturalistic drug studies 
may have had a real impact upon the results gathered in the study, as the rater who 
was facilitating completion of the SPI-A may have been influenced by their 
expectations of the experiences different drug using groups would have (SD for
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frequent and infrequent ketamine users, LM and SH for controls). It is suggested 
that future studies with chronic ketamine users could attempt to control for this 
limitation more appropriately by having a single-blind design (double-blind would 
not be possible as participants will obviously know which group they have been 
allocated to).
Recruitment issues
Recruitment of ketamine users was also a difficulty, partly due to the illicit status of 
the drug, and partly I believe due to higher levels of suspicion amongst (especially 
frequent) ketamine users. I was in email contact with a number of participants who 
understandably questioned my motivation for completing a study into ketamine. 
Following reassurance and more detailed explanation of rationale and aims some 
ketamine users became even more suspicious and at times accusatory (e.g. 
suggesting I was associated with an undercover police operation). It is therefore 
interesting to speculate whether the individuals who participated in the study were 
ketamine users who experienced less psychotic-like symptomatology, and were 
therefore less suspicious and willing to participate than those who did not 
participate. Alternatively, those who participated may have experienced similar or 
higher levels of psychotic-like experiences to those who did not participate, but the 
former may have appraised their experiences differently (i.e. recognising delusional 
ideation / paranoia and wanting to talk about it to further knowledge about chronic 
effects of ketamine). Non-participants may have simply been more aware or fearful 
of the consequences of ‘being caught’ (as ketamine is an illegal substance), perhaps 
due to previous experiences with the police. It is impossible to determine which of 
these explanations is more or less accurate without further investigation. In
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addition, it is hypothesised that there may be a cohort of ketamine users who 
believe chronic ketamine use has no negative effects, and therefore may not be 
motivated to contribute to research studies. Interestingly, only one infrequent 
ketamine users in my study noted ketamine had no negative effects for them 
(despite reporting bodily sensations of numbness and stiffness).
Unsuprisingly, it was more difficult to recruit frequent than infrequent ketamine 
users. It is hypothesised that this may in part be the result of a higher level of 
attenuated negative psychotic-like symptomatology (e.g. social withdrawal and lack 
of motivation). Although frequent users volunteered at similar rates to infrequent 
users, there was a high DNA rate for appointments. Furthermore, when frequent 
ketamine users did attend, it was not always possible to undertake testing, as traces 
of white powder were noticed under their noses, or behaviour was indicative of a 
recent acute dose of ketamine. Furthermore, 2 potential research participants 
(frequent users) were excluded from the study during testing as they had asked to 
go to the toilet and returned clearly under the influence of acute ketamine (i.e. 
slurred expressive speech, impaired receptive speech, glazed eyes).
In addition, a high proportion of infrequent ketamine users who volunteered were 
male. As I wanted to match the frequent and infrequent ketamine groups for gender, 
I stopped recruiting men, which may have introduced bias to the sample. It is 
unclear whether the infrequent population of ketamine users is predominantly male, 
and therefore whether the trends in volunteering reflected this, or whether female 
infrequent ketamine users were less motivated to volunteer, for reasons currently 
unknown. Although it could be argued that the amount of monetary compensation
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provided to participants (£15) biased the sample towards participants on a low 
income and with time to spare, it was apparent that few participants were 
completing the research for the money. Rather, participants frequently noted their 
interest in finding out more about the long-term effects of ketamine, so as to inform 
their community. Indeed, the majority of participants were employed (12 
infrequent, 10 frequent) in posts of varying income (e.g. administrator, recruitment 
consultant). Nevertheless the reliance on participant’s altruism could have
implications for the generalisability of findings to the wider ketamine using
community.
The difficulties with recruitment detailed above will probably have impacted upon 
the results gained, as the ketamine users who participated may not have been 
representative of the whole ketamine using population.
The impact of memory on findings
The SPI-A and subjective rating scales utilised to gather data in this study relied 
heavily on intact episodic memory. However, findings indicated that both groups of 
ketamine users experienced impaired episodic memory in comparison to controls. 
This will no doubt have had an impact upon findings. It is argued that one of the
strengths of the study was the use of the SPI-A, as this measure was a semi­
structured interview, which enabled raters (SD, SH & LM) to use their clinical 
skills to probe participants for detailed answers and descriptions of their 
experiences, rather than accepting simple yes/no answers, or a rating on the SPI-A 
without an explanation or evidence to back up the participants claims. However, 
retrospective reporting is always inaccurate, as it is biased by beliefs, socially
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desirable responses and acquiescence. Therefore, it is inevitable that biases in 
memory would have impacted upon results, perhaps even more so for ketamine 
users in comparison to healthy, drug-naive controls due to their observed episodic 
memory impairment.
The SPI-A explicitly asked participants to rate only experiences that were new or 
had changed since they started using ketamine. Participants were not expected to 
comment on whether they believed these new or altered experiences to be the result 
of ketamine use, but simply to report if they had noticed anything new or anything 
that had significantly changed in the areas the SPI-A questions asked about. 
However, although participants were not asked to attribute perceived changes to 
ketamine use, asking them to think back to how they were when they first started 
taking ketamine, and comparing this to their years of ketamine use and their current 
state would have relied heavily on episodic memory.
Developing an understanding of ketamine use
Although this research project employed quantitative methods and analyses, there 
was much qualitative information gathered through meeting with ketamine users, 
especially when I visited participants at home. This is in line with ethnographic 
research: the task of systematically describing a culture or community from the 
perspective of the people for whom it is a way of life, where the researcher observes 
from within and is thus part of the culture / community. A caveat prior to this 
discussion: the following observations and hypotheses are based upon anecdotal 
evidence, rather than systematically collected data.
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Although I did not explicitly ask ketamine users why they began taking ketamine, 
or the reasons for continuing to use, such information often came up during the SPI- 
A interview. It was evident that ketamine users (whether infrequent or frequent) 
began using ketamine after several years of other poly-drug use (supported by 
Muetzelfeldt et ah, 2008). The trigger for ketamine use was not always clear, 
although some stated that it had been preceded by a significant negative life event 
(e.g. death of a sibling, relationship breakdown). This fits the reasons ketamine 
users provided for continued ketamine use: facilitating a shift of focus from 
negative thoughts about the past, present or future to either not thinking at all (via 
dissociation), or thinking about existential topics and / or minutiae (e.g. pattern of 
light the sun forms on the floor). This shift was associated with a change in affect, 
namely to a contented and happy mood. These findings fit with qualitative data 
gathered by Muetzelfeldt et al. (2008), who found some (but not all) ketamine users 
liked ketamine-induced dissociation and feelings of contentedness (which in cases 
replaced feelings of unhappiness). It is hypothesised that for some users, ketamine’s 
function is as an agent of ‘negative thought avoidance’, which may be indicative of 
self-medication. This was more prominent for frequent users, which fits with the 
higher level of depression revealed in this group (discussed below). For example, 
ketamine users stated:
“I ’m generally more happy than before I took K because I don’t ruminate on bad 
things as much. ” (infrequent user 18).
“I used to be the moodiest, jumpiest teenager ever. I  swear I got happier since I 
started taking ketamine. I  get moody again i f  I  haven’t had K for a while and can’t 
get hold o f it. ” (frequent user 6).
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“I ’ve become more positive because you look into yourself - this has helped me to 
change. It also helps dull unpleasant feelings. Its made me more relaxed. ” (frequent 
user 8).
Although for some users acute ketamine appeared to aid the avoidance of unwanted 
and distressing negative automatic thinking, this study found that chronic ketamine 
use appears to lead to a loss of thought control (SPI-A subscales B & C). 
Interestingly, anecdotally it seems the content of more chaotic, out-of-control 
thinking experienced by ketamine users differs to ruminative thinking: i.e. thoughts 
are focused on unimportant previous events, and attention and thus thoughts are 
drawn to seemingly non-salient stimuli. Such experiences were often rated as 
enjoyable and sometimes encouraged.
Other ketamine users noted that the trigger for ketamine use had been becoming 
more involved in the ‘dance’ or ‘squat’ scene, and they perceived this as a positive 
shift. Therefore it is hypothesised that another potential reason for ketamine use is 
the need to feel part of a social group and the development of one’s own identity 
within this. Indeed, some ketamine users noted that one reason for their continued 
use of ketamine was the context in which they lived. Many users commented that 
although sometimes they thought about stopping or cutting down on their ketamine 
use, their friendships and social activities revolved around the drug within the 
ketamine-using community. The severing of relationships and the loss of identity 
associated with a move away from ketamine use was deemed too high a price to pay 
for ceasing use. Indeed, another study has found that ex-ketamine users had to 
completely remove themselves from the environment of their using patterns in order
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to give up, and they subsequently miss the feeling of being in a ‘team’ 
(Muetzelfeldt et al., 2008).
Ketamine users also reported that one of the primary reasons for continuing with 
ketamine use was their enjoyment of its acute effects. This fits with Muetzelfeldt et 
al.’s (2008) study, which found that “melting into the surroundings”, “visual 
hallucinations” and “out-of-body experiences” were the most appealing aspects of 
ketamine for approximately 66% of users. The increasing recreational ketamine use 
warrants further study in this area, in order to inform interventions for ketamine 
addiction. Furthermore, it would be useful to understand the factors that 
differentiate those who use ketamine daily from those who maintain a recreational 
style of use.
Cultural considerations
Ketamine users (both frequent and infrequent) who reported a history of regular 
heroine or crack cocaine use perceived the change in their drug use as a positive 
step forwards. It is hypothesised that the beliefs of ketamine users were influenced 
by cultural and societal beliefs about drug use.
For the purposes of this critical review, cultural beliefs refer to the ‘squat’ and / or 
‘dance’ cultures which ketamine users are very much a part of. Squatting refers to 
the act of occupying an abandoned or unoccupied space or building the squatter 
does not own, rent or otherwise have permission to use. The ‘squat culture’ refers to 
a counter-culture which calls into question the widely accepted goal of society, to 
own property, and attempts to promote ideas of sharing, hospitality and community
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in societies where such ideas have been marginalised. Squats are often residences, 
but can also be used as social centres, pirate radio stations, cafes and venues for 
dance music events. The dance culture refers to a community who are united by 
their enjoyment of dance music and clubbing. The culture is also commonly 
associated with poly-drug use, hedonism and rave parties.
Anecdotally, it was observed that infrequent users tended to align themselves with 
the ‘dance’ culture, whereas frequent ketamine users aligned themselves more with 
the ‘squat’ culture. Ketamine users noted that within these cultures, the use of 
ketamine is generally appraised positively. It was widely believed that both cultures 
associate ketamine with being open to freeing up your thinking and questioning the 
world around you, as well as sometimes being an indication of an interest in 
philosophy and a sign of intelligence. This fits with findings that ketamine use is 
associated with a desire for experimentation and openness to new experiences 
(Muetzelfeldt et al., 2008). In my study, ketamine users said:
“I  don’t think ketamine causes these experiences, but rather it is a catalyst for these 
experiences, for spiritual activity. The spirits are breaking the boundary o f this 
world and the other side. It (ketamine) helps you to tune in, like tuning a radio 
dial. ” (infrequent user 1).
“It (ketamine) makes you more aware, you see things (not literal reference to visual 
hallucinations) you can’t normally see. ” (frequent user 19).
Therefore it appears that ketamine use may be positively appraised and thus 
reinforced by the beliefs of specific cultures, which associate ketamine with valued
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traits. It is important to note this information was gained through discussions with 
ketamine users, whose accounts may be biased and thus not representative of the 
wider beliefs of the ‘squat’ and / or ‘dance’ cultures. Nevertheless, ketamine users 
clearly perceive a cultural acceptance and value of their drug use. Indeed, another 
limitation of naturalistic drug studies is that it is not possible to separate the 
neurochemical effects of the recreational drug of interest (in this case ketamine) 
from the culture drug users reside within.
Some ketamine users also noted that society in general does not appear to have any 
particular beliefs about ketamine use, as it is a relatively new drug in the vocabulary 
of the general population. In contrast, it was suggested that societal beliefs about 
crack cocaine and heroine use are extremely negative, and are propagated by the 
media. An interesting area of future research may be to qualitatively explore the 
attitudes of individuals within the above cultures, or within the general population 
towards ketamine use.
Clinically relevant observations
Why might ketamine users enjoy positive psychotic-like symptomatology?
The observation that some ketamine users noted enjoying and at times actively 
encouraging unusual thought processes (including uncontrollable perseverative 
focus on thoughts and images), a decreased ability to discriminate between fantasy 
and reality, unstable ideas of reference and derealisation is reminiscent of the 
concept of the ‘happy schizotype’, coined by McCreery and Claridge (1995). This 
term refers to particular groups of individuals in the general population who show 
similar positive psychotic-like symptomatology to that found in an exaggerated
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form in the idiopathic psychoses, but who are not distressed by these experiences. 
Examples include individuals who believe in the paranormal (Thalboume & Delin, 
1994), those who have out-of-body experiences (McCreery & Claridge, 1995), 
members of specific new religious movements (Day & Peters, 1999), and those who 
have profound religious experiences (Jackson & Fulford, 1997). Studies (e.g. 
Peters, Day, McKenna & Orbach, 1999; Day & Peters, 1999) have shown that 
although such individuals do not show as florid delusions as individuals with 
psychoses, they experience similar levels of delusional ideation as the clinical 
cohort and have similar levels of conviction in those beliefs. However they are 
significantly less distressed and preoccupied by their experiences, suggesting that 
positive psychotic-like experiences are not always associated with distress, 
withdrawal or difficulties in adjustment. Indeed, it has been argued that a moderate 
degree of schizotypy (i.e. psychosis proneness) may even have adaptive value, 
being helpful and constructive for the individual and in some cases being associated 
with creativity (Claridge, 1985, as cited in Day & Peters, 1999).
It may be that some chronic ketamine users appraise the positive non-acute 
psychotic-like symptomatology they experience as non-aversive, and furthermore 
enjoyable and sought after because of the cultural contexts in which they live. 
Indeed, it is well known that drug users often take hallucinogenic or dissociative 
substances to open the gateways of perception and creativity, and thus positively 
appraise the consequences of acute drug consumption. For example, as the famous 
literary icon Aldous Huxley once stated:
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“To be shaken out o f the ruts o f ordinary perception, to be shown for a few timeless 
hours the outer and inner world, not as they appear to an animal obsessed with 
survival or to a human being obsessed with words and notions, but as they are 
apprehended, directly and unconditionally, by Mind at Large - this is an experience 
o f inestimable value to everyone and especially to the intellectual” (The doors of 
perception, 1954).
As a result of using ketamine in a social context which places value and positive 
meaning on unusual experiences, and where the aetiology of such experiences is 
explainable and controllable, some ketamine users may appraise their longer-term 
unusual experiences positively. This explanation is supported by my study’s finding 
that although both groups of ketamine users had higher levels of delusional ideation 
on the PDI compared with controls, there was no evidence of increased distress or 
preoccupation associated with these delusional ideas. It is also supported by 
Claridge (1997) who noted that it is the way in which positive psychotic-like 
experiences are reacted to or appraised which causes them to become distressing or 
deemed an ‘illness’.
It is important to note that I am not proposing chronic ketamine users fit the ‘happy 
schizotype’ model. Evidence suggests this is not the case as firstly, not all chronic 
ketamine users stated non-acute positive psychotic-like symptomatology was 
benign or enjoyable. Secondly, some positive psychotic-like experiences were 
consistently appraised in a negative way. Finally, all ketamine users also 
experienced negative psychotic-like symptomatology, which was always appraised 
negatively, and is absent in the ‘happy schizotype’ model. Rather, it is proposed
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that the appraisal pathways of some chronic ketamine users and ‘happy schizotypes’ 
may be similar, as a direct result of cultural context. Further research is required to 
explore this matter because chronic ketamine is proposed to be a model of the pre- 
psychotic state. Using chronic ketamine as a way of exploring cultural influence 
upon appraisals of psychotic-like symptomatology may have clinical implications 
for those deemed to be in the pre-psychotic state.
Depressive symptomatology
Another main finding of my study was the high levels of depression in frequent 
ketamine users. This seems at odds with the concept of the ‘happy schizotype’. 
Furthermore, the proposal that ketamine appears to induce depression seems at odds 
with current research which suggests ketamine has prolonged antidepressant 
qualities (e.g. Berman et al., 2000; Zarate et al., 2006). An explanation of this 
disparity may be that whereas acute ketamine appears to have anti-depressant 
qualities, chronic ketamine (at higher doses) may have depressant qualities. The 
latter hypothesis is speculative as the causal relationship between high levels of 
depressive symptomatology and chronic ketamine use is currently unclear. If 
chronic ketamine use is shown to reliably induce depression, then this has clinical 
implications for the ketamine using population.
Although it was found that negative life events in the year prior to testing were not 
associated with level of depression for frequent ketamine users, it is not known how 
lifestyle impacted (if at all) on levels of depression, and conversely, how levels of 
depressive symptomatology impacted upon lifestyle. Anecdotally, it appeared that 
frequent ketamine users had a tendency to neglect themselves. Through discussion I
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learnt of the many physical ailments ketamine users experienced as a result of 
ketamine use, and the infrequency with which they consulted a medical professional 
about them or self-treated. Frequent ketamine users sometimes appeared to neglect 
their personal hygiene, and could wear stained clothing (the latter could be the 
result of not having access to a washing machine in squats). Furthermore, when I 
visited a squat to undertake research interviews and cognitive testing, a high level 
of neglect was evident. For example, rooms were littered and dirty, with mouldy 
food left out to rot. Further research is required to systematically investigate the 
relationship between depressive symptomatology, past life events, lifestyle and 
frequent ketamine use.
The construct of the *prodrome’
“The tendency has always been strong to believe that whatever received a name 
must be an entity or being, having an independant existence o f its own. And if  no 
entity answering to the name could be found, men did not for that reason suppose 
that none existed, but imagined that it was something peculiarly abstruse and 
mysterious. ” (John Stuart Mill, quoted in Sarbin, 1991, p. 173).
As part of my thesis, I read around the concept of ‘schizophrenia’ to develop my 
own knowledge of the various proposed states (i.e. prodrome, acute, chronic), and 
the associated signs and symptoms. An area of discussion within the literature that 
particularly took my interest was Mary Boyle’s (2002; 2004) work on 
‘schizophrenia’ as a social construct. This position opposes the medical view that 
‘schizophrenia’ is a diagnosable disorder or ‘illness’, which has biological 
antecedents, the exact nature of which will be discovered in the future. Instead the
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conceptual framework suggests ‘schizophrenia’ is a construct which encompasses 
an organised set of beliefs that has been propagated by the dominant systems in 
society, namely medicine and science (Sarbin, 1991).
Boyle (2002) argued that the ‘schizophrenia’ construct is not a scientific concept for 
several reasons. Firstly, the concept of ‘schizophrenia’ and its predecessor 
‘dementia praecox’, were introduced in the absence of any supporting empirical 
evidence. Interestingly, Kraepelin’s construct of ‘dementia praecox’, which formed 
the basis of the modem construct of ‘schizophrenia’, was in part based upon post­
encephalitic parkinsonism and other organic conditions which were unknown to 
Kraepelin and Bleuer in the early 20th century. Secondly, Boyle (2002) noted that 
the development and use of ‘schizophrenia’ as a diagnosis bears no relationship to 
the development and use of concepts in medicine and science, and is instead based 
upon inference from a pattern of regularities which conform to a syndrome (i.e. a 
meaningful cluster of signs and symptoms). Finally, she stated that DSM criteria for 
‘schizophrenia’ do not refer to a meaningful pattern of phenomena which would 
justify the use of a diagnostic concept. Boyle (2002) therefore concluded that there 
is no clear evidence to confirm ‘schizophrenia’ as a brain disease, despite evidence 
showing unknown genetics play a key role.
I therefore decided to focus both my literature review and empirical paper on 
whether chronic ketamine models patterns of symptomatology, rather than focusing 
on whether ketamine provides a model of a specific categorical diagnosis (e.g. 
schizophrenia, schizoaffective or bipolar disorders). I reviewed findings from 
studies which recruited participants from across the functional psychoses, and
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focused rather on types of symptomatology: namely positive and negative psychotic 
symptomatology and cognitive dysfunction. This approach was in line with Abi- 
Saab, D'Souza, Moghaddam and Krystal (1998) who suggested drug models may 
prove better at offering insight into psychotic symptomatology in general, rather 
than specific DSM-IV or ICD-10 diagnoses.
Reading Mary Boyle’s work shifted my thinking, and I found myself questioning 
the validity of the construct of the ‘prodrome’, a concept which is disputed by 
theorists working within the area of the functional psychoses. Boyle (2002) wrote 
about the role language plays in maintaining the ‘schizophrenia’ construct, in that it 
reflects a reality already discovered or about to be discovered, thus making the label 
‘schizophrenia’ part of our reality (e.g. through conducting research into 
‘schizophrenia’). In recognition of this, I therefore used language which reflected 
my position. I used the term pre-psychotic state throughout my literature review and 
empirical paper to indicate that I was not aligned with a position that accepts the 
‘prodrome’ as a ‘reality’. Rather, the term I used reflected the position that some 
individuals might transition to develop fully-manifest psychotic symptomatology 
(and thus receive a diagnosis), but that is not necessarily the case.
In 2004, Boyle published a paper that focused on the prevention of ‘schizophrenia’. 
In it she stated that trying to prevent ‘schizophrenia’ as one would attempt to 
prevent lung cancer or diabetes makes little theoretical sense. In addition, she noted 
the ethical dilemma of prevention, as some individuals will not transition to fully- 
manifest psychotic symptomatology, and those who do can report finding positive 
symptomatology helpful, comforting and constructive (i.e. the ‘happy schizotype’
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model). Although these points led me to think more about the complexities 
surrounding prevention of psychotic symptomatology, I would argue that exploring 
the ketamine model of the psychoses with a view to prevention is still a useful 
endeavour. Given ketamine’s unique ability to model attenuated negative psychotic 
symptomatology and cognitive dysfunction associated with idiopathic psychoses, 
glutamate agonists may nevertheless prove attractive interventions for individuals 
with such symptomatology, despite their potential for attenuating desirable positive 
symptomatology. I believe that this would be an interesting area of future research, 
whereby opinions on this matter are explored in cohorts of individuals who have 
experienced psychotic symptomatology and possibly been given a diagnostic label.
Reading Boyle (2004) also increased my awareness of how the potential role of 
social and interpersonal factors (e.g. social and educational disadvantage, child 
abuse and neglect) has been de-emphasised and obscured in the presentation of 
‘schizophrenia’ research, possibly to discourage discussion of theoretical 
mechanisms which might link them to psychotic experiences. I believe that 
although this imbalance needs to be addressed, it is possible to have a both / and 
approach to research in this area. I believe research into social and interpersonal 
factors with clinical implications for more universal preventive interventions (e.g. 
involving public education aimed at normalising psychotic experiences to reduce 
stigma and social isolation), can be conducted side-by-side with research into more 
specific biological mechanisms (e.g. glutamate pathways).
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Appendix 1 
Details of joint thesis
218
This thesis was completed as part of a joint project to investigate the chronic effects 
of ketamine, cocaine and cannabis on pre-psychotic symptomatology and cognitive 
dysfunction.
Three separate theses were completed as a result of the joint project. They were 
entitled:
1) Do ketamine users show psychotic symptomatology and cognitive dysfunction 
associated with the pre-psychotic state of the psychoses?
(Suzanna Duffin, Trainee Clinical Psychologist, UCL)
2) Prodromal symptoms in daily skunk users.
(Suzanna Hunt, Trainee Clinical Psychologist, UCL)
3) Chronic cocaine use and prodromal symptoms of schizophrenia 
(Lisa Monaghan, Trainee Clinical Psychologist, Royal Holloway)
All trainees designed their studies together, and some participants were shared.
Below is an outline of the contribution of each individual member to the joint 
project:
1) Suzanna Duffin: Completed the semi-structured interview protocol for the SPI-A 
alongside Suzanna Hunt, and created a scoring sheet for the SPI-A. Collected data 
as outlined in my methodology from 21 frequent and 20 infrequent ketamine users.
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Data for 20 matched control participants was selected from control data gathered by 
Suzanna Hunt and Lisa Monaghan.
2) Suzanna Hunt: Completed the semi-structured interview protocol for the SPI-A 
alongside Suzanna Duffin. Piloted full assessment battery with 1 recreational drug 
user and 2 controls. Collected data as outlined in her methodology for 29 daily 
skunk users and 15 controls (reporting no illicit drug use).
3) Lisa Monaghan: Piloted the SPI-A with recreational drug users. Collected data as 
outlined in her methodology for 30 cocaine users.
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Appendix 2 
Approved ethics application form
221
UCL RESEARCH ETHICS-COMMITTEE
A f r >
j(c>
Amendment Approval Request Form
1. ID Number
0052/001
Name and Address of Principal Investigator:
Prof H Valerie Curran 
Clinical Health Psychology, UCL
2. Title of Project:
The determinants and psychological consequences of ketamine use
3. Information about the amendment:
(a) Is the amendment purely administrative? YES
(b) Has the Participant Information Sheet/Consent Form been changed as a result of the 
amendment? YES If yes, please enclose a copy - enclosed
4. Summarise the issues contained in the amendment Mr Justin Grayer, a postgraduate student 
(on the UCL Doctorate in Clinical Psychology), will be using a different psychological test (indirect 
semantic priming) with three of the groups involved in the main project (ketamine users, polydrug 
users and drug naive controls). He will recruit new participants who are not involved in the main 
project. The test of semantic priming asks participants to determine whether each of a series of 
stimuli is a real English word or not. Priming is indexed by reaction times to words which follow 
semantically related words. It is a widely used 20 minute test which does not produce any distress or 
fatigue. Mr Grayer will also be administering some of the questionnaires used in study 0052/001.
5. Please give any other information you feel may be necessary:
As in the main study, participants will be paid £7.50 per hour to compensate for their time and 
inconvenience. They will also be asked to provide a urine sample to screen for recent drug use (this 
project does not have the funding of the main project to analyse saliva and hair). There will be 16 
volunteers in each of the three groups.
Signature of Principal Investigator Date of Submission:
2nd December 2005
FOR OFFICE USE ONLY:
Amendments to the proposed protocol have been by the Research Ethics
Committee. ’ *
Chair’s S i g e : D a t e :  "ij 13-J C'^ •
Please return completed form to:
Ms Helen Dougal, Secretary of the UCL Research Ethics Committee 
Graduate School, North Cloisters, Wilkins Building 
Gower Street, London WCIE6BT
Appendix 3 
Volunteer Information Sheet
SUB-DEPARTMENT OF CLINICAL HEALTH PSYCHOLOGY
UCL PSYCHOLOGY
INFORMATION LEAFLET FOR VOLUNTEERS
Version 2 February 2007
The determinants and psychological consequences of ketamine use
Investigators: Lisa Monaghan, Suzanna Duffin, Suzanna Hunt,, Leslie Muetzelfeldt, Dr. Celia 
Morgan, Dr O Mason, Prof. H. Valerie Curran
Purpose of the study:
To determine the long term effects of recreational cannabis use
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends and relatives if you wish. Ask us if there 
is anything that is not clear or if you would like more information. Take time to decide whether or 
not you wish to take part.
WHAT IS THE PURPOSE OF THE STUDY?
To determine the effects of using different types of recreational drugs upon mental functioning and 
mood.
SOME BACKGROUND TO THE RESEARCH
Many drugs have long term effects; for instance people who drink lots of alcohol often find their 
memories are not as good as they were. This can often be affected by factors such as the length of 
time they have been drinking and the quantity that they drink. The present study aims to find out 
what the long-term effects of using recreational drugs may be on mental state and cognition.
WHAT WILL BE STUDIED?
We will be looking at memory, problem solving and concentration as well as mood and mental state 
in people who use cannabis, people who take other drugs but not cannabis (eg cocaine; ketamine) 
and people who do not take any recreational drugs.
HOW WOULD I BE INVOLVED IF I AGREED TO TAKE PART?
If you do decide to take part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any time and without 
giving a reason.
Version 2, dated 16/02/07
If you agree to participate, on the testing day you will come to the Psychopharmacology 
Laboratories at UCL or if you do not live locally the experimenter will come to your home. The 
experimenter will then record some information about your current drug use and patterns of use, 
including giving a hair and urine sample, and then complete some computer-based cognitive tasks, 
which will last for approximately 1 hour and will be followed by a break. You will take part in an 
interview about your mood and mental state, and this may take up to an hour. You will then be paid 
for participation.
CONFIDENTIALITY
Any information collected about you will be held in accordance with the 1998 Data Protection Act. 
All the information that is collected about you during the course of the research will be kept strictly 
confidential. Your results will have your name and any other details about you removed first so that 
you cannot be recognized from them.
If you require further information please ask the investigator
Thank you for reading this leaflet and we hope that you will be able to take part in the study.
You do not have to take part in the study if you do not want to. If you decide to take part, you 
may withdraw at any time without having to give a reason.
Contacts:
Dr. Celia Morgan c.morgan@ucl.ac.uk;  
Dr Oliver Mason: o.mason@ucl.ac.uk;  
Prof. H.Valerie Curran: v.curran@uc 1.ac.uk; 
Clinical Psychopharmacology Unit
Sub-department of Clinical Health Psychology
University College London Gower Street London WC1E 6BT
Email: v.curran@ucl.ac.uk
Tel: +44 (0)20 7679 1898
Assistant: Sharinjeet K Dhiman
Email: s.dhiman@ucl.ac.uk
Tel: +44 (0)20 7679 8231
Fax: +44 (0)20 7916 1989
www.ucl.ac.uk/clinical-health-psvcholoqy
All proposals for research involving human subjects are reviewed by an ethics committee before they can 
proceed. This proposal was reviewed by the UCL Cdhimittee for the Ethics of noii-NHS Hurridh Resdatch.
Version 2, dated 16/02/07
Appendix 4 
Participant consent form
SUB-DEPARTMENT OF CLINICAL HEALTH PSYCHOLOGY
UCL PSYCHOLOGY
JUJU
Consent Form
CONFIDENTIAL
The determinants and psychological consequences of ketamine use
Investigators: Dr. Celia Morgan, Suzanna Duffen, Suzanna Hunt, Lisa Monaghan, Leslie 
Muetzelfeldt, Prof. H.Valerie Curran
Please complete the following: delete as neccessary
1. Have you read the information sheet ? YES / NO
2. Have you had an opportunity to ask 
questions and discuss this study ? YES / NO
3. Have you received satisfactory answers
to all your questions ? YES / NO
4. Have you received enough information
about this study ? YES /NO
5. Which investigator have you spoken to 
about this study ?
6. Do you understand that you are free to withdraw from 
this study:
* at any time YES / NO
* without giving a reason for withdrawing YES / NO
7. Do you agree to take part in this study ? YES/ NO
Signed............................................................  Date........................
Name (please print)............................................................................
Investigator.
Appendix 5
Semi-structured interview for the Schizophrenia Prediction 
Instrument -  Adult Version (SPI-A)
SCHIZOPHRENIA PRONENESS INSTRUMENT-ADULT 
VERSION (SPI-A) INTERVIEW SCHEDULE
(30 MINS)
I would like to ask you a number of questions about some of your experiences 
since you started taking ketamine. I need to emphasise that I am not asking you 
about experiences you may have had WHILST you were on the drug or whilst you 
were coming down from the drug, BUT rather I'm interested in your everyday 
experiences.
A) Affective-dynamic disturbances
A1: Impaired tolerance to  certain stressors
GENERAL QUESTION
- Do you think your ability to tolerate stress has decreased since you started taking 
ketamine? So specifically I am asking about stress that involves unusual or new things, 
social everyday situations (like having a chat or watching TV), and working under time 
pressure?
IF YES
OK -  I’m going to ask you a few more specific questions about this now 
GO TO A1.1
IF NO
move to A2
A1.1 Impaired tolerance fo r unusual, unexpected o r specific  novel demands
• Can you handle new, unusual or suddenly occurring tasks as well as before you 
started taking ketamine? Things like a specific demand at work or a visit to the 
local authorities, or moving or having a holiday?
• Do you feel like you can’t handle it when something unusual or unplanned 
happens, so a situation like this would be too exhausting or too much?
• Do unusual or unplanned things happening cause feelings like being nervous, 
tense, restless, or dizzy, or problems with sleeping?
Rating: Frequency I
If needed: Effects on performance behaviour (VI)
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A1.2 Impaired tolerance for certain social everyday situations (which are 
socially neutral)
• Can you still tolerate being around others or having conversations with others since 
you started taking ketamine?
• Can you still do things like go to the shops, go on public transport, or go to public 
events as comfortably as you did before you started taking ketamine?
• Do any of these situations cause feelings like nervousness, tenseness, 
restlessness, heart beating, sweating, pain or concentration difficulties?
• Do you sometimes feel like watching or hearing things like the radio or TV is just 
too much for your senses, like its exhausting or you can’t handle it?
Rating: Frequency I
If needed: Effects on performance behaviour (VI)
A1.3 Reduced ability to work under pressure of time or rapidly changing 
different dem ands, therefore start to avoid such situations or be more 
rigid in their behaviour
(NOT B1 which is more to do with a cognitive deficit in not being able to 
divide attention)
• Are you as able to deal with having several different things to do at once and 
working under time pressure, as you were before you started taking ketamine?
• Does having multiple tasks to do, or being in time pressured situations make you 
more nervous and agitated now? Do you find you have problems with 
concentration during such situations, or you experience nervousness, heart racing, 
restlessness, sweating or pain?
• Do you have to avoid being rushed since starting to take ketamine?
Rating: Frequency I
If needed: Effects on perform ance behaviour (VI)
A2 Change in mood both positive and negative (usually low or 
emotionless mood -  always unrelated to external events) AND 
emotional responsiveness
(NOT brief or transient change; NOT A3 which is to do with activities and 
interests losing their positive impact on client)
• Has your GENERAL mood changed overall since you started taking ketamine -  for 
example has it become more negative and low?
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• Can you be as happy, laugh and enjoy things as much as you used to?
• Do you think your feelings have become less intense since you started taking 
ketamine?
• Do you think you have become less emotionally involved in things since you 
started taking ketamine? Is this generally the case or just with certain things?
Rating: Frequency I
If needed: Subjective burden (IV), Effects on quality of life (VI), Areas of life
(VIII)
A3 Decrease in positive emotional responsiveness towards others, 
(decreased feelings of love, affection, sympathy, pity and/or interest 
towards other persons or previously important activities/hobbies. DO NOT 
score this item if decrease in responsiveness & hobbies, etc is a coping 
behaviour to a decreased stress tolerance with respect to everyday 
situations)
• Are you still as interested and emotionally involved in things you like to do - your 
hobbies etc. -  as you were before you started taking ketamine?
• Do you still feel the same affection and/or interest for your relatives and friends as 
before you started taking ketamine?
Rating: Frequency I
If needed: Subjective burden (IV), Effects on behaviour (VI)
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B) Cognitive-Attentional impediments
OK -  I’m now going to ask you about your thinking and attention abilities since you started 
taking ketamine.
B1 Inability to divide attention
(difficulty splitting attention between stimuli which require different senses; 
problems switching attention not scored here)
• Can you do two things at the same time as easily as before you started taking
ketamine? So for example, can you write notes whilst you talk to someone on the
phone, or can you do the cooking AND talk to someone at the same time?
• Do you have to just do one thing at a time to make sure it gets done properly?
Rating; Frequency II
If needed: Subjective burden (IV), Effects on B&P (VI)
B2 Feeling overly distracted by stimuli
(one’s attention is raised randomly by external stimuli you don’t want to 
attend to); NOT difficulties intentionally splitting attention -  this is scored in 
B1 or any sort of cognitive interference that occurs without the presence of 
an external stimulus (C2 &D3)
• Do you think that since you started taking ketamine, everything around you catches 
your attention, even if you don’t want it to?
• Is your thinking interrupted, aimless or disturbed by being too aware of other 
things? For example, have you ever found that you can’t focus on something 
because other things around you have randomly taken your attention away?
Rating; Frequency II
If needed; Subjective burden (IV), Effects on B&P (VI)
B3 Difficulties concentrating
(NOT because of any other cog disturbance such as intruding thoughts (C2) 
obsessive/ perseveration of thoughts (01), thought pressure (D3), thought 
blocking (C3), disturbance of comprehension of visual or auditory material 
(C4), attn disturbances (B1, B2,07) language problems; could be because of 
memory disturbances -  score this in C.1.8./9 too)
• Concentration problems are when you find it difficult to keep your mind on a task 
for several minutes, like watching TV or reading, or making a cup of tea. Thinking
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about that, do you think you have had more difficulties concentrating since you 
started taking ketamine?
• Do you know the reasons for your concentration problems -  for example, are they 
because of your thoughts racing or are they triggered by work, or difficulties 
understating what others are saying to you?
• When you are concentrating on something, do thoughts about other things come 
into your mind? Are your thoughts suddenly gone or do you simply loose the train 
of thoughts? Is it always things like that which cause your difficulties 
concentrating?
• Can your concentration problems occur at any time or just when you feel quite 
stressed?
Rating: Frequency I
If needed: Subjective burden (IV), Coping (V), Effects on B&P (VI)
B4 Difficulties to hold things in mind for less than half an hour
• Have you noticed you have more difficulties keeping things in mind, even for half 
an hour, since you started taking ketamine? For example, after you have read 
something or watched something on TV, can you still remember the main content 
half an hour after?
Rating: Frequency II
If needed: Subjective burden (IV), Coping (V), Effects on B&P (VI)
Do not ask B5 if criteria B3 scored (NOTE: if C4 or C5 are scored, then score
for B5 is invalid -  see paper for explanation why)
B5 ‘Slowed-down* thinking
(general complaint that thinking has become slower and harder; which might 
occur AS A RESULT of other cognitive disturbances)
• Do you sometimes feel that your thinking has become slower, harder or more 
sluggish since you started to take ketamine?
• For example, is every answer in this interview a real effort?
Rating: Frequency II
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If needed: Subjective burden (IV), Coping (V), Effects on B&P (VI)
B6 Lack of thought energy' or goal-directed thoughts
(NOT loss of performance of automatically performed skills - 011)
• Do you think you sometimes lack the strength or energy to think or speak, since 
you started taking ketamine?
• Do you sometimes have difficulties developing your own ideas or planning things, 
such as cooking?
Rating: Frequency II
If needed: Subjective burden (IV), Coping (V), Effects on B&P (VI)
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C) Cognitive disturbances
OK - I’d now like to ask you some questions about your thinking and your decision making
abilities since you started to take ketamine.
C1 Increased Indecisiveness with regard to insignificant choices 
between equal alternatives
(different to loss of spontaneity and carefree responding - B3)
• Is it more difficult to make decisions since you started taking ketamine, even about 
the most unimportant things, such as which washing powder to go for?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on behaviour (VI), Areas of life
(VIII)
C2 Thought interference
(when random thoughts, unrelated to current thoughts or external events 
disturb the person's train of thought); NOT obsessive perseveration of 
thought (01), thought blocking (C3), or distraction of attention by external 
stimuli (B2)
• Since you started taking ketamine, do you sometimes find it difficult to take part in 
a conversation or concentrate on a book or TV, because unimportant and 
unrelated thoughts enter your mind?
• Do you sometimes have difficulties participating in a conversation, because your 
thoughts drift away to other things that have nothing to do with what’s being 
discussed since you started taking ketamine?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on performance (VI)
C3 Thought blockages
(5 subtypes: sudden disappearance of old thought without replacement by 
new one / sudden disappearance of old thought with replacement by new 
one / slow and gradual disappearance of old thought without new thought 
afterwards / slow and gradual disappearance of old thought, as new intrude 
at same time / loss of thread, train of thoughts)
• Since you started taking ketamine, do you sometimes lose your train of thought, or 
do your thoughts suddenly disappear as if they were cut short?
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• Do your thoughts suddenly stop sometimes, as if they are being blocked or as if 
the thought gradually fades?
• Does another thought take the place of the old one?
Rating: Frequency If
If needed: Subjective burden (IV), Coping with it by increasing effort (V),
Effects on performance (VI)
C4 Disturbance of receptive speech
(When reading or listening to others, the person has difficulties or is unable
to comprehend and recognise the meaning of words, word sequences or 
sentences, e.g. in conversations, movies, TV or radio) DO NOT score when 
due to concentration difficulties or when occurance is only during very high 
demand tasks such as a scientific lecture.
• Do you sometimes have difficulties understanding conversations, or when reading 
simple books or articles, since starting ketamine?
• Since you started to take ketamine, is it sometimes difficult to understand simple 
words or sentences -  is it like you are reading or hearing something in a foreign, 
but well-known language: so you recognise the word but have to think about its 
meaning?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on performance, avoidance (VI)
C5 Disturbance of expressive speech
(problems producing adequate words -  word fluency and precision slowed 
down, difficulty finding correct words, sometimes words used which are 
associated but not correct); NOT a difficulty expressing feelings verbally and 
non-verbally.
• Do you speak as fluently and precisely as before you started taking ketamine? For 
example, is it sometimes difficult to find the right words or build the right sentences?
• Have you begun to use the same words and phrases again and again to avoid 
these difficulties?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on performance, speaking (VI)
C6 Disturbance of immediate recall
(complaints about not being able to remember things for even a very short 
time - 5 to 40 sec)
• Do you sometimes have difficulties remembering things immediately since you 
started taking ketamine? For example, are the questions I’m asking hard to 
remember straight after I’ve asked them?
• Do you sometimes have difficulties to follow a conversation, because you quickly 
forget what was just said?
Rating: Frequency II
If needed: Subjective burden (IV), Coping (V), Effects on performance (VI)
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D) Disturbances in experiencing self and surrounding
I’m now going to ask you some questions about your emotions and your beliefs about 
yourself.
D1 Decreased capacity to discriminate between different kinds of 
emotions
(all feelings often experienced as monotone or tainted with a dysphoric 
quality, even positive ones). NOT change in mood and emotional 
responsiveness (A2) or a decrease of positive feeling toward others/ 
previously enjoyed activities (A3)
• Are you always able to tell the difference between unpleasant and pleasant, 
negative and positive feelings clearly and easily? How does this compare to before 
you started taking ketamine?
• Have all emotions become somehow unpleasant since you started ketamine?
Rating: Frequency II
If needed: Subjective burden (IV)
D2 Increased emotional reactivity in response to routine social 
interactions that affect the patient or his/her significant others 
(emphasis on social interaction not everyday events like sad music, TV or 
books BUT on emotional reactivity to self and significant others which may 
have not been so  strong previously AND the participant is aware they are 
over-reacting); NOT as the result of a specific trigger like thought 
perseveration (01)
• Do the actions or comments of others, or discussions and arguments, get you 
more worked up now than before you started taking ketamine?
• Do you have the feeling that you are more sensitive now -  that almost everything 
gets under your skin?
Rating: Frequency I
If needed: Subjective burden (IV), Effects on B&P (VI)
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D3 Thought pressure
(great number of random, different thoughts/ images enter the mind and 
disappear again in quick sequences without the person being able to 
suppress or guide them) NOT thought interference (C1), nor though 
perseveration where many thoughts/ images come from shared theme (01)
• Do you sometimes have the feeling that you are not able to control your thoughts, 
in comparison to the time before you started taking ketamine - Do your thoughts 
just run wild, impossible to control?
• Do you sometimes jump from one subject to another so much that your single 
thoughts feel unrelated to each other, since you started taking ketamine?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on B&P (VI)
D4 Unstable ideas of reference, 'subject-centrism'
(individual feels they are the focus of attention but has no clear reason for 
this and overcomes this quickly NOT ideas of reference related to 
depressive, social anxiety or paranoid beliefs)
• Do you sometimes feel that things going on around you have a special meaning 
for you, even though you know at the same time that this is improbable or 
impossible? How does this compare to before you started taking ketamine?
• Do you sometimes feel as if random things were meant especially for you, e.g.
comments on the radio or TV? What does it take for you to realise that this is just 
a sudden idea and not true? How long does this idea last?
Rating: Frequency II
If needed: Severity (III), Subjective burden (IV), Areas of life (VIII)
D5 Changed perception of the face or body of others
(face or body of others is seen as strange and peculiar, e.g. colour of skin, 
eyes or hair - may lead to impaired ability to recognise facial expressions)
• Do the faces or bodies of other people sometimes appear different or distorted
since you started taking ketamine?
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Rating: Frequency il
If needed: Severity (III), Subjective burden (IV), Effects on B&P (VI)
12
E) Body perception disturbances
E1 Unusual bodily sensations of numbness and stiffness
(resemble paraesthesias incl. numbness and stiffness, wandering sensations 
of stiffness, which can be transient or chronic. NOT real motor blockages 
(010; where person can not move), NOR slowing down of movements 
UNLESS slowing down is accompanied by sensations of stiffness, NOR the 
feeling that the body, or parts of it do not belong to oneself (F6)
• Have you sometimes experienced unusual, numb or stiff feelings in your arms or 
legs or in another part of your body, since you started taking ketamine?
• When you experience this stiffness / numbness, do you feel as if you are paralysed 
and cant move, or are you actually moving slower? (qu to rule out 010 etc)
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance
(VI), Consulting a doctor (VII) 
E2 Unusual bodily sensations of pain in a distinct area
(painful, often long-lasting sensations with a piercing, tearing or shooting 
quality, which cant be neurologically explained. Often occur at certain times 
of day, like sudden attack; often accompanied by affective disturbances; 
depth location is also often difficult. NOT Intense feelings of being electrified 
(E4)
• Do you sometimes have a peculiar pain, like a piercing, tearing or shooting feeling, 
since you started taking ketamine? Where is it located; how deep is it?
• Is this pain different from pains you had before you started taking ketamine?
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance
(VI), Consulting a doctor (VII)
E3 Migrating bodily sensations wandering through the body
(fluctuating, wandering sensations around body, which can increase to 
sometimes painful I attack-like severity); NOT a more static sensation (E5)
• Do you sometimes have irritating and uncomfortable body sensations that move 
through your body, and can even become painful since you started taking 
ketamine? If you do, what route do they take?
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• Is this moving sensation different from sensations or pains you had before you 
started taking ketamine?
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance
(VI), Consulting a doctor (VII)
E4 Electric bodily sensations, feelings of being electrified
(feeling like being given an electric shock, which are not related to external 
influences. If described as painful, only score here NOT E2. If the electric 
sensations whirl, wander or circle around the body, score at E3 too)
• Since starting to take ketamine, do you sometimes experience a feeling that is like 
being given an electric shock?
Rating: Frequency II
If needed: Severity (III), Quality o f being new/different (IV), Subjective 
burden, (VI), Effects on performance (VI), Consulting a doctor,
(VII)
E5 Bodily sensations of movement, pulling or pressure inside the 
body or on its surface
(sensations perceived as if something is actually moving inside the body, 
organs or on the skin - itching, vibrating, shaking, knocking, trembling, 
quivering, twitching, crawling, digging, tearing, stroking); NOT just a 
sensations swirling, circling around body (E3)
• Since you started taking ketamine, do you sometimes have the feeling as if 
something is moving inside your body, or on your skin?
• How would you describe this feeling? Is it like a twitching, jumping, 
vibrating, knocking or trembling?
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance
(VI), Consulting a doctor (VII)
14
E6 Sensations of the body or parts of it extending, diminishing, 
shrinking, enlarging, growing or constricting
(can affect whole body or just parts, and generally ‘attack-like’. Often 
accompanied by affective changes, which can escalate to panic depending 
on the ‘reality’ of the sensations); NOT sensations of body being heavy, light 
or empty, falling or sinking, NOR depersonalisation.
• Do you sometimes feel as if your whole body or parts of it is going to shrink 
or grow or change in some way?
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV), Effects on performance
(VI), Consulting a doctor (VII)
F) Perception disturbances
I’m going to ask you a few more questions about your vision and hearing now.
F1 Hypersensitivity to light or certain optic stimuli
(NOT scored if these experiences occur as a result of a migraine, epileptic 
aura or another known physical illness)
• Have you become much more sensitive to sunlight, or felt things were brighter than 
usual, since you started taking ketamine?
• Have you consulted a doctor about this? If so, what did they say?
Rating: Frequency II
If needed: Subjective burden (IV), Coping (V), Effects on B&P (VI)
F2 Photopsia
(are simple moving or fixed white, bright or coloured hallucinations in form 
of flashes, stars, flames, circles or very strong, blinding light. ONLY SCORE 
when it causes SUBJECTIVE complaints and is NOT related by the individual 
to the outside world but to themselves)
• Do you sometimes see flashes of light or other very bright figures like stars, dots or 
flames in your eyes? Have you always had this, or has it developed since you started 
taking ketamine?
• Have you consulted a doctor about this? If so, what did they say?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on B&P (VI)
F3 Micropsia, Macropsia
• Do objects ever appear bigger or smaller than they really are, or distorted in any
way?
• Have you always had this, or has this developed since you started taking 
ketamine?
Rating: Frequency II
If needed: Severity (III), Subjective burden (IV), Effects on B&P (VI)
16
F4 Hypersensitivity to sounds or noise
(sounds of unchanged intensity or quality are experienced as too loud, 
distracting or annoying; NOT changed intensity, quality of sound, F5)
• Are you much more sensitive to sounds and noise in comparison to before you 
started taking ketamine?
• Have you consulted a doctor about this? If so, what did they say?
Rating: Frequency II
If needed: Subjective burden (IV), Effects on B&P (VI)
F5 Changes in the perceived intensity or quality of acoustic stimuli
(Do not score a sole hypersensitivity to sounds without any qualitative 
changes in auditory perceptions (F4) or derealisation -  which also requires 
visual perceptual distortions (08) here)
• Do you sometimes have strange problems with hearing? Can you describe them?
• Do you sometimes have sudden and short-lived difficulties with your hearing such as 
sounds seeming muffled or less loud or short periods of deafness?
• Have you always had these experiences, or have they developed since you started 
taking ketamine?
• Have you consulted a doctor about this? If so, what did they say?
Rating: Frequency II
If needed: Severity (III), Subjective burden (IV), Effects on B&P (VI)
F6 Somatopsychic bodily depersonalisation
The body or parts of it are perceived as not belonging to oneself anymore, as 
isolated or separated from each other or not existing at all OR body is 
perceived as falling apart/ body parts seem no longer to be connected, 
although all parts still belong to the person affected. (NOT depersonalisation 
nor visual perceptions of changes in the person’s face or expression which 
cause the individual to repeatedly check themselves in the mirror)
• Do you sometimes feel as if parts of your body have been separated from the rest
of your body or do not exist anymore?
• Are you sometimes unable to feel your body or parts of it?
• Do you sometimes have a feeling as if your body could fall apart like a jigsaw?
• Have you always had this, or is it an experience that has developed since starting
to take ketamine?
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Rating:
If needed:
Frequency II
Severity (III), Subjective burden (IV), Effects on B&P (VI), 
C onsulting a doctor (VII)
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O) Optional Extras:
01 Thought perseveration
(usually re: events, conversations, mundane things that have happened a 
few hours earlier, maybe even the day before; thoughts all following the 
same theme. NOT a depressive rumination about a negative future, NOR 
thought interference (C2) where unimportant thought/image interferes with 
funcitoning without being constantly repeated, NOR thought pressure (D3) 
where there is a succession of unrelated thoughts)
• Do you sometimes have to think about past unimportant conversations or events, 
when you want to think about something else?
• Does this ever take the form of images in your mind’s eye?
Rating: Frequency II
If needed: Subjective Burden (IV), Coping (V), Effects on B&P (VI)
02  Decreased ability to discriminate between ideas and perception, 
pure fantasy and true memories
• Are you sometimes unsure whether you actually see or hear something, or if you 
just imagined it?
• Do you sometimes become confused whether you have actually done certain 
things in the past or just imagined them? Do you ever ask others to make sure?
• Have you always had these experiences, or have they developed since you started 
taking ketamine?
Rating: Frequency II
If needed: Subjective Burden (IV), Coping (V), Effects on B&P (VI)
07 Captivation of attention by details of the visual field
(NOT ‘feeling overly distracted by stimuli’ (B2) where attention is easily 
distracted by all kind of things going on in the environment, so  that s/he has 
difficulties to focus on one thing, here, the attention is fixed on one thing and 
the rest of the environment is not paid any attention anymore)
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• Since you starting taking ketamine, have you ever noticed that specific aspects of 
the environment you are looking at really stand out in a striking way, and seem 
somehow isolated from the rest?
• Do you ever have to stare at these details, without actually wanting to?
Rating: Frequency II
If needed: Subjective Burden (IV), Coping (V), Effects on B&P (VI)
08 Derealisation
• Since starting ketamine, do you sometimes experience your surroundings as 
changed, unreal or strange? As if the world around you isn’t quite real? (subtype 1)
• Have there been times when you have experienced a high, euphoric mood during 
which your surroundings, the landscape, animals or people seemed different, 
somehow great, impressive and moving? (subtype 2)
Rating: Frequency II
If needed: Severity (III), Subjective Burden (IV)
010 Motor Blockages
(Impediment or complete blockage of intended motor actions that appear 
attack-like, all of a sudden, and vanish quickly)
• Are you sometimes, especially in the morning, suddenly unable to speak or move 
although you are fully awake?
Rating: Frequency II
If needed: Subjective Burden (IV), Coping (V), Effects on B&P (VI)
AND FINALLY....
Are there any other changes to how your mind works I may have missed? or 
any feelings or behaviours that you think have changed since you started 
taking ketamine?
How often has this affected you?
How much does it affect you?
2 0
Frequency
Looking at this scale and taking into account everything you have just told me, how 
frequently do you believe th is ............. has occurred in the last week?
Severity (III)
Taking into account everything you have told me how severe has this been?
Subjective Burden (IV)
Taking into account everything you have just told me, how burdened do you feel by this? 
Coping (V)
Taking into account everything you have just told me, do you believe you are currently
able to cope with difficulties with this or do you think that the difficulties are not bad
enough to have to “cope” with them?
Effects on Behaviour & Performance (VI)
Do you currently avoid certain places, situations, people or activities because of 
this....................... ...?
Include information the participant has told you previously about their behaviour and 
functioning to judge this answer.
Effects on quality of life (VI)
Taking into account everything you have just told me, how h a s  x  affected your
quality of life?
Consultation with a doctor (VII)
Have you considered consulting a doctor about these experiences? If so, how many
appointments have you had, and how many doctors have you seen?
Areas of life (VIII)
Taking into account everything you have just told me, how many areas of your life do you
believe x has affected in the last week?
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Appendix 6 
SPI-A item self-rating cards
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FREQUENCY TWO PARTICIPANT
SCORING SHEET
ABSENT (0) RARE (1) MILD (2) MODERATE (3)
/
MODERATELY 
SEVERE (4)
SEVERE (5) EXTREME (6)
(II) FREQUENCY NEVER LESS THAN ONCE 
A MONTH
SHORT PERIODS 
about ONCE 
IN A MONTH
i
SEVERAL TIMES 
IN A MONTH 
OR WEEKLY
SEVERAL TIMES 
A WE EK,
RATHER DAILY 
PERIODS OF 
IMPROVEMENT 
POSSIBLE
DAILY BUT 
NOT NECESSARILY 
CONTINUOUSLY
Use ONLY when frequency is in doubt
ABSENT
(0)
RARE (1) MILD (2) MODERATE (3) MODERATELY 
SEVERE (4)
SEVERE (5) EXTREME (6)
(3) SEVERITY
VERY LOW
LOW,
SLIGHTLY
IRRITATING
MODERATE,
IRRITATING
MODERATELY
SEVERE,
IRRITATING
SEVERE, VERY 
IRRITATING
EXTREME,
REALITY
TESTING
HARDLY
POSSIBLE
(4) SUBJECTIVE 
BURDEN
NONE MINIMAL HARDLY ANY LOW MODERATE HIGH
(5) COPING 
WITH IT BY 
INCREASING 
EFFORT
DOES NOT 
REQUIRE 
COPING
EASILY AND 
ALWAYS 
POSSIBLE
ALWAYS
POSSIBLE
MOSTLY
POSSIBLE
HARDLY/
RARELY
POSSIBLE
NOT
POSSIBLE
(6) EFFECTS ON
BEHAVIOUR,
PERFORMANCE.
LEVEL OF
FUNCTIONING
OR
ENVIRONMENT
NONE NONE
HARDLY ANY 
EFFECT
LITTLE
AVIODANCE
OF
RESPECTIVE 
SITUATIONS, 
□KITING 
ACTIVITIES. 
NO TO MILD 
DECREASE IN 
PERFORMACE
AVIODANCE OF 
RESPECTIVE 
SITUATIONS, 
OBVIOUS 
DECREASE IN 
PERFORMANCE, 
SOCIAL 
DIFFICULTIES
AVIODANCE.
SIGNIFICANT
DECREASE
IN
FUCNTIOING
AND/OR
CONFLICTS
WITH
ENVIRNMENT
(7) CONSULTING 
A DOCTOR FOR 
THE PROBLEM
NOT
CONSIDERED CONSIDERED
SERIOUSLY
CONSDIERED
SINGLE
CONTACT
ONE OT MORE 
APPOINTMENTS 
WITH SAME 
DOCTOR
CONSULTING
VARIOUS
DOCTORS
(8) AREAS OF 
LIFE
VERY 
CIRCUMSCRIPT 
WITHIN ONE 
AREA
ONE FEW AND 
VERY 
CIRCUMSCRIPT
FEW MOST ALL
Appendix 7 
SPI-A score sheets
SPIA SCORE SHEET Participant ID:
A = Affective-Dynamic Disturbances
1 2 3 4 5 6 7 8 9
A l.l: Impaired tolerance to unusual, unexpected or specific 
novel demands
A1.2: Impaired tolerance to certain social everyday situations
B1 A1.3: Impaired tolerance to working under pressure of time or 
rapidly changing different demands
A3 A2: Change in mood and emotional responsiveness
A3: Decrease in positive emotional responsiveness towards 
others
SUM SCORES 1-6 ONLY |
Extra information / verbatim quotes:
SPIA SCORE SHEET Participant ID:
B = Cognitive-Attentional Impediments
1 2 3 4 5 6 7 8 9
Bl: Inability to divide attention
Bl, C2, D3 B2: Feeling overly distracted by stimuli
Bl, B2, B4 C2, 
Ol, 07, D3, C3, 
C4, C6
B3: Difficulties concentrating
B4: Difficulties to hold things in mind for less 
than half an hour
B3, C4, C5 B5: Slowed-down thinking
o n B6: Lack of ‘thought energy’, purposive thoughts
SUM SCORES 1-6 ONLY |
Extra information /  verbatim quotes:
SPIA SCORE SHEET Participant ID:
C = Cognitive Disturbances
1 2 3 4 5 6 7 8 9
B3 Cl: Increased indecisiveness with regard to insignificant 
choices between equal alternatives
B2, C3, 
Ol
C2: Thought interference
C3: Thought blockages
C4: Disturbance of receptive speech
C5: Disturbance of expressive speech
C6: Disturbance in immediate recall
SUM SCORES 1-6 ONLY \
Extra information / verbatim quotes:
SPIA SCORE SHEET Participant ID:
D = Disturbances in Experiencing Self and Surrounding
1 2 3 4 5 6 7 8 9
A2, A3 Dl: Decreased capacity to discriminate between different 
kinds of emotions
Ol D2: Increased emotional reactivity in response to routine 
social interactions
Cl, Ol D3: Thought pressure
D4: Unstable ideas of reference
D5: Changed perception of the face or body of others
SUM SCORES 1-6 ONLY |
Extra information / verbatim  quotes:
SPIA SCORE SHEET Participant ID:
E = Body Perception Disturbances
1 2 3 4 5 6 7 8 9
F6,
010
El: Bodily sensations of numbness and stiffness
E4 E2: Bodily sensations of pain in a distinct area
E5 E3: Bodily sensations migrating through the body
E2 E4: Bodily sensations of being electrified
E3 E5: Bodily sensations of movement or pressure
E6: Bodily sensations of body / body parts changing size
SUM SCORES 1-6 ONLY |
Extra information / verbatim quotes:
SPIA SCORE SHEET Participant ID:
F -  Perception Disturbances
F I: Hypersensitivity to light / optic stimuli
F2: Photopsia
F3: Micropsia, macropsia
1 2 3 4 5 6 1 8 9
F4,Q8
*4: Hypersensitivity to sounds / noise
F5. Changed intensity / quality of acoustic stimuli
F6: Somatopsychic bodil&de^^rsBhdfisatitin)
SUM SCORES 1-6 ONLY’" ' |----------
Extra information / verbatim quotes:
SPIA SCORE SHEET
O -  Optional Extras
Participant ID:
C2, D3 Ol: Thought perseveration 8
02: Less discrimination between ideas & perception, fantasy & true 
memories
07: Captivation of attention by details of the visual field
08: Derealisation
010: Motor blockages 
SUM SCORES 1-6 ONLY
